,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,368,2,3,,8139972,37542,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
1,374,2,3,,8139972,37542,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
2,421,1,3,,17389529,37542,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
3,422,1,5,,17405619,37542,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
4,426,1,2,,17389529,37542,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
5,427,1,1,,17389529,37542,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
6,429,1,5,,17405619,37542,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
7,429,1,5,,17405619,37542,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
8,433,1,1,,17389529,37542,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
9,434,1,2,,17389529,37542,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
10,435,1,2,,17389529,37542,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
11,436,2,1,,17405619,37542,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
12,445,3,1,,17389529,37542,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,485,1,8,,8139972,37542,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
14,530,1,1,,17389529,37542,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
15,539,1,2,,8139972,37542,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
16,540,1,1,,17389529,37542,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
17,541,1,1,,17389529,37542,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
18,542,1,1,,17389529,37542,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
19,543,1,1,,17389529,37542,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
20,544,2,1,,17389529,37542,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
21,545,1,1,,17389529,37542,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
22,546,1,1,,17389529,37542,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
23,547,1,4,,17405619,37542,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
24,555,1,2,,8139972,37542,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
25,556,1,3,,8139972,37542,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
26,565,1,4,,8139972,37542,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
27,568,1,7,,8139972,37542,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
28,568,1,7,,8139972,37542,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
29,573,1,4,,8139972,37542,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
30,577,1,1,,8139972,37542,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
31,583,2,6,,8139972,37542,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
32,584,1,3,,17389529,37542,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
33,585,1,4,,17389529,37542,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
34,595,1,3,,17389529,37542,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
35,596,1,2,,17389529,37542,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
36,603,1,2,,17389529,37542,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
37,605,1,2,,17389529,37542,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
38,606,1,3,,8139972,37542,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
39,606,1,3,,8139972,37542,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
40,618,2,6,,8139972,37542,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
41,620,2,5,,8139972,37542,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
42,631,1,4,,8139972,37542,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
43,631,1,4,,8139972,37542,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
44,645,1,4,,8139972,37542,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
45,654,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
46,655,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
47,656,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
48,657,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
49,658,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
50,659,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
51,660,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
52,661,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
53,662,1,1,,17389529,37542,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
54,663,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
55,664,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
56,665,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
57,666,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
58,667,1,1,,17389529,37542,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
59,694,1,1,,17405619,37542,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
60,708,1,4,,8139972,37542,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
61,709,1,2,,8139972,37542,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
62,731,1,5,,8139972,37542,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
63,731,1,5,,8139972,37542,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
64,732,1,2,,17405619,37542,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
65,750,1,3,,8139972,37542,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
66,757,1,4,,8139972,37542,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
67,758,1,4,,8139972,37542,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
68,759,1,4,,8139972,37542,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
69,760,1,4,,8139972,37542,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
70,761,1,4,,8139972,37542,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
71,764,1,4,,8139972,37542,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
72,774,1,2,,8139972,37542,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
73,775,1,3,,8139972,37542,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
74,781,1,1,,8139972,37542,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
75,782,1,2,,8139972,37542,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
76,782,1,2,,8139972,37542,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
77,793,1,2,,8139972,37542,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
78,797,1,1,,8139972,37542,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
79,798,2,12,,8139972,37542,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
80,799,1,5,,8139972,37542,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
81,800,2,11,,8139972,37542,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
82,803,1,4,,8139972,37542,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
83,804,1,3,,8139972,37542,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
84,811,1,2,,26538475,37542,Inactive,55662034.0,,,,Primary Cell Based High Throughput Screening Assay for Inhibitors of TLR4-MyD88 binding,Screening,,
85,817,1,1,,8139972,37542,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
86,818,1,2,,8139972,37542,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
87,827,1,2,,8139972,37542,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
88,828,1,5,,8139972,37542,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
89,833,1,2,,26538475,37542,Inactive,2578455.0,29234.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of GALR2,Screening,,
90,841,1,1,,8139972,37542,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
91,847,1,2,,8139972,37542,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
92,861,1,1,,8139972,37542,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
93,862,1,2,,8139972,37542,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
94,868,1,3,,8139972,37542,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
95,871,1,2,,8139972,37542,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
96,873,1,13,,8139972,37542,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
97,875,1,2,,17389529,37542,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
98,878,1,2,,8139972,37542,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
99,879,1,2,,17389529,37542,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
100,879,1,2,,17389529,37542,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
101,880,2,1,,8139972,37542,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
102,880,2,1,,8139972,37542,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
103,880,2,1,,17389529,37542,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
104,880,2,1,,17389529,37542,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
105,880,2,1,,50105410,37542,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
106,880,2,1,,50105410,37542,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
107,881,2,2,,17389529,37542,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
108,884,1,2,,17389529,37542,Inactive,13435386.0,1576.0,0.7943,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
109,885,1,2,,17389529,37542,Inconclusive,13435386.0,1576.0,0.7943,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
110,886,1,2,,17389529,37542,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
111,886,1,2,,17389529,37542,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
112,887,1,2,,17389529,37542,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
113,889,1,3,,17389529,37542,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
114,892,1,2,,17389529,37542,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
115,893,1,2,,17389529,37542,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
116,893,1,2,,17389529,37542,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
117,894,2,1,,8139972,37542,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
118,894,2,1,,17389529,37542,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
119,894,2,1,,50105410,37542,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
120,895,1,2,,17389529,37542,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
121,898,1,1,,8139972,37542,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
122,900,1,3,,17389529,37542,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
123,901,1,2,,17389529,37542,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
124,902,1,2,,17389529,37542,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
125,912,1,2,,17389529,37542,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
126,917,1,3,,17389529,37542,Inconclusive,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
127,918,1,3,,17389529,37542,Inconclusive,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
128,920,1,2,,8139972,37542,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
129,921,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
130,923,1,2,,17389529,37542,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
131,924,1,2,,17389529,37542,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
132,925,1,2,,17389529,37542,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
133,926,1,2,,17389529,37542,Inconclusive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
134,927,1,3,,17389529,37542,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
135,928,1,2,,17389529,37542,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
136,932,1,4,,8139972,37542,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
137,938,1,2,,17389529,37542,Inactive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
138,940,1,2,,8139972,37542,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
139,940,1,2,,17405619,37542,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
140,940,1,2,,26612558,37542,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
141,943,1,2,,17389529,37542,Inconclusive,18249941.0,25229.0,0.0501,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
142,944,1,2,,17389529,37542,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
143,945,1,4,,17389529,37542,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
144,946,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
145,947,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
146,948,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
147,950,1,1,,8139972,37542,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
148,951,1,1,,8139972,37542,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
149,952,1,1,,8139972,37542,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
150,954,1,2,,17389529,37542,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
151,955,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
152,957,1,2,,17389529,37542,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
153,958,1,2,,17389529,37542,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
154,959,1,4,,17389529,37542,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
155,960,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
156,961,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
157,962,1,2,,17389529,37542,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
158,963,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
159,964,1,2,,17389529,37542,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
160,965,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
161,966,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
162,967,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
163,968,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
164,969,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
165,970,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
166,971,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
167,972,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
168,973,1,2,,17389529,37542,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP2-019,Confirmatory,,
169,974,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
170,975,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
171,976,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
172,977,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
173,978,1,2,,17389529,37542,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP2-006,Confirmatory,,
174,979,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
175,980,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
176,981,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
177,982,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
178,983,1,2,,17389529,37542,Inconclusive,,,79.4328,Potency,Cell Viability - LYMP2-014,Confirmatory,,
179,984,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
180,985,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
181,986,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
182,987,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
183,988,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
184,989,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
185,992,1,3,,17389529,37542,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
186,993,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
187,994,1,2,,17389529,37542,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
188,995,1,2,,17389529,37542,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
189,997,1,2,,17389529,37542,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
190,998,1,2,,17389529,37542,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
191,1001,2,2,,8139972,37542,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
192,1006,1,6,,8139972,37542,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
193,1007,1,1,,8139972,37542,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
194,1008,1,2,,8139972,37542,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
195,1009,1,2,,8139972,37542,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
196,1012,1,4,,8139972,37542,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
197,1016,1,4,,8139972,37542,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
198,1018,2,5,,8139972,37542,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
199,1019,1,4,,8139972,37542,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
200,1020,1,5,,8139972,37542,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
201,1021,1,1,,8139972,37542,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
202,1022,1,1,,8139972,37542,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
203,1027,1,3,,8139972,37542,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
204,1030,2,1,,8139972,37542,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
205,1030,2,1,,17389529,37542,Active,30582681.0,216.0,25.1189,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
206,1030,2,1,,50105410,37542,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
207,1032,1,2,,8139972,37542,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
208,1032,1,2,,8139972,37542,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
209,1040,1,2,,8139972,37542,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
210,1044,1,1,,26538475,37542,Inactive,13027636.0,1901.0,,,Primary cell-based high-throughput screening assay to identify agonists of Sphingosine 1-Phosphate receptor 1 (S1P1),Screening,,
211,1046,1,6,,8139972,37542,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
212,1048,1,1,,8139972,37542,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
213,1048,1,1,,8139972,37542,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
214,1049,1,1,,8139972,37542,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
215,1049,1,1,,8139972,37542,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
216,1051,1,1,,8139972,37542,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
217,1051,1,1,,8139972,37542,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
218,1063,1,1,,8139972,37542,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
219,1066,1,2,,8139972,37542,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
220,1085,1,1,,8139972,37542,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
221,1135,1,3,,8139972,37542,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
222,1136,1,3,,8139972,37542,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
223,1195,1,2,,48416516,37542,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
224,1203,1,3,,8139972,37542,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
225,1209,2,2,,8139972,37542,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
226,1214,1,4,,8139972,37542,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
227,1216,1,5,,8139972,37542,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
228,1217,1,4,,8139972,37542,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
229,1220,2,2,,8139972,37542,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
230,1222,1,6,,8139972,37542,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
231,1229,1,3,,8139972,37542,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
232,1236,1,1,,8139972,37542,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
233,1239,1,3,,8139972,37542,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
234,1239,1,3,,8139972,37542,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
235,1242,1,1,,8139972,37542,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
236,1251,1,1,,8139972,37542,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
237,1273,1,1,,8139972,37542,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
238,1274,1,2,,8139972,37542,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
239,1276,1,1,,8139972,37542,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
240,1285,1,1,,8139972,37542,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
241,1296,1,1,,8139972,37542,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
242,1304,1,2,,8139972,37542,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
243,1321,1,2,,8139972,37542,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
244,1325,1,2,,8139972,37542,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
245,1326,1,4,,8139972,37542,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
246,1332,1,1,,49699015,37542,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
247,1359,1,4,,8139972,37542,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
248,1362,1,2,,8139972,37542,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
249,1376,1,2,,8139972,37542,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
250,1377,1,1,,8139972,37542,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
251,1379,1,2,,8139972,37542,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
252,1379,1,2,,50105410,37542,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
253,1381,1,1,,8139972,37542,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
254,1385,2,2,,8139972,37542,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
255,1415,1,2,,8139972,37542,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
256,1415,1,2,,8139972,37542,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
257,1416,1,2,,8139972,37542,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
258,1422,1,1,,8139972,37542,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
259,1422,1,1,,17405619,37542,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
260,1422,1,1,,26612558,37542,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
261,1423,1,2,,8139972,37542,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
262,1423,1,2,,8139972,37542,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
263,1424,1,1,,8139972,37542,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
264,1430,1,1,,8139972,37542,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
265,1434,2,3,,8139972,37542,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
266,1434,2,3,,8139972,37542,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
267,1439,1,1,,8139972,37542,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
268,1439,1,1,,8139972,37542,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
269,1440,1,1,,8139972,37542,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
270,1440,1,1,,8139972,37542,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
271,1441,1,1,,8139972,37542,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
272,1441,1,1,,8139972,37542,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
273,1443,1,3,,8139972,37542,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
274,1445,1,1,,8139972,37542,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
275,1446,1,3,,8139972,37542,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
276,1448,1,3,,8139972,37542,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
277,1452,1,1,,8139972,37542,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
278,1452,1,1,,17389529,37542,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
279,1454,1,1,,8139972,37542,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
280,1454,1,1,,50105410,37542,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
281,1456,1,1,,8139972,37542,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
282,1457,1,1,,8139972,37542,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
283,1457,1,1,,17389529,37542,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
284,1457,1,1,,50105410,37542,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
285,1458,1,1,,8139972,37542,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
286,1458,1,1,,17389529,37542,Inconclusive,10937869.0,6607.0,19.9526,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
287,1458,1,1,,50105410,37542,Inconclusive,10937869.0,6607.0,22.3872,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
288,1459,1,1,,50105410,37542,Inconclusive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
289,1460,1,3,,8139972,37542,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
290,1460,1,3,,50105410,37542,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
291,1461,1,2,,8139972,37542,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
292,1461,1,2,,50105410,37542,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
293,1463,1,1,,8139972,37542,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
294,1463,1,1,,50105410,37542,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
295,1465,1,1,,8139972,37542,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
296,1466,1,2,,8139972,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
297,1467,1,3,,8139972,37542,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
298,1467,1,3,,50105410,37542,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
299,1468,1,1,,8139972,37542,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
300,1468,1,1,,50105410,37542,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
301,1469,1,1,,8139972,37542,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
302,1469,1,1,,17389529,37542,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
303,1469,1,1,,50105410,37542,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
304,1471,2,1,,17389529,37542,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
305,1476,2,1,,8139972,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
306,1476,2,1,,17389529,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
307,1476,2,1,,50105410,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
308,1477,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
309,1477,1,1,,17389529,37542,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
310,1477,1,1,,50105410,37542,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
311,1478,2,1,,8139972,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
312,1478,2,1,,17389529,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
313,1478,2,1,,50105410,37542,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
314,1479,1,2,,8139972,37542,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
315,1479,1,2,,17389529,37542,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
316,1479,1,2,,50105410,37542,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
317,1481,1,2,,8139972,37542,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
318,1486,1,3,,8139972,37542,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
319,1487,1,1,,8139972,37542,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
320,1487,1,1,,50105410,37542,Inconclusive,27436948.0,4000.0,0.004,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
321,1490,2,1,,8139972,37542,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
322,1496,1,4,,8139972,37542,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
323,1496,1,4,,8139972,37542,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
324,1509,1,2,,8139972,37542,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
325,1510,1,3,,8139972,37542,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
326,1511,1,3,,8139972,37542,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
327,1515,1,2,,8139972,37542,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
328,1519,1,3,,50105410,37542,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
329,1527,1,3,,8139972,37542,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
330,1529,1,1,,8139972,37542,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
331,1530,1,1,,8139972,37542,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
332,1531,1,1,,8139972,37542,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
333,1532,1,1,,8139972,37542,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
334,1554,1,1,,8139972,37542,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
335,1556,1,4,,8139972,37542,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
336,1565,2,2,,8139972,37542,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
337,1566,2,3,,8139972,37542,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
338,1578,3,2,,8139972,37542,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
339,1580,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
340,1581,1,1,,8150084,37542,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
341,1582,1,1,,8150084,37542,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
342,1583,1,1,,8150084,37542,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
343,1584,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
344,1585,1,1,,8150084,37542,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
345,1586,1,1,,8150084,37542,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
346,1587,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
347,1588,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
348,1589,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
349,1590,1,1,,8150084,37542,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
350,1593,1,1,,8150084,37542,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
351,1594,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
352,1595,1,1,,8150084,37542,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
353,1596,1,1,,8150084,37542,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
354,1597,1,1,,8150084,37542,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
355,1598,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
356,1599,1,1,,8150084,37542,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
357,1600,1,1,,8150084,37542,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
358,1601,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
359,1602,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
360,1603,1,1,,8150084,37542,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
361,1604,1,1,,8150084,37542,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
362,1605,1,1,,8150084,37542,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
363,1606,1,1,,8150084,37542,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
364,1607,1,1,,8150084,37542,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
365,1608,1,1,,8150084,37542,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
366,1609,1,1,,8150084,37542,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
367,1610,1,1,,8150084,37542,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
368,1612,1,1,,8150084,37542,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
369,1613,1,1,,8150084,37542,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
370,1614,1,1,,8150084,37542,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
371,1616,1,1,,8150084,37542,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
372,1619,1,2,,8139972,37542,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
373,1621,1,2,,8139972,37542,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
374,1626,1,2,,8139972,37542,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
375,1631,3,1,,8139972,37542,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
376,1634,3,1,,8139972,37542,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
377,1654,2,2,,8139972,37542,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
378,1656,2,2,,8139972,37542,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
379,1662,1,2,,8139972,37542,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
380,1663,1,2,,8139972,37542,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
381,1672,1,3,,8139972,37542,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
382,1688,1,1,,8139972,37542,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
383,1700,1,2,,8139972,37542,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
384,1705,1,2,,50105410,37542,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
385,1706,1,2,,8139972,37542,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
386,1707,1,3,,50105410,37542,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
387,1708,1,3,,50105410,37542,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
388,1721,1,2,,8139972,37542,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
389,1722,1,2,,8139972,37542,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
390,1766,1,1,,8139972,37542,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
391,1766,1,1,,8139972,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
392,1766,1,1,,50105410,37542,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
393,1766,1,1,,50105410,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
394,1768,1,1,,8139972,37542,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
395,1768,1,1,,8139972,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
396,1768,1,1,,50105410,37542,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
397,1768,1,1,,50105410,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
398,1775,1,2,,8139972,37542,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
399,1776,1,2,,8139972,37542,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
400,1777,3,2,,8139972,37542,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
401,1778,3,3,,8139972,37542,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
402,1779,2,2,,8139972,37542,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
403,1789,1,2,,8139972,37542,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
404,1792,1,1,,26538475,37542,Inactive,83699673.0,27035.0,,,Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of NADPH oxidase 1 (Nox1): Maybridge Library,Screening,,
405,1800,1,2,,8139972,37542,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
406,1813,1,2,,8139972,37542,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
407,1814,1,2,,8139972,37542,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
408,1815,1,1,,50105410,37542,Inconclusive,,,15.8489,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
409,1816,1,1,,50105410,37542,Inconclusive,,,14.1254,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
410,1817,2,2,,8139972,37542,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
411,1822,1,3,,8139972,37542,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
412,1823,1,1,,26538475,37542,Inactive,,,,,Luminescence-based counterscreen for inhibitors of NADPH oxidase 1 (Nox1): biochemical high throughput screening assay to identify inhibitors of luminol (Maybridge Library),Screening,,
413,1825,1,1,,8139972,37542,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
414,1828,2,1,,50105410,37542,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
415,1832,2,1,,8139972,37542,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
416,1845,1,2,,8139972,37542,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
417,1850,2,1,,8139972,37542,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
418,1861,2,1,,8139972,37542,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
419,1863,2,1,,8139972,37542,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
420,1865,1,1,,8139972,37542,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
421,1865,1,1,,50105410,37542,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
422,1875,2,1,,8139972,37542,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
423,1876,1,1,,50105410,37542,Active,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
424,1877,1,1,,50105410,37542,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
425,1882,1,1,,50105410,37542,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
426,1883,1,1,,50105410,37542,Inconclusive,,,2.8184,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
427,1885,2,1,,8139972,37542,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
428,1886,1,1,,50105410,37542,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
429,1899,1,3,,8139972,37542,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
430,1903,2,3,,8139972,37542,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
431,1906,1,3,,8139972,37542,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
432,1910,1,2,,8139972,37542,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
433,1947,1,2,,8139972,37542,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
434,1948,1,1,,17389529,37542,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
435,1948,1,1,,50105410,37542,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
436,1950,1,3,,8139972,37542,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
437,1956,1,1,,8139972,37542,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
438,1961,2,2,,8139972,37542,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
439,1962,1,2,,8139972,37542,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
440,1967,1,1,,50105410,37542,Inconclusive,4505907.0,5376.0,23.9341,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
441,1974,1,2,,8139972,37542,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
442,1984,1,3,,8139972,37542,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
443,1986,1,2,,8139972,37542,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
444,1987,1,2,,8139972,37542,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
445,2006,3,2,,8139972,37542,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
446,2006,3,2,,8139972,37542,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
447,2006,3,2,,8139972,37542,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
448,2012,3,2,,8139972,37542,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
449,2013,2,2,,8139972,37542,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
450,2014,3,2,,8139972,37542,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
451,2016,1,3,,8139972,37542,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
452,2023,1,3,,8139972,37542,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
453,2025,1,3,,8139972,37542,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
454,2029,1,3,,8139972,37542,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
455,2052,2,1,,8139972,37542,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
456,2057,1,2,,8139972,37542,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
457,2058,3,2,,8139972,37542,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
458,2066,1,4,,8139972,37542,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
459,2071,2,2,,8139972,37542,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
460,2073,2,3,,8139972,37542,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
461,2073,2,3,,8139972,37542,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
462,2094,1,2,,8139972,37542,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
463,2094,1,2,,8139972,37542,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
464,2094,1,2,,8139972,37542,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
465,2097,1,2,,8139972,37542,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
466,2098,1,1,,8139972,37542,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
467,2099,1,1,,8139972,37542,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
468,2100,1,1,,8139972,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
469,2101,1,1,,8139972,37542,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
470,2101,1,1,,17389529,37542,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
471,2101,1,1,,50105410,37542,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
472,2107,1,1,,8139972,37542,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
473,2107,1,1,,17389529,37542,Inconclusive,757912.0,2717.0,50.1187,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
474,2107,1,1,,50105410,37542,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
475,2112,1,1,,8139972,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
476,2112,1,1,,17389529,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
477,2112,1,1,,50105410,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
478,2120,1,1,,17389529,37542,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
479,2129,1,2,,8139972,37542,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
480,2130,1,3,,8139972,37542,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
481,2147,1,1,,8139972,37542,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
482,2147,1,1,,50105410,37542,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
483,2156,2,2,,8139972,37542,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
484,2174,1,3,,8139972,37542,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
485,2177,1,3,,8139972,37542,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
486,2205,1,1,,8139972,37542,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
487,2216,1,3,,8139972,37542,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
488,2221,1,2,,8139972,37542,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
489,2227,1,2,,8139972,37542,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
490,2234,1,2,,8139972,37542,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
491,2235,1,2,,8139972,37542,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
492,2237,1,2,,8139972,37542,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
493,2239,1,2,,8139972,37542,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
494,2242,1,1,,8139972,37542,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
495,2247,1,2,,8139972,37542,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
496,2280,2,3,,8139972,37542,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
497,2288,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
498,2289,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
499,2291,1,3,,26538475,37542,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
500,2300,1,3,,8139972,37542,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
501,2314,1,2,,8139972,37542,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
502,2314,1,2,,8139972,37542,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
503,2315,1,2,,8139972,37542,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
504,2315,1,2,,8139972,37542,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
505,2323,1,1,,50105410,37542,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
506,2326,1,1,,8139972,37542,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
507,2326,1,1,,50105410,37542,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
508,2353,1,3,,50105410,37542,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
509,2364,1,2,,50105410,37542,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
510,2380,1,2,,8139972,37542,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
511,2391,1,1,,8139972,37542,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
512,2417,1,1,,8139972,37542,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
513,2435,1,2,,8139972,37542,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
514,2445,1,2,,8139972,37542,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
515,2451,1,2,,8139972,37542,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
516,2451,1,2,,50105410,37542,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
517,2462,1,1,,8139972,37542,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
518,2462,1,1,,8139972,37542,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
519,2472,1,2,,8139972,37542,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
520,2517,2,1,,8139972,37542,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
521,2517,2,1,,17389529,37542,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
522,2517,2,1,,50105410,37542,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
523,2520,1,4,,8139972,37542,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
524,2521,1,3,,8139972,37542,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
525,2524,1,2,,8139972,37542,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
526,2528,1,2,,8139972,37542,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
527,2528,1,2,,50105410,37542,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
528,2540,1,2,,8139972,37542,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
529,2544,1,2,,8139972,37542,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
530,2546,1,1,,8139972,37542,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
531,2546,1,1,,17389529,37542,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
532,2549,1,1,,8139972,37542,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
533,2549,1,1,,17389529,37542,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
534,2549,1,1,,50105410,37542,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
535,2550,1,3,,8139972,37542,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
536,2551,1,1,,8139972,37542,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
537,2551,1,1,,17389529,37542,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
538,2553,1,2,,8139972,37542,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
539,2557,1,3,,8139972,37542,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
540,2563,1,1,,8139972,37542,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
541,2599,1,2,,8139972,37542,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
542,2606,1,2,,8139972,37542,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
543,2629,1,1,,8139972,37542,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
544,2642,1,2,,8139972,37542,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
545,2648,1,2,,8139972,37542,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
546,2650,2,1,,8139972,37542,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
547,2660,1,1,,90341426,37542,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
548,2661,1,1,,8139972,37542,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
549,2662,2,1,,8139972,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
550,2662,2,1,,50105410,37542,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
551,2666,1,1,,90341426,37542,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
552,2667,1,1,,90341426,37542,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
553,2668,1,1,,90341426,37542,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
554,2675,1,1,,8139972,37542,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
555,2675,1,1,,50105410,37542,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
556,2676,1,2,,8139972,37542,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
557,2685,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
558,2690,1,2,,8139972,37542,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
559,2716,1,1,,8139972,37542,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
560,2717,1,2,,8139972,37542,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
561,2718,1,1,,8139972,37542,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
562,2732,1,1,,8139972,37542,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
563,2732,1,1,,17405619,37542,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
564,2751,2,2,,8139972,37542,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
565,2774,1,3,,92303126,37542,Inactive,,,,,LOPAC Circadian Assay,Screening,,
566,2796,1,4,,8139972,37542,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
567,2797,1,2,,8139972,37542,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
568,2805,2,2,,8139972,37542,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
569,2806,2,2,,8139972,37542,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
570,2825,1,2,,8139972,37542,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
571,9873,6,3,,103619997,37542,Unspecified,,,100.0,IC50,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Confirmatory,,
572,21263,3,3,,103619997,37542,Unspecified,,,,,Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s),Other,8941388.0,
573,29735,5,2,,103619997,37542,Unspecified,,,,,Toxic level was evaluated; None,Other,2995666.0,
574,32219,8,1,,103619997,37542,Unspecified,,,,,"Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase",Other,2427720.0,
575,32220,3,4,,103619997,37542,Unspecified,,,,,Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC),Other,2427720.0,
576,33367,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in african green monkey (Vero B) cells,Other,2540332.0,
577,34142,3,3,,103619997,37542,Unspecified,,,,,Virus rating against adenovirus type 2,Other,2539476.0,
578,34143,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 100 uM determined in a culture of Adenovirus type 2; IA = inactive,Other,2542559.0,
579,41896,3,7,,103619997,37542,Unspecified,,,,,Beta-blocking activity measured by applying the stepwise linear discriminate analysis; Inactive,Other,,
580,43689,6,3,,103619997,37542,Active,,,19.0,IC50,Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line,Confirmatory,,
581,44369,6,3,,103619997,37542,Unspecified,,,100.0,IC50,Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.,Confirmatory,,
582,44803,6,3,,103619997,37542,Unspecified,,,100.0,IC50,Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.,Confirmatory,,
583,45416,6,3,,103619997,37542,Unspecified,,,50.0,IC50,Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.,Confirmatory,,
584,46601,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell growth in CEM cell line,Other,8246242.0,
585,54474,6,2,,103619997,37542,Unspecified,,,,,Tested for its anti-polio activity against Coxsackie B virus type-3,Other,11992785.0,
586,54477,3,3,,103619997,37542,Unspecified,,,,,Selectivity index as the ratio of CC50/EC50 against Coxsackie B virus type-3,Other,11992785.0,
587,54500,7,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce Coxsackie virus type B4 induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
588,54505,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells coxsackie virus type 4,Other,6737436.0,
589,54506,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%,Other,3820218.0,
590,54507,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells coxsackie virus type B4,Other,6737436.0,
591,63604,6,3,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts,Other,11858989.0,
592,63609,6,3,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast,Other,11858989.0,
593,63758,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells,Other,7932543.0,
594,63759,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain),Other,7932543.0,
595,63760,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain),Other,7932543.0,
596,63761,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain),Other,7932543.0,
597,63762,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain),Other,7932543.0,
598,63763,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain),Other,7932543.0,
599,63764,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain),Other,7932543.0,
600,63765,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain),Other,7932543.0,
601,63766,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus,Other,7932543.0,
602,63767,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus,Other,7932543.0,
603,63768,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells for morphological alteration,Other,7932543.0,
604,63914,6,2,,103619997,37542,Unspecified,,,320.0,EC50,Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
605,63915,6,2,,103619997,37542,Active,,,0.005,EC50,Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
606,63916,6,2,,103619997,37542,Unspecified,,,320.0,EC50,Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
607,63917,6,2,,103619997,37542,Unspecified,,,65.0,EC50,Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
608,63918,6,2,,103619997,37542,Active,,,40.0,EC50,Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
609,63919,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to elicit microscopically visible cell morphology in E6SM cell lines,Other,11495586.0,
610,63939,6,2,,103619997,37542,Unspecified,,,960.0,EC50,concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells,Confirmatory,9748360.0,
611,63940,6,2,,103619997,37542,Unspecified,,,128.0,EC50,concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells,Confirmatory,9748360.0,
612,63941,6,2,,103619997,37542,Unspecified,,,960.0,EC50,concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells,Confirmatory,9748360.0,
613,63942,6,2,,103619997,37542,Unspecified,,,192.0,EC50,concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells,Confirmatory,9748360.0,
614,63943,6,2,,103619997,37542,Unspecified,,,192.0,EC50,concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells,Confirmatory,9748360.0,
615,63945,6,2,,103619997,37542,Unspecified,,,,,Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
616,63947,6,3,,103619997,37542,Unspecified,,,,,Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM),Other,11858989.0,
617,63948,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells,Other,8411010.0,
618,64115,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in E6SM cells,Other,9748360.0,
619,64116,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitor concentration against vesicular stomatitis virus (VSV) in E6SM cells,Other,8411010.0,
620,64118,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells,Other,8411010.0,
621,64120,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells,Other,8411010.0,
622,65705,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology,Other,11472207.0,
623,65707,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cell cultures,Other,11472207.0,
624,65708,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures,Other,11472207.0,
625,65709,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures,Other,11472207.0,
626,65710,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures,Other,11472207.0,
627,65711,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures,Other,11472207.0,
628,65712,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures,Other,11472207.0,
629,65844,6,2,,103619997,37542,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells,Other,8709116.0,
630,65996,5,3,,103619997,37542,Unspecified,,,,,Cytotoxicity (to alter cell morphology) against E6SM cell cultures,Other,,
631,66001,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
632,66002,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
633,66003,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
634,66004,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
635,66005,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
636,66006,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
637,66007,6,2,,103619997,37542,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
638,66009,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-B2006 in E6SM cell cultures,Other,,
639,66010,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-VMW1837 in E6SM cell cultures,Other,,
640,66011,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1(KOS) in E6SM cell cultures,Other,,
641,66012,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-2 (G) in E6SM cell cultures,Other,,
642,66013,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vaccinia virus in E6SM cell cultures,Other,,
643,66014,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in E6SM cell cultures,Other,,
644,66939,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells,Other,1326633.0,
645,66940,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells,Other,1326633.0,
646,66941,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells,Other,1326633.0,
647,66942,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells,Other,1326633.0,
648,66943,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells,Other,1326633.0,
649,68118,6,2,,103619997,37542,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration of normal ESM cell morphology.,Other,1319491.0,
650,68119,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(B2006) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
651,68120,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(VMW 1837) induced cytopathogenicity in by 50% ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
652,68121,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
653,68122,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-2(G) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
654,68123,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
655,68124,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
656,68125,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line,Other,8246242.0,
657,68126,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line,Other,8246242.0,
658,68127,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line,Other,8246242.0,
659,68128,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line,Other,8246242.0,
660,68129,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on DNA virus VV in ESM cell line,Other,8246242.0,
661,68130,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell morphology in ESM cell line,Other,8246242.0,
662,68252,6,3,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
663,68253,6,3,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
664,68254,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
665,68255,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
666,68256,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
667,68257,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM),Other,8176708.0,
668,69823,6,2,,103619997,37542,Unspecified,,,,,Tested for the antimicrobial activity minimum inhibitory concentration) against Escherichia coli,Other,11858989.0,
669,70209,6,2,,103619997,37542,Unspecified,,,1024.6,EC50,Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells,Confirmatory,12729645.0,
670,71777,6,2,,103619997,37542,Active,,,8.3,EC50,Concentration that reduces Friend murine leukemia virus titer by 50%,Confirmatory,1992143.0,
671,71890,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell growth in FM3A cell line,Other,8246242.0,
672,81374,6,3,,103619997,37542,Active,,,45.0,IC50,Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.,Confirmatory,,
673,81760,3,4,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
674,81761,3,4,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against parainfluenza type 3 (para 3) type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
675,81802,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against (HIV-1) in MT-4 cells Value in parentheses is inhibitory concentration for cell growth (MT-4),Other,1335077.0,
676,81897,3,4,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against vaccinia(VV) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
677,82034,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV-1 virus infected HEF cell lines.,Other,8765514.0,
678,82035,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV-2 virus infected HEF cell lines.,Other,8765514.0,
679,82037,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against TK-HSV-1 virus infected HEF cell lines.,Other,8765514.0,
680,82039,6,2,,103619997,37542,Unspecified,,,,,Effects on cell morphology of HEF cell lines.,Other,8765514.0,
681,82041,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vaccinia virus infected HEF cell lines.,Other,8765514.0,
682,82043,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus infected HEF cell lines.,Other,8765514.0,
683,82045,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HEF cell line,Other,8071937.0,
684,82047,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-1 virus,Other,8071937.0,
685,82048,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-2 virus,Other,8071937.0,
686,82050,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with thymidine kinase-deficient herpes simplex virus type 1 (TK-HSV-1),Other,8071937.0,
687,82051,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vaccinia virus,Other,8071937.0,
688,82052,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vesicular stomatitis virus,Other,8071937.0,
689,82315,8,1,,103619997,37542,Unspecified,,,67.0,ID50,Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (HL-60),Confirmatory,2296029.0,
690,83887,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cells,Other,6737436.0,
691,83889,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.,Other,6699874.0,
692,84084,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
693,84217,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
694,84218,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
695,84228,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
696,84402,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
697,84599,8,1,,103619997,37542,Unspecified,,,190.0,ED50,"In vitro antiviral activity was tested against, herpes simplex type 2 virus (HSV-2)",Confirmatory,2995666.0,
698,84611,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%,Other,3820218.0,
699,84957,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cells,Other,6737436.0,
700,84959,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.,Other,6699874.0,
701,85112,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
702,85120,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
703,85127,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
704,85279,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
705,85570,7,2,,103619997,37542,Unspecified,,,,,"Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%",Other,3820218.0,
706,85704,3,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and HSV-1 virus control cells,Other,6092634.0,
707,86111,8,3,,103619997,37542,Inconclusive,,,,,Compound was tested for its effect on the proliferation of HT-29 human colon adenocarcinoma; Not determined,Other,,
708,86349,5,3,,103619997,37542,Unspecified,,,,,Cytotoxicity (to alter cell morphology) against HeLa cells,Other,,
709,86354,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus B4 in HeLa cells,Other,,
710,86355,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Polio virus-I in HeLa cells,Other,,
711,86356,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in HeLa cells,Other,,
712,86357,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of Polio-1 virus induced cytopathicity in HeLa cells,Other,9135038.0,
713,86482,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of coxsackie B4 virus induced cytopathicity in HeLa cells,Other,9135038.0,
714,86483,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of morphology virus induced cytopathicity in HeLa cells,Other,9135038.0,
715,86484,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in HeLa cells,Other,9135038.0,
716,86492,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against coxsackie-B4 virus in human epithelial cell line,Other,11858989.0,
717,86500,6,2,,103619997,37542,Unspecified,,,,,The compound was tested for antiviral activity against VSV-virus in human epithelial cells,Other,11858989.0,
718,86511,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HeLa cell line,Other,8071937.0,
719,86512,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with RSV virus,Other,8071937.0,
720,86513,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with polio 1 virus,Other,8071937.0,
721,86523,7,1,,103619997,37542,Unspecified,,,,,Minimum toxic concentration required to cause a microscopically detectable alteration of normal HeLa cell morphology,Other,7658442.0,
722,86682,6,2,,103619997,37542,Unspecified,,,320.0,EC50,Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines,Confirmatory,11495586.0,
723,86683,6,2,,103619997,37542,Active,,,1.5,EC50,Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines,Confirmatory,11495586.0,
724,86684,6,2,,103619997,37542,Unspecified,,,1000.0,EC50,Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines,Confirmatory,11495586.0,
725,86687,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HeLa cell lines,Other,11495586.0,
726,86688,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie B4 virus infected HeLa cell lines.,Other,8765514.0,
727,86799,6,2,,103619997,37542,Unspecified,,,,,Effects on cell morphology of HeLa cell lines.,Other,8765514.0,
728,86801,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against polio 1 virus infected HeLa cell lines.,Other,8765514.0,
729,86803,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus infected HeLa cell lines.,Other,8765514.0,
730,86834,6,2,,103619997,37542,Unspecified,,,320.0,EC50,concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells,Confirmatory,9748360.0,
731,86836,6,2,,103619997,37542,Unspecified,,,192.0,EC50,concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells,Confirmatory,9748360.0,
732,87033,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 1-3 uM determined in a culture of Herpes simplex virus type 2; IA = inactive,Other,2542559.0,
733,87045,3,3,,103619997,37542,Unspecified,,,,,Virus rating of against herpes simplex virus type 2,Other,2539476.0,
734,87131,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Coxsackie virus B4 in HeLa cells.,Other,3950905.0,
735,87132,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Polio virus-1 in HeLa cells.,Other,3950905.0,
736,87134,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Vesicular stomatitis virus in HeLa cells.,Other,3950905.0,
737,87137,7,2,,103619997,37542,Unspecified,,,,,Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
738,87139,6,2,,103619997,37542,Unspecified,,,,,Concentration required for microscopically detectable alteration of the normal cell morphology in HeLa cells.,Other,3950905.0,
739,87141,7,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration in HeLa cell cultures,Other,2754698.0,
740,87142,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in HeLa cells,Other,2540332.0,
741,87143,7,2,,103619997,37542,Unspecified,,,,,"Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with HeLa cells",Other,3585910.0,
742,87144,6,2,,103619997,37542,Unspecified,,,,,Tested for cytotoxic activity in human epithelial cell line (HeLa),Other,11858989.0,
743,87146,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
744,87147,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
745,87148,7,2,,103619997,37542,Unspecified,,,,,Compound was evaluated for antiviral activity against respiratory syncitial virus (long) in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
746,87149,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
747,87153,7,2,,103619997,37542,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against HeLa cells (human carcinoma) infected with VSV, Coxs, B4, polio-1 virus",Other,2158560.0,
748,87154,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Coxsackie virus B4 in HeLa cell cultures,Other,2754698.0,
749,87155,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Vesicular stomatitis virus in HeLa cell cultures,Other,2754698.0,
750,87156,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against polio virus 1 in HeLa cell cultures,Other,2754698.0,
751,87157,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells,Other,1326633.0,
752,87158,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against polio 1 virus in HeLa cells,Other,1326633.0,
753,87160,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells,Other,1326633.0,
754,87161,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in HeLa cells,Other,2540332.0,
755,87162,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce polio virus -1 induced cytopathogenicity by 50% in HeLa cells,Other,2540332.0,
756,87163,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cells,Other,2540332.0,
757,87164,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in HeLa cells,Other,9748360.0,
758,87165,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in HeLa cells,Other,3585910.0,
759,87166,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Polio virus-1 in HeLa cells,Other,3585910.0,
760,87192,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Herpes simplex virus 1(KOS),Other,2552118.0,
761,87281,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in HeLa cells,Other,3585910.0,
762,87304,6,2,,103619997,37542,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures.,Other,6699874.0,
763,87320,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Herpes simplex virus 2(G),Other,2552118.0,
764,87339,5,1,,103619997,37542,Unspecified,,,,,"Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1), cytopathic effect induced by the virus (CPE)",Other,2989521.0,
765,87351,5,1,,103619997,37542,Unspecified,,,,,"Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1)",Other,2989521.0,
766,87502,6,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus type 1 (strain KOS) in primary rabbit kidney cell culture,Other,3027326.0,
767,87672,8,1,,103619997,37542,Unspecified,,,1900000.0,ED50,In vitro antiviral activity was tested against herpes simplex type 2 (HSV-2),Confirmatory,2993613.0,
768,87798,6,1,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells,Other,3820218.0,
769,87822,6,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus type 2 (strain G) in primary rabbit kidney cell culture,Other,3027326.0,
770,88195,6,2,,103619997,37542,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells,Other,8709116.0,
771,88196,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against HeLa cells,Other,14505657.0,
772,88275,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
773,88277,7,2,,103619997,37542,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against KOS, F, McIntyre strains of Herpes simplex virus (HSV-1) in primary rabbit kidney cells",Other,2158560.0,
774,88278,7,2,,103619997,37542,Unspecified,,,,,Evaluated for minimum inhibitory concentration against TK-B2006 strain of Herpes simplex virus (HSV-1) in primary rabbit kidney cells,Other,2158560.0,
775,88279,3,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against herpes simplex virus/1(HSV/1) expressed as viral rating (VR),Other,6276541.0,
776,88296,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce HSV-2 (G) induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
777,88297,7,2,,103619997,37542,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against G,196, Lyons strains of Herpes simplex virus (HSV-2) in primary rabbit kidney cells",Other,2158560.0,
778,88349,6,2,,103619997,37542,Unspecified,,,,,Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells,Other,14505657.0,
779,88350,6,2,,103619997,37542,Unspecified,,,,,Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells,Other,14505657.0,
780,88351,6,2,,103619997,37542,Unspecified,,,,,Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells,Other,14505657.0,
781,88523,6,2,,103619997,37542,Active,,,11.4,IC50,Inhibitory concentration against respiratory syncytial virus in HeLa cells,Confirmatory,7658442.0,
782,88685,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line,Other,8246242.0,
783,88686,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus RSV in HeLa cell line,Other,8246242.0,
784,88687,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus VSV in HeLa cell line,Other,8246242.0,
785,88688,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line,Other,8246242.0,
786,89114,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration in primary rabbit kidney cell cultures,Other,2754698.0,
787,90600,5,3,,103619997,37542,Unspecified,,,,,Effective dose required for plaque reduction in human cytomegalovirus (HCMV) was determined,Other,,
788,92309,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 10-30 uM determined in a culture of Influenza A; IA = inactive,Other,2542559.0,
789,92317,5,3,,103619997,37542,Unspecified,,,,,"Effective dose required to reduce virus induced cytopathogenicity by Influenza A(H1N1,Fu 88) was determined",Other,,
790,92339,5,3,,103619997,37542,Unspecified,,,,,Effective dose required to reduce virus induced cytopathogenicity by Influenza B(Fu 207) was determined,Other,,
791,92340,5,3,,103619997,37542,Unspecified,,,,,Effective dose required to reduce virus induced cytopathogenicity by Influenza B(singapore) was determined,Other,,
792,92451,3,3,,103619997,37542,Unspecified,,,,,Virus rating is measurement of degree of inhibition of virus-induced cytopathogenic effects and the degree of cytotoxicity produced by the test compound for influenza type A2,Other,3033247.0,
793,92456,5,1,,103619997,37542,Unspecified,,,,,Inhibitory dose of compound required to inhibit cytopathogenic effects of influenza virus with A2/Aichi/2/68 strain in MDCK cells,Other,3411597.0,
794,92457,3,3,,103619997,37542,Unspecified,,,,,Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against influenza virus with A2/Aichi/2/68 strain in MDCK cell,Other,3411597.0,
795,94049,6,2,,103619997,37542,Unspecified,,,,,Tested for the antimicrobial activity minimum inhibitory concentration) against Klebsiella pneumoniae,Other,11858989.0,
796,94737,8,1,,103619997,37542,Active,,,36.0,ID50,Evaluated for cell growth inhibition and induction of cellular differentiation of Murine leukemia cell line (L-1210),Confirmatory,2296029.0,
797,94762,5,1,,103619997,37542,Unspecified,,,,,Inhibitory dose of compound required to inhibit cytopathogenic effects of Japanese encephalitis virus with najayama strain in vero cells,Other,3411597.0,
798,94763,3,3,,103619997,37542,Unspecified,,,,,Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Japanese encephalitis virus with najayama strain in vero cell,Other,3411597.0,
799,94995,8,1,,103619997,37542,Unspecified,,,50.0,ID50,Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (K562),Confirmatory,2296029.0,
800,96660,5,1,,103619997,37542,Unspecified,,,,,Dose required to inhibit proliferation of L-1210 Cells by 50%,Other,6699874.0,
801,98395,6,3,,103619997,37542,Active,,,16.6,IC50,Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.,Confirmatory,,
802,98936,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell growth in L1210 cell line,Other,8246242.0,
803,99572,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against COXB1 virus in human laryngeal epithelioma cell line,Other,7328597.0,
804,99696,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against HSV-1 virus in human laryngeal epithelioma cell line,Other,7328597.0,
805,99700,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Para 3 virus in human laryngeal epithelioma cell line,Other,7328597.0,
806,99706,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against V V virus in human laryngeal epithelioma cell line,Other,7328597.0,
807,99707,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against VSV virus in human laryngeal epithelioma cell line,Other,7328597.0,
808,105204,6,3,,103619997,37542,Active,,,23.0,IC50,Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.,Confirmatory,,
809,105300,6,3,,103619997,37542,Active,,,5.7,IC50,Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.,Confirmatory,,
810,105621,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for cytotoxicity by MTT assay in MDCK cells,Other,,
811,105627,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells,Other,,
812,105628,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells,Other,,
813,105629,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells,Other,,
814,105630,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells,Other,,
815,105631,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells,Other,,
816,105632,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells,Other,,
817,105633,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells,Other,,
818,105634,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells,Other,,
819,105635,6,3,,103619997,37542,Unspecified,,,,,The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells,Other,,
820,105769,6,2,,103619997,37542,Active,,,4.9,IC50,Inhibitory concentration against influenza virus A in MDCK cells,Confirmatory,7658442.0,
821,105770,6,2,,103619997,37542,Active,,,16.3,IC50,Inhibitory concentration against influenza virus B in MDCK cells,Confirmatory,7658442.0,
822,105775,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line,Other,8246242.0,
823,105776,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line,Other,8246242.0,
824,105777,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line,Other,8246242.0,
825,105787,6,2,,103619997,37542,Unspecified,,,,,"Antiviral activity tested against influenza A,H1N1 virus infected MDCK cell lines.",Other,8765514.0,
826,105788,6,2,,103619997,37542,Unspecified,,,,,"Antiviral activity against influenza A,H2N2 virus infected MDCK cell lines.",Other,8765514.0,
827,105790,6,2,,103619997,37542,Unspecified,,,,,"Antiviral activity against influenza A,H3N2 virus infected MDCK cell lines.",Other,8765514.0,
828,105792,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza B virus infected MDCK cell lines.,Other,8765514.0,
829,105793,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity of compound was tested against morphology virus infec+ted MDCK cell lines.,Other,8765514.0,
830,105799,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on MDCK cell line,Other,8071937.0,
831,105800,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza A virus,Other,8071937.0,
832,105801,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza B virus,Other,8071937.0,
833,105806,7,1,,103619997,37542,Unspecified,,,,,Minimum toxic concentration required to cause a microscopically detectable alteration of normal MDCK cell morphology,Other,7658442.0,
834,105946,6,2,,103619997,37542,Active,,,3.7,EC50,Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells,Confirmatory,12729645.0,
835,105958,7,2,,103619997,37542,Unspecified,,,,,Compound was evaluated in MDCK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
836,105959,7,1,,103619997,37542,Unspecified,,,,,"Minimum cytotoxic concentration required to cause a microscopically detectable alteration of MDCK, Madin-Darby canine kidney cell morphology.",Other,12729645.0,
837,105960,7,1,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in madin-Darby canine kidney cells (MDCK),Other,11514155.0,
838,105963,7,1,,103619997,37542,Active,,,31.1,MIC50,Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H2N2 strain (A2 Japan/305/57),Confirmatory,10617092.0,
839,105964,7,1,,103619997,37542,Active,,,41.0,MIC50,Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H3N2 (X31),Confirmatory,10617092.0,
840,105965,7,1,,103619997,37542,Active,,,41.0,MIC50,Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza B (Hong Kong/5/72),Confirmatory,10617092.0,
841,105967,7,1,,103619997,37542,Unspecified,,,614.8,MIC50,Minimum inhibitory concentration required to reduce influenza A H2N2 virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK),Confirmatory,11514155.0,
842,105968,7,1,,103619997,37542,Unspecified,,,122.9,MIC50,Minimum inhibitory concentration required to reduce influenza A H3N2 (X31) virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK),Confirmatory,11514155.0,
843,105973,7,1,,103619997,37542,Unspecified,,,,,Concentration required to reduce the viability of MDCK cells,Other,10617092.0,
844,105976,5,1,,103619997,37542,Unspecified,,,,,In vitro minimum drug concentration that inhibited the influenza virus-induced cytopathogenic effects by 50% in Madin-Darby canine kidney (MDCK) host cell cultures,Other,2157013.0,
845,105977,5,1,,103619997,37542,Unspecified,,,,,Minimum concentration (ug/mL) for in vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures,Other,2157013.0,
846,105978,3,5,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures (MTC/ID50),Other,2157013.0,
847,105979,3,5,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures,Other,2157013.0,
848,106223,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line,Other,8246242.0,
849,106224,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line,Other,8246242.0,
850,106225,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line,Other,8246242.0,
851,108456,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50%,Other,3820218.0,
852,108459,8,1,,103619997,37542,Active,,,30.0,ED50,"In vitro antiviral activity was tested against, measles virus",Confirmatory,2995666.0,
853,108463,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity against measles virus in vero cells,Other,6737436.0,
854,108464,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
855,114980,3,3,,103619997,37542,Unspecified,,,,,The maximum tolerated dose was evaluated in mice (mg/kg of body weight).,Other,2993613.0,
856,142441,6,2,,103619997,37542,Unspecified,,,52.0,IC50,Cytotoxicity was evaluated,Confirmatory,1992143.0,
857,155439,8,1,,103619997,37542,Unspecified,,,160.0,ED50,"In vitro antiviral activity was tested against, parainfluenza type 3 (Para 3) virus",Confirmatory,2995666.0,
858,155582,8,1,,103619997,37542,Unspecified,,,1600000.0,ED50,In vitro antiviral activity was tested against parainfluenza type 3 (para3),Confirmatory,2993613.0,
859,155586,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%,Other,3820218.0,
860,155587,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 10-30 uM determined in a culture of Parainfluenza virus type 3; IA = inactive,Other,2542559.0,
861,155590,5,1,,103619997,37542,Unspecified,,,,,Inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line,Other,2544721.0,
862,155591,3,3,,103619997,37542,Unspecified,,,,,Viral rating activity against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line,Other,2544721.0,
863,155592,3,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Parainfluenza type 3 virus control cells.,Other,6092634.0,
864,155596,3,3,,103619997,37542,Unspecified,,,,,Virus rating against parainfluenza virus type 3,Other,2539476.0,
865,155597,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
866,155599,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells parainfluenza virus type 3,Other,6737436.0,
867,156079,8,4,,103619997,37542,Inconclusive,,,,,Inhibitory activity against purine nucleoside phosphorylase (PNPase); E means not determined,Other,3123692.0,
868,156687,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Herpes simplex virus (HSV-1 KOS) in rabbit kidney cells.,Other,3950905.0,
869,156688,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Herpes simplex virus (HSV-2 G) in rabbit kidney cells.,Other,3950905.0,
870,156689,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Vaccinia virus in rabbit kidney cells.,Other,3950905.0,
871,156690,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Vesicular stomatitis virus in rabbit kidney cells.,Other,3950905.0,
872,156693,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration in primary rabbit kidney (PRK) cell cultures,Other,2552118.0,
873,156694,7,2,,103619997,37542,Unspecified,,,,,Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
874,156696,6,2,,103619997,37542,Unspecified,,,,,Concentration required for microscopically detectable alteration of the normal cell morphology in PRK cells.,Other,3950905.0,
875,156699,7,2,,103619997,37542,Unspecified,,,,,"Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with PRK cells",Other,3585910.0,
876,156702,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
877,156703,7,2,,103619997,37542,Unspecified,,,,,Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
878,156704,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1 (McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
879,156705,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
880,156706,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
881,156707,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
882,156708,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
883,156709,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
884,156710,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
885,156843,6,3,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-1 (KOS)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK),Other,2540332.0,
886,156845,6,3,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-2 (G)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK),Other,2540332.0,
887,156849,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK),Other,2540332.0,
888,156851,6,3,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK),Other,2540332.0,
889,161449,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in primary rabbit kidney (PRK) cells,Other,2540332.0,
890,162241,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce polio virus type I induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
891,162251,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%,Other,3820218.0,
892,162252,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells polio virus type 1,Other,6737436.0,
893,164600,5,1,,103619997,37542,Unspecified,,,,,Inhibitory dose of compound required to inhibit cytopathogenic effects of Punta toro virus with adames strain in vero cells,Other,3411597.0,
894,164602,3,3,,103619997,37542,Unspecified,,,,,Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Punta toro virus with adames strain in vero cell,Other,3411597.0,
895,166201,6,3,,103619997,37542,Unspecified,,,56.0,IC50,Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.,Confirmatory,,
896,166671,6,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity in primary rabbit kidney cell culture,Other,3027326.0,
897,167151,6,1,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells,Other,3820218.0,
898,167327,6,2,,103619997,37542,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures.,Other,6699874.0,
899,197658,6,2,,103619997,37542,Active,,,32.1,EC50,Concentration that reduces Rauscher murine leukemia virus titer by 50%,Confirmatory,1992143.0,
900,198426,3,3,,103619997,37542,Unspecified,,,,,"Percent increase in survival rate of Rift Valley fever virus infected mice on day 21, by administering 100 (mg/kg)/day of compound",Other,7328597.0,
901,198431,8,1,,103619997,37542,Unspecified,,,1100000.0,ED50,In vitro antiviral activity was tested against rift valley fever virus(RVF),Confirmatory,2993613.0,
902,198433,3,3,,103619997,37542,Unspecified,,,,,Therapeutic index against Rift valley fever virus.,Other,2993613.0,
903,199168,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%,Other,3820218.0,
904,199174,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce reovirus type I induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
905,199175,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells reovirus type 1,Other,6737436.0,
906,199875,3,3,,103619997,37542,Unspecified,,,,,Virus rating against rhinovirus type 1A,Other,2539476.0,
907,200185,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 100 uM determined in a culture of Rhinovirus type 1-A; IA = inactive,Other,2542559.0,
908,204956,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%,Other,3820218.0,
909,204960,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells sindbis virus,Other,6737436.0,
910,204964,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
911,206521,6,2,,103619997,37542,Unspecified,,,,,Tested for the antimicrobial activity minimum inhibitory concentration) against Staphylococcus hominis,Other,11858989.0,
912,216100,8,1,,103619997,37542,Active,,,42.0,ID50,Evaluated for cell growth inhibition and induction of cellular differentiation of human B-lymphoblast cell line (WI-L2),Confirmatory,2296029.0,
913,216127,6,3,,103619997,37542,Unspecified,,,100.0,IC50,Compound was tested for its effect on the proliferation of WIL-2-NS cell line.,Confirmatory,,
914,216177,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line,Other,8246242.0,
915,216178,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus JV in Vero cell line,Other,8246242.0,
916,216179,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus PV-3 in Vero cell line,Other,8246242.0,
917,216180,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line,Other,8246242.0,
918,216181,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus SFV in Vero cell line,Other,8246242.0,
919,216182,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus SV in Vero cell line,Other,8246242.0,
920,216183,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus TV in Vero cell line,Other,8246242.0,
921,216184,6,2,,103619997,37542,Unspecified,,,,,Tested for inhibitory effect on RNA virus cell morphology in Vero cell line,Other,8246242.0,
922,216197,6,3,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration (to alter cell morphology) against vero cells,Other,,
923,216199,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against parainfluenza virus in african green monkey kidney cell (Vero),Other,11858989.0,
924,216200,6,2,,103619997,37542,Unspecified,,,,,Tested for cytotoxic activity in African green monkey kidney cells (Vero),Other,11858989.0,
925,216203,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus in vero cells,Other,,
926,216204,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Parainfluenza-3 virus in vero cells,Other,,
927,216205,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Reovirus-1 in vero cells,Other,,
928,216206,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against forest virus in vero cells,Other,,
929,216207,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Sindbis virus in vero cells,Other,,
930,216229,6,2,,103619997,37542,Unspecified,,,,,Tested for its anti-polio activity against Vesicular stomatitis virus,Other,11992785.0,
931,216230,3,3,,103619997,37542,Unspecified,,,,,Selectivity index as the ratio of CC50/EC50 against Vesicular stomatitis virus,Other,11992785.0,
932,216346,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against Punta toro virus in African green monkey kidney cell (Vero),Other,11858989.0,
933,216347,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against Reo-1 virus in African green monkey kidney cell (Vero),Other,11858989.0,
934,216348,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against Sindbis virus in African green monkey kidney cell (Vero),Other,11858989.0,
935,216349,6,2,,103619997,37542,Unspecified,,,,,Tested for antiviral activity against coxsackie B-4 virus in African green monkey kidney cell (Vero),Other,11858989.0,
936,216362,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie B4 virus infected vero cell lines.,Other,8765514.0,
937,216364,6,2,,103619997,37542,Unspecified,,,,,Effects on cell morphology of Vero cell lines.,Other,8765514.0,
938,216366,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against parainfluenza 3 virus infected Vero cell lines.,Other,8765514.0,
939,216368,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reo 1 virus infected vero cell lines.,Other,8765514.0,
940,216370,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against sindbis virus infected Vero cell lines.,Other,8765514.0,
941,216372,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Semliki forest virus infected Vero cell lines.,Other,8765514.0,
942,216381,3,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vesicular stomatitis virus control cells,Other,6092634.0,
943,216386,5,1,,103619997,37542,Unspecified,,,,,"Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV), cytopathic effect induced by the virus (CPE)",Other,2989521.0,
944,216392,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Vesicular stomatitis virus,Other,2552118.0,
945,216396,5,1,,103619997,37542,Unspecified,,,,,"Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV)",Other,2989521.0,
946,216403,5,3,,103619997,37542,Unspecified,,,,,Effective dose required for plaque reduction in vesicular stomatitis virus (VSV) was determined,Other,,
947,216406,6,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against vesion stomatitis virus in primary rabbit kidney cell culture,Other,3027326.0,
948,216407,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells vesicular stomatitis virus (VSV),Other,6737436.0,
949,216409,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cells,Other,6737436.0,
950,216410,7,2,,103619997,37542,Unspecified,,,,,Evaluated for minimum inhibitory concentration against Vesicular stomatitis virus (VSV) in primary rabbit kidney cells,Other,2158560.0,
951,216436,6,2,,103619997,37542,Unspecified,,,,,Concentration required for microscopically detectable alteration of the normal cell morphology in Wi-38 cells.,Other,3950905.0,
952,216502,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on vero cell line,Other,8071937.0,
953,216503,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with Reo 1 virus,Other,8071937.0,
954,216504,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with coxsackie B4 virus,Other,8071937.0,
955,216505,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with parainfluenza 3 virus,Other,8071937.0,
956,216507,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with semliki forest virus,Other,8071937.0,
957,216508,6,2,,103619997,37542,Unspecified,,,,,Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with sindbis virus,Other,8071937.0,
958,216522,7,1,,103619997,37542,Unspecified,,,,,Minimum toxic concentration required to cause a microscopically detectable alteration of normal vero cell morphology,Other,7658442.0,
959,216538,7,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce VSV induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
960,216714,5,2,,103619997,37542,Inactive,,,,,Antiviral activity at 1-3 uM determined in a culture of Visna virus; IA = inactive,Other,2542559.0,
961,216823,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against COXB1 virus in (vero) V cells,Other,7328597.0,
962,216939,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against HSV-1 virus in (vero) V cells of african green monkey kidney,Other,7328597.0,
963,216942,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Para 3 virus in (vero) V cells of african green monkey kidney,Other,7328597.0,
964,216945,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against V V virus in (vero) V cells of african green monkey kidney,Other,7328597.0,
965,216947,3,4,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against VSV virus in (vero) V cells,Other,7328597.0,
966,216969,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of Parainfluenza-3 virus induced cytopathicity in Vero cells,Other,9135038.0,
967,216970,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of Reo-1 virus induced cytopathicity in Vero cells,Other,9135038.0,
968,216971,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of forest virus induced cytopathicity in Vero cells,Other,9135038.0,
969,216972,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of Sindbis virus induced cytopathicity in Vero cells,Other,9135038.0,
970,216973,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of alteration of morphology in Vero cells,Other,9135038.0,
971,216979,3,5,,103619997,37542,Unspecified,,,,,"Percentage plaque reduction was determined against Sandfly fever (SF) virus in african green monkey kidney (vero,V) at a conc of 25-100 ug/mL. Toxic level(>1000 ug/mL); 61-90",Other,7143371.0,
972,217099,3,5,,103619997,37542,Unspecified,,,,,"Percentage plaque reduction was determined against pichinde(PICH) virus in african green monkey kidney (vero,V). Toxic level(>1000 ug/mL); 61-90",Other,7143371.0,
973,217102,3,5,,103619997,37542,Unspecified,,,,,"Percentage plaque reduction was determined against rift valley fever(RVF) virus in african green monkey kidney (vero,V) at a conc of 100-250 ug/mL. Toxic level(>1000 ug/mL); 31-60",Other,7143371.0,
974,217114,3,5,,103619997,37542,Unspecified,,,,,"Percentage plaque reduction was determined against venezuelan equine encephalitis (VEE) virus in african green monkey kidney (vero,V) at a conc of 250-500 ug/mL. Toxic level(>1000 ug/mL); 10-30",Other,7143371.0,
975,217118,3,5,,103619997,37542,Unspecified,,,,,"Percentage plaque reduction was determined against yellow fever(YF) virus in african green monkey kidney (vero,V).Toxic level(>1000 ug/mL); 61-90",Other,7143371.0,
976,217250,3,5,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
977,217254,3,5,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against parainfluenza type 3(para 3) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
978,217262,3,5,,103619997,37542,Unspecified,,,,,"In vitro antiviral activity against vaccinia(VV) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)",Other,7143371.0,
979,217264,6,2,,103619997,37542,Active,,,40.0,EC50,Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines,Confirmatory,11495586.0,
980,217267,6,2,,103619997,37542,Unspecified,,,196.0,EC50,Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines,Confirmatory,11495586.0,
981,217268,6,2,,103619997,37542,Active,,,40.0,EC50,Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines,Confirmatory,11495586.0,
982,217269,6,2,,103619997,37542,Unspecified,,,1600.0,EC50,Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines,Confirmatory,11495586.0,
983,217270,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to elicit microscopically visible cell morphology in Vero cell lines,Other,11495586.0,
984,217478,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%,Other,3820218.0,
985,217479,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%,Other,3820218.0,
986,217560,6,2,,103619997,37542,Unspecified,,,1600.0,EC50,concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells,Confirmatory,9748360.0,
987,217561,6,2,,103619997,37542,Unspecified,,,64.0,EC50,concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells,Confirmatory,9748360.0,
988,217562,6,2,,103619997,37542,Unspecified,,,64.0,EC50,concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells,Confirmatory,9748360.0,
989,217563,6,2,,103619997,37542,Unspecified,,,64.0,EC50,concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells,Confirmatory,9748360.0,
990,217564,6,2,,103619997,37542,Unspecified,,,64.0,EC50,concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells,Confirmatory,9748360.0,
991,217585,8,1,,103619997,37542,Unspecified,,,160.0,ED50,In vitro antiviral activity against Parainfluenza type 3 was evaluated.,Confirmatory,4020823.0,
992,217586,8,1,,103619997,37542,Unspecified,,,190.0,ED50,In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.,Confirmatory,3950908.0,
993,217587,8,1,,103619997,37542,Unspecified,,,190.0,ED50,In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.,Confirmatory,4020823.0,
994,217588,8,1,,103619997,37542,Unspecified,,,99.0,ED50,In vitro antiviral activity against measles virus in Vero cells,Confirmatory,3950908.0,
995,217589,8,1,,103619997,37542,Active,,,33.0,ED50,In vitro antiviral activity against measles virus was evaluated.,Confirmatory,4020823.0,
996,217590,8,1,,103619997,37542,Unspecified,,,160.0,ED50,In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.,Confirmatory,3950908.0,
997,217591,8,1,,103619997,37542,Unspecified,,,90.0,ED50,In vitro antiviral activity against vaccinia virus in Vero cells.,Confirmatory,3950908.0,
998,217592,8,1,,103619997,37542,Unspecified,,,85.0,ED50,In vitro antiviral activity against vaccinia virus was evaluated.,Confirmatory,4020823.0,
999,217824,8,1,,103619997,37542,Unspecified,,,85.0,ED50,"In vitro antiviral activity was tested against, vaccinia virus (VV)",Confirmatory,2995666.0,
1000,217836,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%,Other,3820218.0,
1001,217867,8,1,,103619997,37542,Unspecified,,,2500000.0,ED50,In vitro antiviral activity was tested against venezuelan equine encephalomyelitis (VEE),Confirmatory,2993613.0,
1002,217870,3,3,,103619997,37542,Unspecified,,,,,Therapeutic index against Venezuelan equine encephalomyelitis virus.,Other,2993613.0,
1003,217884,7,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration in Vero cell cultures,Other,2754698.0,
1004,217890,7,2,,103619997,37542,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against Vero cells (African green monkey) infected with PV-3, RV-1, SV, Coxs B4, SFV virus",Other,2158560.0,
1005,217892,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Coxsackie virus B4 in Vero cell cultures,Other,2754698.0,
1006,217893,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against forest virus in Vero cell cultures,Other,2754698.0,
1007,217894,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Sindbis virus in Vero cell cultures,Other,2754698.0,
1008,217895,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against parainfluenza 3 virus in Vero cell cultures,Other,2754698.0,
1009,217896,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against reovirus in Vero cell cultures,Other,2754698.0,
1010,217899,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells,Other,1326633.0,
1011,217902,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against parainfluenza 3 virus in Vero cells,Other,1326633.0,
1012,217903,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells,Other,1326633.0,
1013,217904,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells,Other,1326633.0,
1014,217905,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells,Other,1326633.0,
1015,217906,8,1,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in Vero cells,Other,9748360.0,
1016,217967,3,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vaccinia virus control cells,Other,6092634.0,
1017,217989,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration against vaccinia virus embryonic skin muscle cell cultures,Other,2552118.0,
1018,217990,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration against vaccinia virus in HeLa cell cultures,Other,2552118.0,
1019,217991,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration against vaccinia virus in Vero cell cultures,Other,2552118.0,
1020,217993,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration against vaccinia virus in primary rabbit kidney cell cultures,Other,2552118.0,
1021,217994,6,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell culture,Other,3027326.0,
1022,217996,6,2,,103619997,37542,Unspecified,,,,,Compound was tested for antiviral activity against vaccinia virus in primary rabbit kidney cells,Other,6737436.0,
1023,217998,7,2,,103619997,37542,Unspecified,,,,,Evaluated for minimum inhibitory concentration against Vaccinia virus (VV) in primary rabbit kidney cells,Other,2158560.0,
1024,218002,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus embryonic skin muscle cell cultures,Other,2552118.0,
1025,218004,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 1,Other,2552118.0,
1026,218005,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 2,Other,2552118.0,
1027,218006,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 1,Other,2552118.0,
1028,218007,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2,Other,2552118.0,
1029,218029,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Coxsackie virus B4 in african green monkey kidney (Vero B) cells.,Other,3950905.0,
1030,218030,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Parainfluenza virus-3 in african green monkey kidney (Vero B) cells.,Other,3950905.0,
1031,218031,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Reo virus-1 in african green monkey kidney (Vero B) cells.,Other,3950905.0,
1032,218032,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against forest virus in african green monkey kidney (Vero B) cells.,Other,3950905.0,
1033,218033,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Sindbis virus in african green monkey kidney (Vero B) cells.,Other,3950905.0,
1034,218035,6,2,,103619997,37542,Unspecified,,,,,Concentration required for microscopically detectable alteration of the normal cell morphology in Vero B cells.,Other,3950905.0,
1035,218036,7,2,,103619997,37542,Unspecified,,,,,"Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with Vero B cells",Other,3585910.0,
1036,218044,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in African green monkey kidney (Vero B)cells,Other,3585910.0,
1037,218062,3,4,,103619997,37542,Unspecified,,,,,Maximum tolerated concentration against Vero cells.,Other,3950908.0,
1038,218063,3,4,,103619997,37542,Unspecified,,,,,Maximum tolerated concentration (MTC) was evaluated in vero cells.,Other,2993613.0,
1039,218065,6,1,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells,Other,3820218.0,
1040,218072,5,2,,103619997,37542,Unspecified,,,,,Toxicity level was reported; none,Other,4020823.0,
1041,218127,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2,Other,2552118.0,
1042,218128,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Vaccinia virus,Other,2552118.0,
1043,218131,6,2,,103619997,37542,Unspecified,,,,,The minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity in primary rabbit kidney cells by 50%,Other,6438321.0,
1044,218166,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Parainfluenza virus-3 in African green monkey kidney (Vero B)cells,Other,3585910.0,
1045,218167,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Reo virus-1 in African green monkey kidney (Vero B)cells,Other,3585910.0,
1046,218169,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against forest virus in African green monkey kidney (Vero B)cells,Other,3585910.0,
1047,218170,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Sindbis virus in African green monkey kidney (Vero B)cells,Other,3585910.0,
1048,218249,7,2,,103619997,37542,Unspecified,,,,,Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
1049,218251,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
1050,218252,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against forest virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
1051,218253,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against Sindbis virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
1052,218254,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
1053,218369,6,2,,103619997,37542,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells,Other,8709116.0,
1054,218376,7,2,,103619997,37542,Unspecified,,,,,Evaluation for antiviral activity against reo virus-1 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
1055,218401,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in african green monkey (VeroB) cells,Other,2540332.0,
1056,218402,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells,Other,2540332.0,
1057,218404,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce parainfluenza virus-3 induced cytopathogenicity by 50% in african green monkey (VeroB) cells,Other,2540332.0,
1058,218405,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce reovirus-1 induced cytopathogenicity by 50% in african green monkey (VeroB)cells,Other,2540332.0,
1059,218406,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration required to reduce semliki forest virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells,Other,2540332.0,
1060,218430,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Rhino virus-1A in human diploid (WI-38) cells.,Other,3950905.0,
1061,218431,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity was measured against Rhino virus-9 in human diploid (WI-38) cells.,Other,3950905.0,
1062,218432,7,2,,103619997,37542,Unspecified,,,,,"Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with WI-38 cells",Other,3585910.0,
1063,218433,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus 9 in human diploid (WI-38)cells,Other,3585910.0,
1064,218434,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus-1A in human diploid (WI-38)cells,Other,3585910.0,
1065,218448,3,4,,103619997,37542,Unspecified,,,,,Percent purine accumulated in human B lymphoblast WI-L2 cells cultured medium was determined,Other,3123692.0,
1066,218449,3,4,,103619997,37542,Unspecified,,,,,Percent purine synthesized in human B lymphoblast WI-L2 cells was determined,Other,3123692.0,
1067,218532,6,2,,103619997,37542,Unspecified,,,286.8,IC50,Inhibitory concentration against parainfluenza-3 virus in vero cells,Confirmatory,7658442.0,
1068,220033,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackie B4 in Vero cell culture lines,Other,1335077.0,
1069,220034,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in HeLa cell culture lines,Other,1335077.0,
1070,220035,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures.,Other,6699874.0,
1071,220038,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures.,Other,6699874.0,
1072,221963,3,3,,103619997,37542,Unspecified,,,,,Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IFN-gamma,Other,10715165.0,
1073,221964,3,3,,103619997,37542,Unspecified,,,,,Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IL-2.,Other,10715165.0,
1074,221965,3,3,,103619997,37542,Unspecified,,,,,Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine TNF-alpha,Other,10715165.0,
1075,223404,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against the influenza Ao/PR/8/34 virus strain,Other,3035178.0,
1076,223406,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity is expressed as virus rating (VR) against the influenza Ao/PR/8/34 virus strain,Other,3035178.0,
1077,223410,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza virus A strain H7N7 (FPV) was determined as zone of cytotoxicity,Other,,
1078,223411,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza virus A strain H7N7 (FPV) was determined as zone of plaque inhibition,Other,,
1079,223413,3,4,,103619997,37542,Unspecified,,,,,Antiviral effect against influenza virus A strain H7N7 (FPV) by the difference between zone of plaque inhibition and zone of cytotoxicity; (11-12 mm),Other,,
1080,223415,7,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce influenza virus A (ishikawa) induced cytopathogenicity by 50%,Other,1324318.0,
1081,223416,7,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce influenza virus B (singapore) induced cytopathogenicity by 50%,Other,1324318.0,
1082,223836,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against pseudorabies virus strain Anjeszky A2 was determined as zone of cytotoxicity,Other,,
1083,223837,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against pseudorabies virus strain Anjeszky A2 was determined as zone of plaque inhibition,Other,,
1084,223839,2,4,,103619997,37542,Unspecified,,,,,Antiviral effect against pseudorabies virus strain Anjeszky A2 by the difference between zone of plaque inhibition and zone of cytotoxicity; (21-40 mm),Other,,
1085,224344,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against G strain of Herpes simplex virus-2 in primary rabbit kidney cells,Other,3585910.0,
1086,224345,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against KOS strain of Herpes simplex virus-1 in primary rabbit kidney cells,Other,3585910.0,
1087,224346,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vaccinia virus in primary rabbit kidney cells,Other,3585910.0,
1088,224347,7,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in primary rabbit kidney cells,Other,3585910.0,
1089,224916,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines,Other,1335077.0,
1090,224918,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures.,Other,6699874.0,
1091,225768,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against polio virus type 1 in HeLa cell culture lines,Other,1335077.0,
1092,225769,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures.,Other,6699874.0,
1093,225877,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against newcastle disease virus strain Russeff (NDV) was determined as zone of cytotoxicity,Other,,
1094,225878,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against newcastle disease virus strain Russeff (NDV) was determined as zone of plaque inhibition,Other,,
1095,225881,2,4,,103619997,37542,Unspecified,,,,,Antiviral effect against newcastle disease virus strain Russeff (NDV) by the difference between zone of plaque inhibition and zone of cytotoxicity; (21-40 mm),Other,,
1096,226098,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Herpes simplex virus 1(KOS) in primary rabbit kidney cell cultures,Other,2754698.0,
1097,226099,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Herpes simplex virus 2 (G) in primary rabbit kidney cell cultures,Other,2754698.0,
1098,226100,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Vaccinia virus in primary rabbit kidney cell cultures,Other,2754698.0,
1099,226101,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against Vesicular stomatitis virus in primary rabbit kidney cell cultures,Other,2754698.0,
1100,226341,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against sindbis virus in Vero cell culture lines,Other,1335077.0,
1101,226343,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures.,Other,6699874.0,
1102,228408,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against reovirus type 1 in Vero cell culture lines,Other,1335077.0,
1103,228410,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures.,Other,6699874.0,
1104,228733,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation.,Other,9046339.0,
1105,228856,8,1,,103619997,37542,Unspecified,,,9000000.0,ED50,In vitro antiviral activity was tested against vaccinia virus(VV),Confirmatory,2993613.0,
1106,228985,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines,Other,1335077.0,
1107,229022,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.,Other,6699874.0,
1108,229024,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
1109,229026,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
1110,229059,6,2,,103619997,37542,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures.,Other,6699874.0,
1111,229230,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures.,Other,6699874.0,
1112,229232,6,2,,103619997,37542,Unspecified,,,,,Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.,Other,6699874.0,
1113,229234,6,2,,103619997,37542,Unspecified,,,,,"Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines,",Other,1335077.0,
1114,229235,6,2,,103619997,37542,Unspecified,,,,,Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
1115,229236,6,3,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines,Other,1335077.0,
1116,231386,3,3,,103619997,37542,Unspecified,,,,,Adenylate to guanylate ratio for the cell fraction was determined,Other,3123692.0,
1117,232057,4,4,,103619997,37542,Unspecified,,,,,Selectivity index ratio of CC50 / EC50 was determined,Other,,
1118,232125,3,3,,103619997,37542,Unspecified,,,,,Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 14 ug/mL,Other,3035178.0,
1119,232130,3,3,,103619997,37542,Unspecified,,,,,Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 54 ug/mL,Other,3035178.0,
1120,232803,5,2,,103619997,37542,Inactive,,,,,Toxic level was evaluated; None,Other,6092634.0,
1121,235487,3,4,,103619997,37542,Unspecified,,,,,Selectivity index is the ratio of IC50 to EC50 of F-MuLV.,Other,1992143.0,
1122,235603,3,3,,103619997,37542,Unspecified,,,,,Ratio of minimum drug concentration to ID50 of the compound(Adems strain),Other,3411597.0,
1123,235606,3,3,,103619997,37542,Unspecified,,,,,Ratio of minimum drug concentration to ID50 of the compound (Najayama strain),Other,3411597.0,
1124,235800,3,4,,103619997,37542,Unspecified,,,,,Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.,Other,1992143.0,
1125,235813,3,3,,103619997,37542,Unspecified,,,,,Selectivity ratio of MCC50 to that of EC50 of influenza A H2N2(A2 japan/305/57),Other,12729645.0,
1126,235890,3,3,,103619997,37542,Unspecified,,,,,Ratio of minimum toxic compound concentration to inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line,Other,2544721.0,
1127,244630,4,4,,103619997,37542,Unspecified,,,,,Selectivity index (TC50/IC50) against Coxsackie virus B3 in Vero cells,Other,15603937.0,
1128,244765,6,2,,103619997,37542,Unspecified,,,,,Minimum cytotoxicity concentration to HeLa cell line was determined,Other,15745816.0,
1129,246174,6,2,,103619997,37542,Active,,,1.5,EC50,Anti BVDV activity in MDBK (Madin-darby bovine kidney) cells,Confirmatory,15456271.0,
1130,246507,6,2,,103619997,37542,Unspecified,,,100.0,EC50,Effective concentrations at which 2-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7),Confirmatory,16033283.0,
1131,246794,7,1,,103619997,37542,Unspecified,,,,,Effective concentrations at which 10-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7I,Other,16033283.0,
1132,247999,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells,Other,15603937.0,
1133,249185,6,1,,103619997,37542,Unspecified,,,,,Cytotoxic concentration required to inhibit Vero cell growth by 50%,Other,15603937.0,
1134,249261,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against coxsackie virus B4 was determined,Other,15745816.0,
1135,249265,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against vesicular stomatitis virus was determined,Other,15745816.0,
1136,249268,6,2,,103619997,37542,Unspecified,,,,,Minimum inhibitory concentration against respiratory syncytial virus was determined,Other,15745816.0,
1137,249868,7,1,,103619997,37542,Active,,,,,Anti BVDV activity relative to ribavirin,Other,15456271.0,
1138,249870,7,1,,103619997,37542,Active,,,,,Anti-bovine viral diarrhoea virus activity relative to ribavirin,Other,15456271.0,
1139,253328,6,2,,103619997,37542,Unspecified,,,71.0,CC50,Cytotoxic concentration against HCV replication in AVA5 cell culture,Confirmatory,16033283.0,
1140,253329,6,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity in MDBK (Madin-darby bovine kidney) cells,Confirmatory,15456271.0,
1141,253419,4,3,,103619997,37542,Unspecified,,,,,Ratio of cytotoxicity to anti BVDV activity of the compound,Other,15456271.0,
1142,257339,3,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV in Huh7 ETcell line at 10 uM assessed by measuring HCV-RNA-derived LUC activity relative to control,Other,16213713.0,
1143,257340,3,4,,103619997,37542,Unspecified,,,,,Cytotoxicity against Huh7ET cell line containg HCV replicon at 10 uM assessed by measuring the beta-actin RNA level relative to control,Other,16213713.0,
1144,257341,3,4,,103619997,37542,Unspecified,,,,,Selectivity index (toxicity/antiviral activity),Other,16213713.0,
1145,257471,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A H3N2 virus in MDCK cells,Other,16183283.0,
1146,257472,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity in MDCK cells infected with influenza A H3N2 virus,Other,16183283.0,
1147,257886,7,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HEL cells,Other,16420056.0,
1148,257887,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vero cells,Other,16420056.0,
1149,257888,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HeLa cells,Other,16420056.0,
1150,257889,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells,Other,16420056.0,
1151,257890,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G strain in HEL cells,Other,16420056.0,
1152,257891,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in HEL cells,Other,16420056.0,
1153,257892,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in HEL cells,Other,16420056.0,
1154,257893,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells,Other,16420056.0,
1155,257894,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza-3 virus in vero cells,Other,16420056.0,
1156,257895,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 in vero cells,Other,16420056.0,
1157,257896,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus in vero cells,Other,16420056.0,
1158,257897,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in vero cells,Other,16420056.0,
1159,257898,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus in vero cells,Other,16420056.0,
1160,257899,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus in HeLa cells,Other,16420056.0,
1161,257900,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells,Other,16420056.0,
1162,257901,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in HeLa cells,Other,16420056.0,
1163,261046,3,3,,103619997,37542,Unspecified,,,,,"Efficacy in cotton rat measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, ip",Other,16368233.0,
1164,261060,3,3,,103619997,37542,Unspecified,,,,,"Efficacy in BALB/c mouse measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, sc",Other,16368233.0,
1165,261583,6,2,,103619997,37542,Active,,,18.0,EC50,Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line,Confirmatory,16539402.0,
1166,261586,6,2,,103619997,37542,Active,,,30.0,EC50,Inhibition of Rluc-FL-WNV replicon in Vero cells,Confirmatory,16539402.0,
1167,261589,6,2,,103619997,37542,Active,,,1.1,EC50,Inhibition of West Nile virus VLP replicon in BHK21 cell line,Confirmatory,16539402.0,
1168,261590,6,2,,103619997,37542,Unspecified,,,119.0,EC50,Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells,Confirmatory,16539402.0,
1169,264705,3,3,,103619997,37542,Unspecified,,,,,Antiviral activity against TMV,Other,16504509.0,
1170,273211,3,4,,103619997,37542,Unspecified,,,,,Viability of human HeLa S3 cells,Other,17034123.0,
1171,273212,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against poliovirus in HeLa S3 cells assessed as reduction in viral titer,Other,17034123.0,
1172,273213,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackievirus B3 in HeLa S3 cells assessed as reduction in viral titer,Other,17034123.0,
1173,275067,6,4,,103619997,37542,Unspecified,,,300.0,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
1174,275068,6,2,,103619997,37542,Unspecified,,,500.0,EC50,Antiviral activity against HSV2 in HEL cells,Confirmatory,17181162.0,
1175,275069,6,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against vaccinia virus in HEL cells,Confirmatory,17181162.0,
1176,275070,6,2,,103619997,37542,Unspecified,,,500.0,EC50,Antiviral activity against vesicular somatitis virus in HEL cells,Confirmatory,17181162.0,
1177,275071,6,2,,103619997,37542,Unspecified,,,500.0,EC50,Antiviral activity against Coxsackie B4 virus in HeLa cells,Confirmatory,17181162.0,
1178,275072,6,2,,103619997,37542,Active,,,12.0,EC50,Antiviral activity against RSV in HeLa cells,Confirmatory,17181162.0,
1179,275073,6,2,,103619997,37542,Unspecified,,,300.0,EC50,Antiviral activity against para influenza 3 virus in Vero cells,Confirmatory,17181162.0,
1180,275074,6,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against reovirus 1 in Vero cells,Confirmatory,17181162.0,
1181,275075,6,2,,103619997,37542,Unspecified,,,500.0,EC50,Antiviral activity against Sindbis virus in Vero cells,Confirmatory,17181162.0,
1182,275076,6,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Punta Toro virus in Vero cells,Confirmatory,17181162.0,
1183,275086,6,4,,103619997,37542,Unspecified,,,500.0,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
1184,275087,6,3,,103619997,37542,Unspecified,,,500.0,CC50,Cytotoxicity against HEL cells,Confirmatory,17181162.0,
1185,275088,6,2,,103619997,37542,Unspecified,,,500.0,CC50,Cytotoxicity against HeLa cells,Confirmatory,17181162.0,
1186,275089,6,2,,103619997,37542,Unspecified,,,500.0,CC50,Cytotoxicity against Vero cells,Confirmatory,17181162.0,
1187,277830,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV,Other,17286431.0,
1188,277831,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV,Other,17286431.0,
1189,277832,8,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against HeLa cells,Other,17286431.0,
1190,277835,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against CV B4,Other,17286431.0,
1191,278037,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV A2 in MA104 cells by CPE assay,Other,17315968.0,
1192,278038,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV A2 in MA104 cells by plaque reduction assay,Other,17315968.0,
1193,278348,3,4,,103619997,37542,Unspecified,,,,,Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 2 ug/ml after 3 days,Other,17060520.0,
1194,278349,3,4,,103619997,37542,Unspecified,,,,,Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 40 ug/ml after 3 days,Other,17060520.0,
1195,278350,4,3,,103619997,37542,Unspecified,,,,,Inhibition of viral RNA levels in HTNV76-118-infected Vero E6 cells at 0.5 ug/ml,Other,17060520.0,
1196,278352,3,4,,103619997,37542,Unspecified,,,,,Decrease in GTP level in Vero E6 cells at 10 ug/ml,Other,17060520.0,
1197,278358,7,1,,103619997,37542,Unspecified,,,,,RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 10 ug/ml after 24 h,Other,17060520.0,
1198,278362,7,1,,103619997,37542,Unspecified,,,,,RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 40 ug/ml after 24 h,Other,17060520.0,
1199,278368,7,1,,103619997,37542,Unspecified,,,,,RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 10 ug/ml after 24 h,Other,17060520.0,
1200,278372,7,1,,103619997,37542,Unspecified,,,,,RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 40 ug/ml after 24 h,Other,17060520.0,
1201,278378,3,4,,103619997,37542,Active,,,,,Decrease in GTP level in Vero E6 cells at 40 ug/ml after 4 h,Other,17060520.0,
1202,278379,3,4,,103619997,37542,Unspecified,,,,,Decrease in GTP level in Vero E6 cells at 40 ug/ml after 24 h,Other,17060520.0,
1203,280192,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1204,280193,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1205,280194,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1206,280195,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1207,280196,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1208,280197,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1209,280198,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1210,280199,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1211,280200,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1212,280203,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against E6SM cells assessed as alteration in cell morphology,Other,17298047.0,
1213,280204,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against HeLa cells assessed as alteration in cell morphology,Other,17298047.0,
1214,280205,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against Vero cells assessed as alteration in cell morphology,Other,17298047.0,
1215,283440,6,4,,103619997,37542,Active,,,43.0,EC50,Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay,Confirmatory,17194832.0,
1216,283441,7,1,,103619997,37542,Active,,,,,Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay,Other,17194832.0,
1217,283442,6,4,,103619997,37542,Active,,,38.1,EC50,Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay,Confirmatory,17194832.0,
1218,283443,7,1,,103619997,37542,Active,,,,,Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay,Other,17194832.0,
1219,283444,6,2,,103619997,37542,Active,,,14.3,EC50,Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay,Confirmatory,17194832.0,
1220,283445,7,1,,103619997,37542,Active,,,,,Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay,Other,17194832.0,
1221,283446,6,2,,103619997,37542,Active,,,35.7,EC50,Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay,Confirmatory,17194832.0,
1222,283447,7,1,,103619997,37542,Active,,,,,Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay,Other,17194832.0,
1223,283448,6,2,,103619997,37542,Unspecified,,,2336.0,CC50,Cytotoxicity against MDCK cells,Confirmatory,17194832.0,
1224,283987,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,17046264.0,
1225,283988,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against encephalomyocarditis virus by CPE assay,Other,17046264.0,
1226,283989,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackie B virus type 3 by CPE assay,Other,17046264.0,
1227,283990,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus by CPE assay,Other,17046264.0,
1228,284525,8,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1229,284527,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1230,284529,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1231,284531,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1232,284533,8,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1233,284535,8,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against E6SM cells,Other,17092728.0,
1234,284537,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells,Other,17092728.0,
1235,284538,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells,Other,17092728.0,
1236,284539,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells,Other,17092728.0,
1237,284540,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells,Other,17092728.0,
1238,288915,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against E6SM cells assessed as alteration in cell morphology,Other,17518459.0,
1239,288916,6,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1240,288917,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1241,288918,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1242,288919,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1243,288920,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1244,288929,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in HeLa cells,Other,17518459.0,
1245,288930,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells,Other,17518459.0,
1246,288931,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus in HeLa cells,Other,17518459.0,
1247,288932,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus1 in vero cells,Other,17518459.0,
1248,288933,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus in vero cells,Other,17518459.0,
1249,290451,6,2,,103619997,37542,Unspecified,,,82.0,IC50,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,Confirmatory,17336519.0,
1250,290452,6,2,,103619997,37542,Unspecified,,,850.0,CC50,Cytotoxicity against Vero E6 cells,Confirmatory,17336519.0,
1251,290453,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for Vero E6 cells to IC50 for SARS-CoV Frankfurt1",Other,17336519.0,
1252,291033,6,2,,103619997,37542,Unspecified,,,150.0,EC50,Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
1253,291034,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
1254,291035,6,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
1255,291036,6,2,,103619997,37542,Unspecified,,,150.0,EC50,Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
1256,291037,6,2,,103619997,37542,Unspecified,,,150.0,EC50,Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
1257,294253,3,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV in Huh7 ET cells assessed as HCV RNA derived luciferase activity at 10 uM by replicon assay relative to control,Other,17300935.0,
1258,294254,3,4,,103619997,37542,Unspecified,,,,,Cytotoxicity against Huh7 ET cells assessed as beta actin level relative to control,Other,17300935.0,
1259,294255,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of toxicity against Huh7 ET cells to viral activity against HCV",Other,17300935.0,
1260,297312,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1261,297313,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza 3 virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1262,297314,8,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1263,297315,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1264,297316,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1265,297317,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1266,297318,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1267,297319,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1268,297320,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1269,297321,8,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1270,300558,6,2,,103619997,37542,Active,,,5.85,IC50,Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1271,300559,6,2,,103619997,37542,Active,,,5.04,IC50,Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1272,300560,6,2,,103619997,37542,Unspecified,,,176.0,IC50,Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1273,300561,6,2,,103619997,37542,Active,,,7.01,IC50,Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1274,300562,6,2,,103619997,37542,Unspecified,,,96.2,IC50,Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1275,300563,6,2,,103619997,37542,Active,,,15.2,IC50,Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay,Confirmatory,17611105.0,
1276,300564,6,2,,103619997,37542,Unspecified,,,164.0,IC50,Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay,Confirmatory,17611105.0,
1277,300569,3,3,,103619997,37542,Active,,,,,"Survival of mouse at 100 mg/kg, ip bid after 5 days",Other,17611105.0,
1278,300574,3,3,,103619997,37542,Unspecified,,,,,"Weight change in mouse at 100 mg/kg, ip bid after 14 days",Other,17611105.0,
1279,300579,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as survival of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days",Other,17611105.0,
1280,300584,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as mean survival time of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days",Other,17611105.0,
1281,301325,6,2,,103619997,37542,Unspecified,,,54.8,EC50,Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay,Confirmatory,17766124.0,
1282,301326,6,3,,103619997,37542,Unspecified,,,200.0,CC50,Cytotoxicity against Huh7 cells by XTT assay,Confirmatory,17766124.0,
1283,301327,3,3,,103619997,37542,Unspecified,,,,,"Antiviral index, ratio of CC50 for Huh7 cells to EC50 for HCV replication",Other,17766124.0,
1284,301691,3,9,,103619997,37542,Unspecified,20141702.0,191.0,,,Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM,Other,17845853.0,
1285,301692,3,3,,103619997,37542,Unspecified,,,,,Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM,Other,17845853.0,
1286,301693,3,9,,103619997,37542,Unspecified,20141702.0,191.0,,,Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM,Other,17845853.0,
1287,301694,3,4,,103619997,37542,Unspecified,,,,,Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM,Other,17845853.0,
1288,301695,7,1,,103619997,37542,Unspecified,20141702.0,191.0,,,Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence,Other,17845853.0,
1289,301696,7,1,,103619997,37542,Unspecified,,,,,Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence,Other,17845853.0,
1290,301697,7,1,,103619997,37542,Unspecified,20141702.0,191.0,,,Binding to human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109,Other,17845853.0,
1291,301698,7,1,,103619997,37542,Unspecified,,,,,Binding to Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109,Other,17845853.0,
1292,301699,9,1,,103619997,37542,Unspecified,20141702.0,191.0,,,Inhibition of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109,Other,17845853.0,
1293,301700,7,1,,103619997,37542,Unspecified,20141702.0,191.0,,,Ratio of kinact for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form to KI for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+,Other,17845853.0,
1294,301701,9,1,,103619997,37542,Unspecified,,,,,Inhibition of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form expressed in Escherichia coli JM109,Other,17845853.0,
1295,301702,7,1,,103619997,37542,Unspecified,,,,,Ratio of kinact for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form to KI for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form,Other,17845853.0,
1296,303221,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days,Other,17948980.0,
1297,303228,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1298,303229,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1299,303230,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1300,303231,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1301,303232,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1302,303233,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
1303,303234,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
1304,303235,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
1305,303236,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
1306,303237,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days,Other,17948980.0,
1307,303238,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days,Other,17948980.0,
1308,307142,5,9,,103619997,37542,Unspecified,6840802.0,132.0,,,Specific activity of human adenosine kinase,Other,17379518.0,
1309,308657,6,2,,103619997,37542,Active,,,8.68,EC50,Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay,Confirmatory,17588747.0,
1310,308658,7,2,,103619997,37542,Active,,,,,Cytotoxicity against MDCK cells assessed as changes in cell morphology,Other,17588747.0,
1311,308659,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of EC50 for influenza A/Hong Kong/7/87 (H3N2) to MCC for MDCK cells",Other,17588747.0,
1312,311338,6,2,,103619997,37542,Unspecified,,,2989.6,IC50,Antiviral activity against Tobacco mosaic virus U1 after 72 hrs by half leaf method,Confirmatory,17822295.0,
1313,311524,4,3,,103619997,37542,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1314,312072,8,1,,103619997,37542,Unspecified,,,,,Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-C primer relative to control,Other,18067241.0,
1315,312073,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 0.5 mM relative to control,Other,18067241.0,
1316,312074,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 2 mM,Other,18067241.0,
1317,320044,8,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect,Other,18160286.0,
1318,320045,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against dog MDCK cells,Other,18160286.0,
1319,320046,8,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect,Other,18160286.0,
1320,324792,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as mean day to death after 21 days post-infection at 50 mg/kg, ip bid for 7 days",Other,17420215.0,
1321,324798,7,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as serum alanine aminotransferase at 50 mg/kg, ip bid for 7 days",Other,17420215.0,
1322,324804,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as weight change at 50 mg/kg, po bid for 7 days",Other,17420215.0,
1323,324822,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as mean day to death at 50 mg/kg/day, ip bid for 8 days",Other,17420215.0,
1324,324823,7,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as alanine aminotransferase at 50 mg/kg/day, ip bid for 8 days",Other,17420215.0,
1325,324824,7,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as weight change at 50 mg/kg/day, ip bid for 8 days",Other,17420215.0,
1326,334376,2,4,,103619997,37542,Active,,,,,Antiviral activity against mouse coronavirus at 10 ug,Other,,
1327,336178,3,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Potato virus X in half leaf of Chenopodium quinoa at 9.3 mg/mL after 10 days,Other,12398535.0,
1328,345881,6,2,,103619997,37542,Active,,,28.7,EC50,Antiviral activity against HCV in human HuH5.2 cells assessed as inhibition of replicon replication,Confirmatory,19170598.0,
1329,345882,6,3,,103619997,37542,Unspecified,,,86.0,CC50,Cytotoxicity against human HuH5.2 cells,Confirmatory,19170598.0,
1330,345883,6,2,,103619997,37542,Unspecified,,,84.0,EC50,Antiviral activity against HCV in human Huh9.13 cells assessed as inhibition of replicon replication,Confirmatory,19170598.0,
1331,345884,6,3,,103619997,37542,Unspecified,,,229.0,CC50,Cytotoxicity against human Huh-9-13 cells,Confirmatory,19170598.0,
1332,345885,6,2,,103619997,37542,Active,,,33.0,EC50,Antiviral activity against HCV in human HuH6 cells assessed as inhibition of replicon replication,Confirmatory,19170598.0,
1333,345886,6,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against human HuH6 cells,Confirmatory,19170598.0,
1334,354679,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against respiratory syncytial virus assessed as effect on virus-induced cytopathic effect,Other,8792629.0,
1335,357949,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect,Other,11678648.0,
1336,357950,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human Hep2 cells,Other,11678648.0,
1337,357951,3,3,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3",Other,11678648.0,
1338,360157,6,2,,103619997,37542,Unspecified,,,58.0,IC50,Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay,Confirmatory,17556358.0,
1339,360158,6,2,,103619997,37542,Active,,,37.0,IC50,Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay,Confirmatory,17556358.0,
1340,360159,6,2,,103619997,37542,Active,,,32.0,IC50,Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay,Confirmatory,17556358.0,
1341,360162,6,2,,103619997,37542,Active,,,39.0,IC50,Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay,Confirmatory,17556358.0,
1342,360164,3,4,,103619997,37542,Unspecified,,,,,Ratio of IC50 for HCV 1b with NS3-4 R155K mutation to IC50 for wild type HCV 1b,Other,17556358.0,
1343,360165,3,4,,103619997,37542,Unspecified,,,,,Ratio of IC50 for HCV 1b with NS3-4A R155T mutation to IC50 for wild type HCV 1b,Other,17556358.0,
1344,360168,3,4,,103619997,37542,Unspecified,,,,,Ratio of IC50 for HCV 1b with NS3-4A R155G mutation to IC50 for wild type HCV 1b,Other,17556358.0,
1345,361406,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells after 2 days by MTT assay,Other,12444692.0,
1346,361407,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B3 Nancy infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay,Other,12444692.0,
1347,361408,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Encephalomyocarditis virus EMC infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay,Other,12444692.0,
1348,361409,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis Indiana virus infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay,Other,12444692.0,
1349,366287,6,2,,103619997,37542,Unspecified,,,512.0,CC50,Cytotoxicity against MDCK cells by MTT assay,Confirmatory,18640042.0,
1350,366288,6,2,,103619997,37542,Active,,,25.62,IC50,Antiviral activity against Influenza A virus Jinan/15/90 H3N2 assessed as reduction of virus-induced cytopathic effect,Confirmatory,18640042.0,
1351,366289,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 to MDCK cells to IC50 to Influenza A Jinan/15/90 H3N2 virus",Other,18640042.0,
1352,366290,7,1,,103619997,37542,Inconclusive,,,,,Cytotoxicity against MDCK cells assessed as maximal non-cytotoxic concentration by MTT assay,Other,18640042.0,
1353,368957,6,2,,103619997,37542,Active,,,11.5,EC50,Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay,Confirmatory,17576833.0,
1354,368958,6,2,,103619997,37542,Active,,,25.3,EC50,Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA,Confirmatory,17576833.0,
1355,368959,6,2,,103619997,37542,Active,,,13.3,EC50,Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay,Confirmatory,17576833.0,
1356,368960,6,2,,103619997,37542,Active,,,16.8,EC50,Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay,Confirmatory,17576833.0,
1357,368961,6,2,,103619997,37542,Active,,,19.0,EC50,Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay,Confirmatory,17576833.0,
1358,368962,6,2,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay,Confirmatory,17576833.0,
1359,368963,6,3,,103619997,37542,Inconclusive,,,,CC50,Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay,Confirmatory,17576833.0,
1360,368964,3,3,,103619997,37542,Inconclusive,,,,,"Therapeutic index, CC50 for human Hep2 cells to EC50 for RSV RSS",Other,17576833.0,
1361,368975,6,2,,103619997,37542,Active,,,20.7,EC50,Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay,Confirmatory,17576833.0,
1362,368976,6,2,,103619997,37542,Active,,,17.6,EC50,Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay,Confirmatory,17576833.0,
1363,368977,3,4,,103619997,37542,Unspecified,,,,,"Drug resistance, ratio of EC50 for plaque picked RSV604-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS",Other,17576833.0,
1364,368978,6,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay,Confirmatory,17576833.0,
1365,369127,3,4,,103619997,37542,Inconclusive,,,,,"Drug resistance, ratio of EC50 for plaque picked A-33903-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS",Other,17576833.0,
1366,369461,6,2,,103619997,37542,Unspecified,,,70.0,EC50,Antiviral activity against La Crosse virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days,Confirmatory,17606691.0,
1367,369462,6,2,,103619997,37542,Unspecified,,,172.0,EC50,Antiviral activity against Punta Toro virus Adames assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days,Confirmatory,17606691.0,
1368,369463,6,2,,103619997,37542,Unspecified,,,53.0,EC50,Antiviral activity against Rift Valley fever virus MP-12 assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days,Confirmatory,17606691.0,
1369,369464,6,2,,103619997,37542,Unspecified,,,90.0,EC50,Antiviral activity against Sandfly fever Naples virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days,Confirmatory,17606691.0,
1370,369465,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for La Crosse virus",Other,17606691.0,
1371,369466,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Punta Toro virus Adames",Other,17606691.0,
1372,369467,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Rift Valley fever virus MP-12",Other,17606691.0,
1373,369468,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Sandfly fever Naples virus",Other,17606691.0,
1374,369861,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1375,369862,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as protection against viral infection at 75 mg/kg, po twice daily for 5 to 7 days",Other,17606691.0,
1376,369867,7,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1377,369869,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1378,369870,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1379,369871,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days 24 hrs post viral challenge",Other,17606691.0,
1380,370198,6,1,,103619997,37542,Unspecified,,,,,Toxicity in po dosed C57BL/6 mouse administered twice daily for 5 days administered 4 hrs before viral challenge,Other,17606691.0,
1381,370199,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1382,370200,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1383,370201,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1384,370202,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1385,370203,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1386,370204,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1387,370205,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1388,370206,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1389,370207,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1390,370208,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1391,370209,3,3,,103619997,37542,Active,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1392,370211,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1393,370212,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1394,370213,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1395,370214,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1396,370215,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1397,370216,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1398,370217,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1399,370218,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1400,370219,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1401,370220,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1402,370221,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1403,370222,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1404,370223,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1405,370225,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge",Other,17606691.0,
1406,370227,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge",Other,17606691.0,
1407,370230,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1408,370233,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1409,371497,6,3,,103619997,37542,Unspecified,,,54.0,CC50,Cytotoxicity against MDBK cells after 3 days by MTS/PMS assay,Confirmatory,18063227.0,
1410,371498,6,2,,103619997,37542,Active,,,4.62,EC50,Antiviral activity against bovine viral diarrhoea virus type-1 NADL in MDBK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,18063227.0,
1411,371503,3,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDBK cells to EC50 for bovine viral diarrhoea virus type-1 NADL",Other,18063227.0,
1412,376980,9,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay,Other,16724853.0,
1413,376981,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect,Other,16724853.0,
1414,376982,3,3,,103619997,37542,Unspecified,,,,,"Selectivity index, CC50 for human Hep2 cells to IC50 for RSV Long",Other,16724853.0,
1415,376983,9,1,,103619997,37542,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay,Other,16724853.0,
1416,376984,7,2,,103619997,37542,Inconclusive,,,,,Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect,Other,16724853.0,
1417,376985,3,4,,103619997,37542,Inconclusive,,,,,"Selectivity index, CC50 for african green monkey Vero cells to IC50 for HSV1 15577",Other,16724853.0,
1418,376986,9,1,,103619997,37542,Inconclusive,,,,,Cytotoxicity against MDCK cells after 3 days by MTT reduction assay,Other,16724853.0,
1419,376987,7,2,,103619997,37542,Inconclusive,,,,,Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect,Other,16724853.0,
1420,376988,3,4,,103619997,37542,Inconclusive,,,,,"Selectivity index, CC50 for MDCK cells to IC50 for influenza A virus H1N1 A/NWS/33",Other,16724853.0,
1421,376989,7,2,,103619997,37542,Inconclusive,,,,,Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect,Other,16724853.0,
1422,376990,3,3,,103619997,37542,Inconclusive,,,,,"Selectivity index, CC50 for human Hep2 cells to IC50 for Cox B3 virus",Other,16724853.0,
1423,383506,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,17583388.0,
1424,383507,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
1425,383508,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
1426,383509,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against respiratory syncytial virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
1427,383510,8,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human E6SM cells,Other,17583388.0,
1428,383511,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology,Other,17583388.0,
1429,383512,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1430,383513,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1431,383514,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1432,383515,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1433,383516,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1434,383517,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1435,383518,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1436,383519,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1437,383520,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1438,383521,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1439,383522,5,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells,Other,17583388.0,
1440,383523,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1441,383524,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1442,383530,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza 3 virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1443,383531,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reo virus 1 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1444,383532,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1445,384286,3,9,,103619997,37542,Inactive,74825913.0,,,,Binding affinity to Plasmodium falciparum spermidine synthase by saturation transfer difference-NMR experiment,Other,18410081.0,
1446,387575,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
1447,387576,6,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay,Confirmatory,18778942.0,
1448,387582,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
1449,387602,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
1450,387854,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
1451,392501,6,2,,103619997,37542,Unspecified,,,100.0,IC50,Antiviral activity against Human adenovirus 2,Confirmatory,19112024.0,
1452,392503,6,2,,103619997,37542,Unspecified,,,215.0,IC50,Antiviral activity against Camelpox virus,Confirmatory,19112024.0,
1453,392504,6,2,,103619997,37542,Unspecified,,,410.0,IC50,Antiviral activity against Cowpox virus,Confirmatory,19112024.0,
1454,392525,6,2,,103619997,37542,Active,,,19.0,IC50,Antiviral activity against influenza B virus,Confirmatory,19112024.0,
1455,392527,6,2,,103619997,37542,Active,,,7.7,IC50,Antiviral activity against influenza H1N1 virus,Confirmatory,19112024.0,
1456,392528,6,2,,103619997,37542,Active,,,13.8,IC50,Antiviral activity against influenza H2N2 virus,Confirmatory,19112024.0,
1457,392529,6,2,,103619997,37542,Active,,,20.0,IC50,Antiviral activity against influenza H3N2 virus,Confirmatory,19112024.0,
1458,392533,6,2,,103619997,37542,Unspecified,,,145.0,IC50,Antiviral activity against Monkeypox virus,Confirmatory,19112024.0,
1459,392536,6,2,,103619997,37542,Unspecified,,,281.0,IC50,Antiviral activity against Vaccinia virus,Confirmatory,19112024.0,
1460,392724,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against EMCV assessed as inhibition of virus-induced cytopathicity,Other,19147352.0,
1461,392725,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B3 assessed as inhibition of virus-induced cytopathicity,Other,19147352.0,
1462,392726,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV assessed as inhibition of virus-induced cytopathicity,Other,19147352.0,
1463,393162,6,2,,103619997,37542,Active,,,8.7,EC50,Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathic effect after 72 hrs by MTS assay,Confirmatory,19195900.0,
1464,393164,6,2,,103619997,37542,Active,,,,,Cytotoxicity against MDCK cells assessed as changes in cell morphology after 72 hrs by MTS assay,Other,19195900.0,
1465,393165,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of MCC for MDCK cells to EC50 for influenza A virus H3N2",Other,19195900.0,
1466,393166,3,3,,103619997,37542,Inactive,,,,,Antiviral activity against influenza B virus,Other,19195900.0,
1467,395665,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1468,395668,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1469,395671,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1470,395674,3,3,,103619997,37542,Active,,,,,"Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as inhibition of liver damage at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection",Other,17606691.0,
1471,395676,6,2,,103619997,37542,Active,,,11.0,EC50,Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days,Confirmatory,17606691.0,
1472,395677,6,2,,103619997,37542,Active,,,13.0,EC50,Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days,Confirmatory,17606691.0,
1473,395678,6,2,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days,Confirmatory,17606691.0,
1474,395679,6,2,,103619997,37542,Unspecified,,,156.0,CC50,Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay,Confirmatory,17606691.0,
1475,395680,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus Candid-1",Other,17606691.0,
1476,395681,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Pichinde virus An 4763",Other,17606691.0,
1477,395682,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Tacaribe virus TRVL11573",Other,17606691.0,
1478,395691,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge",Other,17606691.0,
1479,395695,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1480,395699,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1481,395703,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1482,395707,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1483,395711,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1484,395712,3,3,,103619997,37542,Active,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1485,395713,3,3,,103619997,37542,Active,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge",Other,17606691.0,
1486,395714,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge",Other,17606691.0,
1487,395930,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge",Other,17606691.0,
1488,395931,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1489,395932,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1490,395933,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1491,395934,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1492,395935,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1493,395936,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge",Other,17606691.0,
1494,395937,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1495,395938,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1496,395939,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1497,395940,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1498,395942,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection measured on day 7 of viral infection",Other,17606691.0,
1499,395944,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge",Other,17606691.0,
1500,395945,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge",Other,17606691.0,
1501,395946,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1502,395947,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1503,395948,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1504,395949,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1505,395950,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1506,395951,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1507,395952,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1508,395953,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1509,395954,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1510,395955,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1511,395956,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1512,395957,3,3,,103619997,37542,Active,,,,,"Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection",Other,17606691.0,
1513,395958,6,1,,103619997,37542,Unspecified,,,,,Toxicity in Pichinde virus An 4763 infected po dosed Syrian golden hamster administered twice daily 72 hrs post viral-challenge,Other,17606691.0,
1514,395963,6,1,,103619997,37542,Unspecified,,,,,Toxicity in BALB/c mouse,Other,17606691.0,
1515,395965,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1516,395966,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge",Other,17606691.0,
1517,395967,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1518,395968,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1519,395969,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1520,395970,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1521,395971,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1522,395972,3,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1523,395973,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1524,395974,3,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1525,395975,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1526,395976,8,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection",Other,17606691.0,
1527,396873,3,5,,103619997,37542,Active,,,,,Antiviral activity against Rift Valley fever virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL,Other,3373220.0,
1528,396874,3,5,,103619997,37542,Active,,,,,Antiviral activity against Venezuelan equine encephalomyelitis virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL,Other,3373220.0,
1529,396875,3,4,,103619997,37542,Active,,,,,Antiviral activity against Yellow fever virus infected in rhesus monkey MK2 cells assessed as plaque reduction at 250 ug/mL,Other,3373220.0,
1530,396876,3,4,,103619997,37542,Active,,,,,Antiviral activity against Sandfly fever virus assessed as plaque reduction at 250 ug/mL,Other,3373220.0,
1531,396941,3,4,,103619997,37542,Active,,,,,Antiviral activity against VSV assessed as reduction in plaque formation at 100 ug,Other,2095373.0,
1532,400417,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days,Other,9599250.0,
1533,400418,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay,Other,9599250.0,
1534,400419,7,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against RSV long infected human Hep2 cells after 3 days,Other,9599250.0,
1535,400424,3,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of EC50 for RSV long by cytopathic effect over IC50 for human Hep2 cells",Other,9599250.0,
1536,400425,3,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of EC50 for RSV A-2 by plaque neutralization over IC50 for human Hep2 cells",Other,9599250.0,
1537,400430,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection,Other,9599250.0,
1538,400431,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human Hep2 cells administered 3 hrs postinfection,Other,9599250.0,
1539,400432,3,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of EC50 for RSV administered 3 hrs postinfection over IC50 for human Hep2 cells administered 3 hrs after infection",Other,9599250.0,
1540,400704,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days,Other,9599250.0,
1541,401224,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Other,15104496.0,
1542,401225,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells,Other,15104496.0,
1543,401226,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to IC50 for RSV Long",Other,15104496.0,
1544,401227,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Other,15104496.0,
1545,401228,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to IC50 for PIV3",Other,15104496.0,
1546,401229,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Other,15104496.0,
1547,401230,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to IC50 for influenza virus type A H1N1",Other,15104496.0,
1548,402532,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay,Other,9214738.0,
1549,402534,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells by neutral red assay,Other,9214738.0,
1550,402537,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of IC50 for MDCK cells to EC50 for influenza A virus NWS33",Other,9214738.0,
1551,402750,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect,Other,9784173.0,
1552,406925,3,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for Vero cells to EC50 for Measles virus Leningrad 16",Other,18529043.0,
1553,407614,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay,Other,18445526.0,
1554,407615,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human Huh-5-2 cells,Other,18445526.0,
1555,416748,6,2,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1556,416749,6,2,,103619997,37542,Active,,,22.0,EC50,Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1557,416764,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days,Other,19281225.0,
1558,416765,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days,Other,19281225.0,
1559,416766,6,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1560,416767,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1561,416768,6,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1562,416769,6,2,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1563,416770,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1564,416771,6,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1565,416772,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days,Other,19281225.0,
1566,416773,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1567,416774,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1568,416775,6,2,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1569,416776,6,2,,103619997,37542,Unspecified,,,125.0,EC50,Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1570,416777,6,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1571,416778,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology,Other,19281225.0,
1572,416779,6,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells by MTS assay,Confirmatory,19281225.0,
1573,416780,6,2,,103619997,37542,Unspecified,,,900.0,EC50,Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method,Confirmatory,19281225.0,
1574,416781,6,2,,103619997,37542,Unspecified,,,8400.0,EC50,Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method,Confirmatory,19281225.0,
1575,416782,6,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method,Confirmatory,19281225.0,
1576,416783,6,2,,103619997,37542,Active,,,8.1,EC50,Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method,Confirmatory,19281225.0,
1577,416784,6,2,,103619997,37542,Active,,,4.0,EC50,Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method,Confirmatory,19281225.0,
1578,416785,6,2,,103619997,37542,Active,,,4.8,EC50,Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method,Confirmatory,19281225.0,
1579,419591,7,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology,Other,18851889.0,
1580,419592,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1581,419593,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1582,419594,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1583,419595,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1584,419596,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1585,419597,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as alteration in cell morphology,Other,18851889.0,
1586,419598,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1587,419599,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1588,419600,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1589,419601,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology,Other,18851889.0,
1590,419602,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1591,419603,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1592,419604,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1593,419605,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1594,419606,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1595,421725,6,2,,103619997,37542,Active,,,10.7,IC50,Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay,Confirmatory,19267453.0,
1596,421726,8,1,,103619997,37542,Unspecified,,,256.1,TC50,Cytotoxicity against human Hep2 cells,Confirmatory,19267453.0,
1597,421727,3,3,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells",Other,19267453.0,
1598,421728,6,2,,103619997,37542,Active,,,10.7,IC50,Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay,Confirmatory,19267453.0,
1599,421729,6,2,,103619997,37542,Active,,,42.6,IC50,Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay,Confirmatory,19267453.0,
1600,421730,3,3,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3 infected in human Hep2 cells",Other,19267453.0,
1601,421731,8,1,,103619997,37542,Unspecified,,,256.1,TC50,Cytotoxicity against MDCK cells,Confirmatory,19267453.0,
1602,421732,3,4,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus infected in MDCK cells",Other,19267453.0,
1603,424777,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,19374435.0,
1604,424778,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay,Other,19374435.0,
1605,424779,3,4,,103619997,37542,Unspecified,,,,,"Therapeutic index, CC50 for human HeLa cells to IC50 for Coxsackie virus B3 Nacy",Other,19374435.0,
1606,425652,7,2,,103619997,37542,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1607,425653,7,2,,103619997,37542,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1608,427549,6,2,,103619997,37542,Unspecified,,,58.0,EC50,Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1609,427551,6,2,,103619997,37542,Active,,,22.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1610,427552,6,2,,103619997,37542,Active,,,41.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1611,427553,6,2,,103619997,37542,Active,,,36.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1612,427554,6,2,,103619997,37542,Active,,,36.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1613,427555,6,2,,103619997,37542,Active,,,42.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1614,427558,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1615,427559,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1616,427560,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36L mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1617,427563,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1618,427564,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1619,427565,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1620,427566,3,4,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type,Other,17938182.0,
1621,428948,6,2,,103619997,37542,Active,,,43.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1622,428949,6,2,,103619997,37542,Active,,,33.0,EC50,Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay,Confirmatory,17938182.0,
1623,432169,7,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology,Other,19419804.0,
1624,432170,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1625,432171,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1626,432172,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1627,432173,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1628,432174,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology,Other,19419804.0,
1629,432175,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1630,432176,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1631,432177,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1632,432178,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1633,432179,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology,Other,19419804.0,
1634,432180,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1635,432181,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1636,432182,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection,Other,19419804.0,
1637,432183,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1638,432184,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1639,434306,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as change in cell morphology,Other,19324473.0,
1640,434307,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1641,434308,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity,Other,19324473.0,
1642,434309,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1643,434310,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1644,434311,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1645,434312,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1646,434313,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1647,434314,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1648,434315,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1649,434316,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1650,434317,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1651,434318,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1652,434319,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1653,434320,7,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against HEL cells assessed as change in cell morphology,Other,19324473.0,
1654,434321,7,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as change in cell morphology,Other,19324473.0,
1655,434947,1,2,,8139972,37542,Inactive,,,300.0,EC50_uM,Luminescence Cell-Free Homogeneous Counter Screen to Identify Inhibitors of ADP-glo Reagents,Confirmatory,,
1656,434954,1,1,,8139972,37542,Inactive,21361340.0,2932.0,300.0,EC50_uM,Luminescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of Glycogen Synthase Kinase-3 beta  Activity,Confirmatory,,
1657,434955,1,2,,8139972,37542,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1658,434962,1,2,,8139972,37542,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1659,434973,1,3,,8139972,37542,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1660,434982,1,2,,26538475,37542,Inactive,11275980.0,4851.0,,,Cell-based luminescence-based Maybridge primary high throughput screening assay to identify agonists of NOTCH,Screening,,
1661,434989,1,1,,8139972,37542,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1662,435003,1,3,,8139972,37542,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1663,435005,1,1,,8139972,37542,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1664,435022,2,2,,8139972,37542,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1665,435030,1,2,,8139972,37542,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1666,435030,1,2,,8139972,37542,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1667,436476,5,2,,103619997,37542,Active,,,31.0,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,19482481.0,
1668,436477,5,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,19482481.0,
1669,436478,7,1,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
1670,436479,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
1671,436480,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay,Confirmatory,19482481.0,
1672,436481,5,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining,Confirmatory,19482481.0,
1673,436482,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay,Confirmatory,19482481.0,
1674,436483,5,2,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay,Confirmatory,19482481.0,
1675,436484,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay,Confirmatory,19482481.0,
1676,436485,5,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay,Confirmatory,19482481.0,
1677,436486,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay,Confirmatory,19482481.0,
1678,438025,9,1,,103619997,37542,Unspecified,,,,IC50,Antiviral activity against Dengue virus,Confirmatory,19739651.0,
1679,438029,7,2,,103619997,37542,Unspecified,,,,,Inhibition of Dengue virus IMPDH,Other,19739651.0,
1680,442290,7,2,,103619997,37542,Unspecified,,,,,Antiviral activity HCV in replicon cells assessed as inhibition of NS3-4A protease activity by RT-PCR,Other,19913334.0,
1681,442291,7,3,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV infected in hamster brain assessed as subacute sclerosing panencephalitis,Other,19913334.0,
1682,443827,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay,Confirmatory,19791806.0,
1683,443828,5,2,,103619997,37542,Active,,,9.7,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay,Confirmatory,19791806.0,
1684,443829,5,4,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay,Confirmatory,19791806.0,
1685,443830,5,4,,103619997,37542,Active,,,6.0,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay,Confirmatory,19791806.0,
1686,443831,5,3,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect by cell-based assay,Confirmatory,19791806.0,
1687,443832,5,3,,103619997,37542,Active,,,3.6,EC50,Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability by cell-based MTS assay,Confirmatory,19791806.0,
1688,449728,1,2,,8139972,37542,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1689,449739,1,2,,8139972,37542,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1690,449762,1,2,,8139972,37542,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1691,449763,1,3,,8139972,37542,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1692,449768,1,1,,8139972,37542,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1693,453100,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV by cell based replicon assay,Other,19864149.0,
1694,453101,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Measles virus infected in intracranially dosed hamster assessed as inhibition of subacute sclerosing panencephalitis,Other,19864149.0,
1695,463075,1,1,,8139972,37542,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1696,463079,1,2,,8139972,37542,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1697,463082,1,1,,8139972,37542,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1698,463096,1,1,,50105410,37542,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1699,463097,1,1,,50105410,37542,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1700,463104,1,2,,8139972,37542,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1701,463106,1,2,,90341426,37542,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1702,463111,1,1,,8139972,37542,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1703,463115,1,1,,8139972,37542,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1704,463141,1,2,,8139972,37542,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1705,463165,1,1,,8139972,37542,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1706,463187,1,1,,8139972,37542,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1707,463189,1,1,,53778169,37542,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1708,463190,1,2,,8139972,37542,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1709,463193,1,1,,8139972,37542,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1710,463195,1,2,,8139972,37542,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1711,463210,1,2,,8139972,37542,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1712,463212,1,1,,8139972,37542,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1713,463254,1,1,,8139972,37542,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1714,463981,5,2,,103619997,37542,Active,,,30.0,EC50,Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay,Confirmatory,20034711.0,
1715,463982,5,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay,Confirmatory,20034711.0,
1716,463983,5,2,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay,Confirmatory,20034711.0,
1717,463988,5,2,,103619997,37542,Active,,,30.0,EC50,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,20034711.0,
1718,463989,5,2,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1719,463990,5,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1720,463991,5,2,,103619997,37542,Unspecified,,,85.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1721,463992,5,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay,Confirmatory,20034711.0,
1722,463993,5,2,,103619997,37542,Unspecified,,,125.0,EC50,Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1723,463994,5,2,,103619997,37542,Unspecified,,,95.0,EC50,Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay,Confirmatory,20034711.0,
1724,463995,5,2,,103619997,37542,Unspecified,,,111.0,EC50,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1725,463996,5,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay,Confirmatory,20034711.0,
1726,463997,5,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay,Confirmatory,20034711.0,
1727,464000,5,2,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay,Confirmatory,20034711.0,
1728,464001,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay,Confirmatory,20034711.0,
1729,464002,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay,Confirmatory,20034711.0,
1730,464175,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method,Confirmatory,20034711.0,
1731,464176,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method,Confirmatory,20034711.0,
1732,464177,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method,Confirmatory,20034711.0,
1733,464178,5,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1734,464179,5,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1735,464180,5,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1736,464181,5,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1737,464182,5,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1738,464183,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method,Confirmatory,20034711.0,
1739,464184,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method,Confirmatory,20034711.0,
1740,464185,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method,Confirmatory,20034711.0,
1741,464186,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method,Confirmatory,20034711.0,
1742,464187,5,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method,Confirmatory,20034711.0,
1743,464190,5,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method,Confirmatory,20034711.0,
1744,464191,5,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method,Confirmatory,20034711.0,
1745,464192,5,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method,Confirmatory,20034711.0,
1746,468093,9,1,,103619997,37542,Unspecified,,,95.1,IC50,Antiviral activity against SFV infected in BHK cells after 14 hrs by luciferase reporter gene assay,Confirmatory,19839605.0,
1747,468105,3,3,,103619997,37542,Inactive,,,,,Antiviral activity against SFV infected in BHK cells assessed as surviving virus fraction at 200 uM after 14 hrs by luciferase reporter gene assay in presence of 50 ug/ml guanosine,Other,19839605.0,
1748,472783,5,2,,103619997,37542,Active,,,31.0,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,20359898.0,
1749,472784,5,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,20359898.0,
1750,472785,5,3,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay,Confirmatory,20359898.0,
1751,472786,5,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,20359898.0,
1752,472789,5,2,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method,Confirmatory,20359898.0,
1753,472790,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method,Confirmatory,20359898.0,
1754,472791,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay,Confirmatory,20359898.0,
1755,472792,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay,Confirmatory,20359898.0,
1756,472793,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay,Confirmatory,20359898.0,
1757,472794,5,2,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay,Confirmatory,20359898.0,
1758,472795,5,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay,Confirmatory,20359898.0,
1759,474325,5,2,,103619997,37542,Active,,,35.4,EC50,Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1760,474326,5,2,,103619997,37542,Active,,,32.5,EC50,Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1761,474327,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1762,474328,5,2,,103619997,37542,Active,,,23.6,EC50,Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1763,474329,5,2,,103619997,37542,Active,,,27.4,EC50,Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1764,474330,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1765,474331,5,2,,103619997,37542,Active,,,4.3,EC50,Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1766,474332,5,2,,103619997,37542,Active,,,9.4,EC50,Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1767,474333,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1768,474334,5,2,,103619997,37542,Active,,,8.4,EC50,Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1769,474335,5,2,,103619997,37542,Active,,,13.9,EC50,Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1770,474336,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1771,474337,5,2,,103619997,37542,Unspecified,,,1310.0,IC50,Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay,Confirmatory,20231094.0,
1772,474338,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Duck/MN/1525/81/H5N1,Other,20231094.0,
1773,474339,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Duck/MN/1525/81/H5N1 by neutral red dye uptake assay,Other,20231094.0,
1774,474340,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Duck/MN/1525/81/H5N1 by virus yield reduction assay,Other,20231094.0,
1775,474341,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Gull/PA/4175/83/H5N1,Other,20231094.0,
1776,474342,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Gull/PA/4175/83/H5N1 by neutral red dye uptake assay,Other,20231094.0,
1777,474343,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Gull/PA/4175/83/H5N1 by virus yield reduction assay,Other,20231094.0,
1778,474344,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Hong Kong/213/2003/H5N1,Other,20231094.0,
1779,474345,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Hong Kong/213/2003/H5N1 by neutral red dye uptake assay,Other,20231094.0,
1780,474346,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Hong Kong/213/2003/H5N1 by virus yield reduction assay,Other,20231094.0,
1781,474347,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Vietnam/1203/ 2004H/H5N1,Other,20231094.0,
1782,474348,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by neutral red dye uptake assay,Other,20231094.0,
1783,474349,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by virus yield reduction assay,Other,20231094.0,
1784,474350,5,3,,103619997,37542,Active,,,11.2,EC50,Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1785,474351,5,3,,103619997,37542,Active,,,19.4,EC50,Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1786,474352,3,5,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1787,474353,5,2,,103619997,37542,Active,,,23.3,EC50,Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1788,474354,5,2,,103619997,37542,Active,,,25.1,EC50,Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1789,474355,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1790,474356,5,2,,103619997,37542,Active,,,16.4,EC50,Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1791,474357,5,2,,103619997,37542,Active,,,20.2,EC50,Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1792,474358,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1793,474359,5,2,,103619997,37542,Active,,,10.2,EC50,Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days,Confirmatory,20231094.0,
1794,474360,5,2,,103619997,37542,Active,,,19.5,EC50,Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay,Confirmatory,20231094.0,
1795,474361,3,4,,103619997,37542,Active,,,,,Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 3 days by virus yield reduction assay,Other,20231094.0,
1796,474540,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus California/07/2009 /H1N1,Other,20231094.0,
1797,474541,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus California/07/2009 /H1N1 by neutral red dye uptake assay,Other,20231094.0,
1798,474542,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus California/07/2009 /H1N1 by virus yield reduction assay,Other,20231094.0,
1799,474543,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Solomon Islands/03/2006/H1N1,Other,20231094.0,
1800,474544,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Solomon Islands/03/2006/H1N1 by neutral red dye uptake assay,Other,20231094.0,
1801,474545,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Solomon Islands/03/2006/H1N1 by virus yield reduction assay,Other,20231094.0,
1802,474546,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Wisconsin/67/2005/H3N2,Other,20231094.0,
1803,474547,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Wisconsin/67/2005/H3N2 by neutral red dye uptake assay,Other,20231094.0,
1804,474548,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Wisconsin/67/2005/H3N2 by virus yield reduction assay,Other,20231094.0,
1805,474549,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza B virus Malaysia/2506/2004,Other,20231094.0,
1806,474550,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza B virus Malaysia/2506/2004 by neutral red dye uptake assay,Other,20231094.0,
1807,474551,3,4,,103619997,37542,Unspecified,,,,,Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza B virus Malaysia/2506/2004 by virus yield reduction assay,Other,20231094.0,
1808,475233,5,2,,103619997,37542,Active,,,17.6,EC50,Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay,Confirmatory,20337460.0,
1809,475234,5,3,,103619997,37542,Unspecified,,,1060.0,CC50,Cytotoxicity against human HuH7 cells after3 days by MTT assay,Confirmatory,20337460.0,
1810,475235,3,3,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV 1b",Other,20337460.0,
1811,475851,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells,Other,20207546.0,
1812,475852,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells,Other,20207546.0,
1813,475853,5,2,,103619997,37542,Active,,,19.0,EC50,Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1814,475854,5,2,,103619997,37542,Active,,,22.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1815,475855,5,2,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1816,475856,6,2,,103619997,37542,Unspecified,,,87.0,EC50,Antiviral activity against HCV infected in human HuH5.2 cells carrying subgenomic HCV replicon assessed as inhibition of replicon replication by luciferase reporter gene assay,Confirmatory,20207546.0,
1817,475857,5,2,,103619997,37542,Unspecified,,,183.0,EC50,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1818,475858,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1819,475859,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,20207546.0,
1820,475860,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,20207546.0,
1821,475861,6,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HuH5.2 cells,Other,20207546.0,
1822,476929,3,3,,103619997,37542,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1823,478320,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect,Confirmatory,20381348.0,
1824,478321,5,2,,103619997,37542,Active,,,11.0,EC50,Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay,Confirmatory,20381348.0,
1825,478322,5,2,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect,Confirmatory,20381348.0,
1826,478323,5,2,,103619997,37542,Active,,,8.7,EC50,Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay,Confirmatory,20381348.0,
1827,478324,5,2,,103619997,37542,Active,,,4.0,EC50,Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect,Confirmatory,20381348.0,
1828,478325,5,2,,103619997,37542,Active,,,4.7,EC50,Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay,Confirmatory,20381348.0,
1829,482702,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1830,482703,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1831,482704,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1832,482705,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1833,482706,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1834,482707,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1835,482708,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1836,482709,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human E6SM cells by MTT assay,Other,20377249.0,
1837,482710,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,20377249.0,
1838,482711,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1839,482712,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1840,482713,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1841,482714,6,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1842,482715,6,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells by MTT assay,Other,20377249.0,
1843,485270,1,1,,8139972,37542,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1844,485272,1,1,,8139972,37542,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1845,485273,2,1,,8139972,37542,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1846,485275,1,3,,8139972,37542,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1847,485281,1,1,,8139972,37542,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1848,485290,1,1,,8139972,37542,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1849,485290,1,1,,17389529,37542,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1850,485290,1,1,,50105410,37542,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1851,485294,1,1,,8139972,37542,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1852,485295,1,2,,90341426,37542,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1853,485297,1,1,,8139972,37542,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1854,485297,1,1,,90341426,37542,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1855,485298,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1856,485298,1,1,,90341426,37542,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1857,485313,1,2,,8139972,37542,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1858,485313,1,2,,90341426,37542,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1859,485314,1,1,,8139972,37542,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1860,485314,1,1,,50105410,37542,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1861,485317,1,2,,8139972,37542,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1862,485341,1,1,,8139972,37542,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1863,485342,1,2,,90341426,37542,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1864,485344,1,1,,8139972,37542,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1865,485345,1,2,,90341426,37542,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1866,485346,1,1,,8139972,37542,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1867,485346,1,1,,8139972,37542,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1868,485347,1,2,,8139972,37542,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1869,485349,1,1,,8139972,37542,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1870,485353,2,1,,8139972,37542,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1871,485358,1,1,,8139972,37542,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1872,485360,1,1,,8139972,37542,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1873,485364,1,1,,8139972,37542,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1874,485366,1,2,,90341426,37542,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1875,485367,1,2,,8139972,37542,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1876,485368,1,2,,90341426,37542,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1877,488745,1,4,,50105410,37542,Inconclusive,,,18.526,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1878,488752,1,4,,50105410,37542,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1879,488772,1,1,,90341426,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1880,488773,1,2,,90341426,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1881,488816,1,1,,90341426,37542,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1882,488837,1,1,,8139972,37542,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1883,488837,1,1,,90341426,37542,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1884,488839,1,1,,8139972,37542,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1885,488839,1,1,,8139972,37542,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1886,488847,1,3,,8139972,37542,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1887,488862,1,1,,8139972,37542,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1888,488890,1,2,,8139972,37542,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1889,488895,1,2,,8139972,37542,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1890,488896,1,1,,8139972,37542,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1891,488899,1,1,,8139972,37542,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1892,488922,1,2,,8139972,37542,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1893,488949,1,2,,50105410,37542,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1894,488949,1,2,,90341426,37542,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1895,488953,1,1,,90341426,37542,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1896,488965,1,2,,8139972,37542,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1897,488966,1,1,,8139972,37542,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1898,488975,1,2,,8139972,37542,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1899,488977,1,2,,8139972,37542,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1900,488978,1,1,,90341426,37542,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1901,488979,1,1,,50105410,37542,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1902,488980,1,1,,50105410,37542,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1903,488981,1,1,,90341426,37542,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1904,488982,1,1,,90341426,37542,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1905,488983,1,1,,90341426,37542,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1906,489030,2,1,,8139972,37542,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1907,489031,2,1,,8139972,37542,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1908,489677,8,1,,103619997,37542,Active,,,6.6,EC50,Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,20347509.0,
1909,489678,8,1,,103619997,37542,Unspecified,,,73.1,EC50,Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,20347509.0,
1910,489679,9,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days by MTS assay,Other,20347509.0,
1911,489680,8,1,,103619997,37542,Active,,,17.2,EC50,Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,20347509.0,
1912,492947,1,1,,8139972,37542,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1913,492953,1,1,,8139972,37542,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1914,492956,1,1,,8139972,37542,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1915,492967,1,2,,99301870,37542,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1916,492972,1,1,,8139972,37542,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1917,493005,1,1,,8139972,37542,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1918,493008,1,1,,8139972,37542,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1919,493008,1,1,,8139972,37542,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1920,493008,1,1,,8139972,37542,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1921,493008,1,1,,8139972,37542,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1922,493011,1,1,,8139972,37542,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1923,493012,1,1,,8139972,37542,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1924,493014,1,1,,8139972,37542,Inconclusive,,,32.6427,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1925,493036,1,2,,8139972,37542,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1926,493056,1,1,,8139972,37542,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1927,493084,1,1,,8139972,37542,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1928,493087,1,1,,8139972,37542,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1929,493091,1,1,,8139972,37542,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1930,493098,1,1,,8139972,37542,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1931,493106,1,1,,90341426,37542,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1932,493107,1,1,,90341426,37542,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1933,493127,1,1,,50105410,37542,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1934,493131,1,1,,8139972,37542,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1935,493153,1,1,,90341426,37542,Inactive,,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1936,493153,1,1,,90341426,37542,Inactive,224028257.0,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1937,493160,1,1,,8139972,37542,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1938,493162,1,2,,99301870,37542,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1939,493164,1,2,,90341426,37542,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1940,493164,1,2,,90341426,37542,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1941,493164,1,2,,90341426,37542,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1942,493187,1,2,,8139972,37542,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1943,493189,1,1,,50105410,37542,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1944,493244,1,1,,8139972,37542,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1945,493244,1,1,,8139972,37542,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1946,493244,1,1,,8139972,37542,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1947,493244,1,1,,8139972,37542,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1948,504326,1,2,,8139972,37542,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1949,504326,1,2,,8139972,37542,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1950,504327,1,1,,8139972,37542,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1951,504327,1,1,,90341426,37542,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1952,504329,1,1,,8139972,37542,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1953,504332,1,1,,8139972,37542,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1954,504332,1,1,,50105410,37542,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1955,504332,1,1,,90341426,37542,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1956,504333,1,1,,8139972,37542,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1957,504339,1,1,,8139972,37542,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1958,504357,1,1,,8139972,37542,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1959,504357,1,1,,8139972,37542,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1960,504364,1,1,,50105410,37542,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1961,504406,1,1,,8139972,37542,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1962,504408,2,1,,8139972,37542,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1963,504411,1,1,,8139972,37542,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1964,504414,1,1,,8139972,37542,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1965,504414,1,1,,8139972,37542,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1966,504423,1,1,,8139972,37542,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1967,504441,1,1,,8139972,37542,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1968,504444,1,1,,8139972,37542,Inconclusive,224028257.0,4780.0,10.3225,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1969,504454,1,3,,8139972,37542,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1970,504462,1,1,,8139972,37542,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1971,504466,1,1,,8139972,37542,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1972,504467,1,1,,8139972,37542,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1973,504490,1,2,,8139972,37542,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1974,504523,1,1,,8139972,37542,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1975,504523,1,1,,8139972,37542,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1976,504536,1,1,,90341426,37542,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1977,504547,1,1,,90341426,37542,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1978,504548,1,2,,90341426,37542,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1979,504558,1,1,,8139972,37542,Active,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1980,504577,2,2,,8139972,37542,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1981,504582,2,1,,8139972,37542,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1982,504621,1,1,,8139972,37542,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1983,504634,1,1,,8139972,37542,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1984,504648,1,1,,8139972,37542,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1985,504651,1,1,,8139972,37542,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1986,504652,1,1,,8139972,37542,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1987,504660,1,1,,8139972,37542,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1988,504690,1,3,,8139972,37542,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1989,504692,2,2,,8139972,37542,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1990,504700,1,1,,8139972,37542,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1991,504700,1,1,,8139972,37542,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1992,504706,1,1,,8139972,37542,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1993,504707,1,1,,8139972,37542,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1994,504707,1,1,,8139972,37542,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1995,504720,1,1,,8139972,37542,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1996,504734,1,1,,8139972,37542,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1997,504766,2,1,,8139972,37542,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1998,504775,1,1,,8139972,37542,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1999,504803,1,1,,8139972,37542,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2000,504810,1,2,,8139972,37542,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2001,504810,1,2,,90341426,37542,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2002,504812,1,2,,8139972,37542,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2003,504812,1,2,,90341426,37542,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2004,504821,1,1,,50105410,37542,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2005,504832,1,1,,8139972,37542,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2006,504834,1,1,,8139972,37542,Inactive,,,2.0787,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2007,504836,1,2,,90341426,37542,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2008,504842,1,1,,8139972,37542,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2009,504845,1,1,,8139972,37542,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2010,504845,1,1,,90341426,37542,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2011,504847,1,1,,8139972,37542,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2012,504847,1,1,,90341426,37542,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2013,504861,1,1,,8139972,37542,Inactive,23893668.0,3783750.0,,AC50_uM,Viability counterscreen of potential LMP-1 inhibitors in HEK293 cell background Measured in Cell-Based System Using Plate Reader - 2122-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2014,504865,1,1,,90341426,37542,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2015,504882,1,1,,8139972,37542,Inactive,23893668.0,3783750.0,,AC50_uM,Lymphoblastoid Cells (LCL) Cytotoxicity Secondary Assay Measured in Cell-Based System Using Plate Reader - 2122-03_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
2016,504884,1,2,,8139972,37542,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2017,504891,1,1,,8139972,37542,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2018,504894,1,1,,8139972,37542,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2019,504937,1,2,,8139972,37542,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2020,514138,4,3,,103619997,37542,Unspecified,,,120.0,EC50,Antiviral activity against HCV Con 1 by subgenomic replicon assay,Confirmatory,20579888.0,
2021,514139,4,3,,103619997,37542,Unspecified,,,177.94,CC50,Cytotoxicity against human HuH7 cells,Confirmatory,20579888.0,
2022,514140,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for",Other,20579888.0,
2023,521220,3,3,,103619997,37542,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2024,524794,7,1,,103619997,37542,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2025,527722,2,6,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV 1a infected in human HuH7 cells assessed as reduction of viral RNA level at 20 ug/ml after 2 days by QRT-PCR analysis,Other,20869253.0,
2026,527723,5,3,,103619997,37542,Inconclusive,,,,,Cytotoxicity against human HuH7 cells after 2 days by XTT assay,Other,20869253.0,
2027,528351,1,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 150 uM by guanidine resistance assay,Other,20964406.0,
2028,528352,1,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 300 uM by guanidine resistance assay,Other,20964406.0,
2029,533313,4,3,,103619997,37542,Unspecified,,,,EC50,Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis,Confirmatory,18710916.0,
2030,533314,4,3,,103619997,37542,Unspecified,,,,EC50,Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis,Confirmatory,18710916.0,
2031,533315,4,3,,103619997,37542,Unspecified,,,,EC50,Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis,Confirmatory,18710916.0,
2032,533316,4,2,,103619997,37542,Unspecified,,,77.0,CC50,Cytotoxicity against human RP7 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay,Confirmatory,18710916.0,
2033,533317,4,2,,103619997,37542,Unspecified,,,66.0,CC50,Cytotoxicity against human NTZ-11 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay,Confirmatory,18710916.0,
2034,533318,4,2,,103619997,37542,Unspecified,,,95.0,CC50,Cytotoxicity against human TIZ-9 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay,Confirmatory,18710916.0,
2035,533319,1,3,,103619997,37542,Unspecified,,,,,"Selectivity Index, ratio of CC50 for RP7 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in RP7 replicon cell",Other,18710916.0,
2036,533320,1,3,,103619997,37542,Unspecified,,,,,"Selectivity Index, ratio of CC50 for NTZ-11 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in NTZ-11 replicon cell",Other,18710916.0,
2037,533321,1,3,,103619997,37542,Unspecified,,,,,"Selectivity Index, ratio of CC50 for TIZ-9 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in TIZ-9 replicon cell",Other,18710916.0,
2038,535504,2,8,,103619997,37542,Inactive,47606215.0,63959.0,,,Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2039,535505,2,8,,103619997,37542,Inactive,325511350.0,13340.0,,,Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2040,535506,2,4,,103619997,37542,Inactive,,,,,Transport through CNT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2041,535507,2,8,,103619997,37542,Inactive,341942002.0,269346.0,,,Transport through CNT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2042,535508,2,4,,103619997,37542,Inactive,,,,,Transport through CNT3 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2043,535509,2,9,,103619997,37542,Inactive,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2044,535510,2,8,,103619997,37542,Active,9296970.0,65194.0,,,Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2045,535511,2,8,,103619997,37542,Active,9296931.0,116642.0,,,Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2046,535512,2,8,,103619997,37542,Active,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2047,535513,2,4,,103619997,37542,Active,,,,,Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer,Other,20421393.0,
2048,535514,2,9,,103619997,37542,Active,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay,Other,20421393.0,
2049,535515,2,8,,103619997,37542,Active,9296970.0,65194.0,,,Transport through ENT2 in rat hepatocytes by oil filtration assay,Other,20421393.0,
2050,535516,2,8,,103619997,37542,Active,9296931.0,116642.0,,,Transport through CNT1 in rat hepatocytes by oil filtration assay,Other,20421393.0,
2051,535517,2,8,,103619997,37542,Active,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay,Other,20421393.0,
2052,535518,2,4,,103619997,37542,Active,,,,,Transport through CNT3 in rat hepatocytes by oil filtration assay,Other,20421393.0,
2053,535519,2,9,,103619997,37542,Active,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR,Other,20421393.0,
2054,535520,2,8,,103619997,37542,Active,9296970.0,65194.0,,,Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR,Other,20421393.0,
2055,535521,2,8,,103619997,37542,Inactive,9296931.0,116642.0,,,Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine,Other,20421393.0,
2056,535522,2,8,,103619997,37542,Inactive,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine,Other,20421393.0,
2057,535523,2,4,,103619997,37542,Inactive,,,,,Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine,Other,20421393.0,
2058,535524,2,4,,103619997,37542,Inactive,,,,,Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine,Other,20421393.0,
2059,535525,2,9,,103619997,37542,Inactive,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine,Other,20421393.0,
2060,535526,2,8,,103619997,37542,Inactive,9296970.0,65194.0,,,Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine,Other,20421393.0,
2061,535527,2,8,,103619997,37542,Inactive,9296931.0,116642.0,,,Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine,Other,20421393.0,
2062,535528,2,8,,103619997,37542,Inactive,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine,Other,20421393.0,
2063,535529,2,4,,103619997,37542,Inactive,,,,,Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine,Other,20421393.0,
2064,535530,2,8,,103619997,37542,Inactive,47606215.0,63959.0,,,Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP,Other,20421393.0,
2065,535531,2,9,,103619997,37542,Inactive,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP,Other,20421393.0,
2066,535532,2,8,,103619997,37542,Inactive,47606215.0,63959.0,,,Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP,Other,20421393.0,
2067,535533,2,9,,103619997,37542,Inactive,9296969.0,63997.0,,,Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP,Other,20421393.0,
2068,535534,2,8,,103619997,37542,Inactive,325511350.0,13340.0,,,Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP,Other,20421393.0,
2069,535535,2,8,,103619997,37542,Inactive,9296970.0,65194.0,,,Transport through ENT2 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP,Other,20421393.0,
2070,535536,2,8,,103619997,37542,Active,341942002.0,269346.0,,,Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR,Other,20421393.0,
2071,535537,2,8,,103619997,37542,Active,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR,Other,20421393.0,
2072,535538,2,8,,103619997,37542,Active,341942002.0,269346.0,,,Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer,Other,20421393.0,
2073,535539,2,8,,103619997,37542,Active,9296932.0,60423.0,,,Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer,Other,20421393.0,
2074,536238,4,4,,103619997,37542,Active,,,8.7,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay,Confirmatory,20805012.0,
2075,536241,5,2,,103619997,37542,Active,,,,,Cytotoxicity against MDCK cells by MTS assay,Other,20805012.0,
2076,536243,1,5,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of MCC for MDCK cells to EC50 for Influenza A virus (A/Hong Kong/7/1987(H3N2))",Other,20805012.0,
2077,539914,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
2078,539915,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2079,539916,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2080,539917,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2081,539918,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2082,539919,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2083,539920,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
2084,539921,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2085,539922,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2086,539923,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2087,539924,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2088,539925,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2089,539929,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
2090,539930,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2091,539931,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2092,539932,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2093,539948,4,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells by MTS assay,Other,20724039.0,
2094,539949,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
2095,539953,5,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2096,539954,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2097,539955,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2098,539956,5,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay,Other,20724039.0,
2099,539957,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay,Other,20724039.0,
2100,539958,4,2,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay,Other,20724039.0,
2101,540209,4,3,,103619997,37542,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2102,540210,4,3,,103619997,37542,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2103,540211,2,5,,103619997,37542,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2104,540212,4,3,,103619997,37542,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2105,540213,4,3,,103619997,37542,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2106,540253,1,1,,8139972,37542,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2107,540253,1,1,,8139972,37542,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2108,540253,1,1,,8139972,37542,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2109,540256,1,2,,8139972,37542,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2110,540256,1,2,,50105410,37542,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2111,540256,1,2,,90341426,37542,Active,,,23.0999,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2112,540263,1,1,,8139972,37542,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2113,540263,1,1,,8139972,37542,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2114,540267,1,1,,8139972,37542,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2115,540275,1,1,,8139972,37542,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2116,540276,1,2,,8139972,37542,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2117,540276,1,2,,17389529,37542,Inconclusive,420597.0,,1.0,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2118,540276,1,2,,50105410,37542,Inconclusive,420597.0,,1.0,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2119,540276,1,2,,50105411,37542,Inconclusive,420597.0,,1.0,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2120,540276,1,2,,50105412,37542,Inconclusive,420597.0,,20.5878,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2121,540276,1,2,,50105413,37542,Inconclusive,420597.0,,20.5878,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2122,540276,1,2,,90341426,37542,Inconclusive,420597.0,,20.5878,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2123,540277,1,1,,8139972,37542,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2124,540295,1,1,,8139972,37542,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2125,540303,1,1,,8139972,37542,Inconclusive,6679377.0,18792.0,7.0795,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2126,540303,1,1,,8139972,37542,Inconclusive,7242179.0,18793.0,7.0795,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2127,540303,1,1,,8139972,37542,Inconclusive,257471003.0,18815.0,7.0795,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2128,540308,1,1,,8139972,37542,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2129,540317,1,1,,8139972,37542,Inactive,187960037.0,10951.0,89.1251,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2130,540336,1,1,,8139972,37542,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2131,540336,1,1,,8139972,37542,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2132,540364,1,2,,8139972,37542,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2133,543658,4,2,,103619997,37542,Active,,,28.0,EC50,Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis,Confirmatory,18955536.0,
2134,543659,4,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay,Confirmatory,18955536.0,
2135,543660,4,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay,Confirmatory,18955536.0,
2136,543661,4,2,,103619997,37542,Unspecified,,,4100.0,CC50,Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay,Confirmatory,18955536.0,
2137,543662,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as reduction in virus yield,Other,18955536.0,
2138,543663,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey vero cells to EC90 for Yellow fever virus 17D",Other,18955536.0,
2139,543675,6,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection",Other,18955536.0,
2140,543676,1,3,,103619997,37542,Unspecified,,,,,"Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control",Other,18955536.0,
2141,543686,2,3,,103619997,37542,Unspecified,,,,,"Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control",Other,18955536.0,
2142,543692,2,3,,103619997,37542,Active,,,,,"Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum survival of animal at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection",Other,18955536.0,
2143,546576,2,8,,103619997,37542,Unspecified,,,,,Inhibition of recombinant GSK3-beta at 10 uM by Z'-LYTE kinase assay kit method,Other,21082766.0,
2144,546577,5,2,,103619997,37542,Inconclusive,,,,IC50,Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method,Confirmatory,21082766.0,
2145,546578,3,6,,103619997,37542,Inconclusive,,,,,Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method,Other,21082766.0,
2146,548423,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as altered cell morphology,Other,20971531.0,
2147,548424,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2148,548425,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2149,548426,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2150,548427,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2151,548428,5,4,,103619997,37542,Unspecified,,,,,Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2152,548429,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay,Other,20971531.0,
2153,548430,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as altered cell morphology,Other,20971531.0,
2154,548431,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2155,548432,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2156,548433,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2157,548434,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2158,548435,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2159,548436,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2160,548437,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as cell viability by MTS assay,Other,20971531.0,
2161,548438,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as altered cell morphology,Other,20971531.0,
2162,548439,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2163,548440,5,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2164,548441,5,5,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2165,548442,5,5,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2166,548443,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE,Other,20971531.0,
2167,548444,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2168,548445,4,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as altered cell morphology,Other,20971531.0,
2169,548446,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2170,548447,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2171,548448,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2172,548449,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2173,548450,4,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2174,551034,1,3,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus after 72 hrs by half-leaf juice rubbing method,Other,21095122.0,
2175,555930,3,4,,103619997,37542,Inactive,,,,,Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 2 passages at 30 ug/ml by quantitative RT-PCR,Other,19104013.0,
2176,555931,3,4,,103619997,37542,Inactive,,,,,Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 3 passages at 30 ug/ml by quantitative RT-PCR,Other,19104013.0,
2177,567524,4,2,,103619997,37542,Active,,,18.5,EC50,Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay,Confirmatory,21115214.0,
2178,567525,4,2,,103619997,37542,Unspecified,,,400.0,IC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,21115214.0,
2179,567526,1,5,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus IV4454 infected in african green monkey Vero cells",Other,21115214.0,
2180,569231,4,4,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2181,569232,4,4,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2182,569233,4,4,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2183,569236,4,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2184,569237,4,2,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2185,569238,4,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2186,569239,5,3,,103619997,37542,Unspecified,,,,CC50,Cytotoxicity against HEL cells after 3 days by coulter counter analysis,Confirmatory,21232828.0,
2187,575124,4,4,,103619997,37542,Active,,,4.92,EC50,"Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2188,575125,4,4,,103619997,37542,Active,,,19.67,EC50,"Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2189,575244,4,4,,103619997,37542,Active,,,35.6,EC50,"Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2190,575245,4,4,,103619997,37542,Active,,,46.7,EC50,"Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2191,575247,4,4,,103619997,37542,Active,,,20.92,EC50,"Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2192,575250,4,2,,103619997,37542,Active,,,13.93,EC50,"Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2193,575251,4,2,,103619997,37542,Active,,,25.0,EC50,"Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain",Confirmatory,20350949.0,
2194,588209,2,3,,103619997,37542,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2195,588210,2,4,,103619997,37542,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2196,588211,2,3,,103619997,37542,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2197,588212,2,3,,103619997,37542,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2198,588213,2,3,,103619997,37542,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2199,588214,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2200,588215,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2201,588216,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2202,588217,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2203,588218,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2204,588219,2,3,,103619997,37542,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2205,588220,2,3,,103619997,37542,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2206,588334,1,1,,8139972,37542,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2207,588335,1,1,,8139972,37542,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2208,588342,1,1,,8139972,37542,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2209,588343,1,1,,8139972,37542,Inactive,,,,AC50_uM,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2210,588349,1,1,,90341426,37542,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2211,588352,1,2,,8139972,37542,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2212,588354,1,1,,8139972,37542,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2213,588358,1,2,,8139972,37542,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2214,588378,1,1,,90341426,37542,Inactive,171543895.0,6311.0,31.6228,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2215,588391,1,1,,8139972,37542,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2216,588398,1,1,,8139972,37542,Inactive,23893668.0,3783750.0,,AC50_uM,TES1 - eGFP vs TES2 -dsRED Pathway Differentiation Measured in Cell-Based System Using Imaging - 2122-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2217,588405,1,1,,8139972,37542,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2218,588413,1,2,,8139972,37542,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2219,588436,1,1,,8139972,37542,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2220,588453,1,1,,8139972,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2221,588453,1,1,,50105410,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2222,588453,1,1,,90341426,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2223,588456,1,1,,8139972,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2224,588456,1,1,,90341426,37542,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2225,588458,1,1,,8139972,37542,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2226,588473,1,1,,8139972,37542,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2227,588473,1,1,,8139972,37542,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2228,588475,1,2,,8139972,37542,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2229,588475,1,2,,8139972,37542,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2230,588478,1,2,,124800323,37542,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2231,588489,1,1,,8139972,37542,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2232,588492,1,1,,8139972,37542,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2233,588493,1,2,,8139972,37542,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2234,588497,1,2,,8139972,37542,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2235,588497,1,2,,8139972,37542,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2236,588497,1,2,,8139972,37542,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2237,588499,1,3,,8139972,37542,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2238,588499,1,3,,8139972,37542,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2239,588499,1,3,,8139972,37542,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2240,588501,1,2,,8139972,37542,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2241,588501,1,2,,8139972,37542,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2242,588501,1,2,,8139972,37542,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2243,588511,1,2,,8139972,37542,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2244,588513,1,1,,17389529,37542,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2245,588514,1,1,,17389529,37542,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2246,588515,1,1,,17389529,37542,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2247,588516,1,1,,17389529,37542,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2248,588526,1,1,,17389529,37542,Inconclusive,325495553.0,9971.0,31.6228,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2249,588527,1,1,,17389529,37542,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2250,588532,1,1,,17389529,37542,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2251,588533,1,1,,17389529,37542,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2252,588534,1,1,,17389529,37542,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2253,588535,1,1,,17389529,37542,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2254,588536,1,1,,17389529,37542,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2255,588537,1,1,,17389529,37542,Inconclusive,216409692.0,5468.0,50.1187,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2256,588541,1,1,,17389529,37542,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2257,588543,1,1,,17389529,37542,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2258,588544,1,1,,17389529,37542,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2259,588545,1,1,,17389529,37542,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2260,588546,1,1,,17389529,37542,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2261,588547,1,1,,17389529,37542,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2262,588549,1,1,,8139972,37542,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2263,588579,1,1,,8139972,37542,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2264,588579,1,1,,90341426,37542,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2265,588590,1,1,,8139972,37542,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2266,588590,1,1,,50105410,37542,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2267,588591,1,1,,8139972,37542,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2268,588591,1,1,,50105410,37542,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2269,588621,1,1,,8139972,37542,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2270,588627,1,1,,8139972,37542,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2271,588664,1,2,,8139972,37542,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2272,588664,1,2,,8139972,37542,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2273,588674,1,2,,8139972,37542,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2274,588675,1,1,,8139972,37542,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2275,588676,1,1,,8139972,37542,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2276,588689,1,1,,8139972,37542,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2277,588692,2,1,,8139972,37542,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2278,588726,1,2,,8139972,37542,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2279,588727,1,1,,8139972,37542,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2280,588795,1,1,,8139972,37542,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2281,588795,1,1,,90341426,37542,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2282,588814,1,3,,8139972,37542,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2283,588819,1,4,,8139972,37542,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2284,588834,2,1,,17389529,37542,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2285,588834,2,1,,50105410,37542,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2286,588850,1,1,,8139972,37542,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2287,588852,1,3,,8139972,37542,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2288,588855,1,1,,8139972,37542,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2289,588856,1,1,,8139972,37542,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2290,593220,3,2,,103619997,37542,Unspecified,,,1690.0,IC50,Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method,Confirmatory,21441033.0,
2291,593221,3,2,,103619997,37542,Unspecified,,,910.0,IC50,Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method,Confirmatory,21441033.0,
2292,593222,3,2,,103619997,37542,Unspecified,,,4090.0,IC50,Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method,Confirmatory,21441033.0,
2293,593223,3,2,,103619997,37542,Unspecified,,,2340.0,IC50,Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method,Confirmatory,21441033.0,
2294,593224,2,1,,103619997,37542,Unspecified,,,8190.0,TC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,21441033.0,
2295,593225,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3",Other,21441033.0,
2296,593226,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6",Other,21441033.0,
2297,593227,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus A16",Other,21441033.0,
2298,593228,1,4,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Human enterovirus 71",Other,21441033.0,
2299,602123,1,1,,8139972,37542,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2300,602141,1,1,,8139972,37542,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2301,602162,1,1,,8139972,37542,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2302,602163,1,1,,8139972,37542,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2303,602179,1,2,,8139972,37542,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2304,602229,1,1,,8139972,37542,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2305,602233,1,1,,8139972,37542,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2306,602244,1,2,,8139972,37542,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2307,602247,1,2,,8139972,37542,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2308,602248,1,2,,8139972,37542,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2309,602250,1,2,,8139972,37542,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2310,602252,1,1,,8139972,37542,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2311,602252,1,1,,8139972,37542,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2312,602261,1,1,,8139972,37542,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2313,602274,1,2,,8139972,37542,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2314,602281,1,1,,8139972,37542,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2315,602281,1,1,,8139972,37542,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2316,602310,1,2,,8139972,37542,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2317,602313,1,1,,8139972,37542,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2318,602329,1,1,,8139972,37542,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2319,602332,1,1,,8139972,37542,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2320,602332,1,1,,90341426,37542,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2321,602340,1,2,,8139972,37542,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2322,602342,2,1,,8139972,37542,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2323,602346,1,1,,8139972,37542,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2324,602363,1,1,,8139972,37542,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2325,602393,1,1,,8139972,37542,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2326,602396,1,2,,8139972,37542,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2327,602399,1,2,,8139972,37542,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2328,602405,1,1,,8139972,37542,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2329,602410,1,1,,8139972,37542,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2330,602429,1,1,,8139972,37542,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2331,602438,1,1,,8139972,37542,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2332,602440,1,1,,8139972,37542,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2333,602449,1,2,,8139972,37542,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2334,602481,1,1,,8139972,37542,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2335,611627,3,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy,Confirmatory,21565516.0,
2336,611628,3,4,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy,Confirmatory,21565516.0,
2337,611629,3,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against VSV infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2338,611757,3,2,,103619997,37542,Active,,,14.8,EC50,Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2339,611758,3,2,,103619997,37542,Active,,,3.0,EC50,Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2340,611759,3,2,,103619997,37542,Unspecified,,,69.0,EC50,Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2341,611760,3,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2342,611761,3,2,,103619997,37542,Unspecified,,,121.0,EC50,Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2343,611762,3,2,,103619997,37542,Unspecified,,,174.0,EC50,Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2344,611763,3,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2345,611764,3,2,,103619997,37542,Unspecified,,,125.0,EC50,Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2346,611765,3,2,,103619997,37542,Inconclusive,,,,EC50,Antiviral activity against Feline coronavirus infected in CRFK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2347,611766,3,3,,103619997,37542,Active,,,9.8,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2348,611767,3,3,,103619997,37542,Active,,,12.5,EC50,Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2349,611768,3,3,,103619997,37542,Active,,,7.3,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2350,611769,3,2,,103619997,37542,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells assessed as alteration of cell morphology after 3 days by microscopy,Other,21565516.0,
2351,611770,3,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against dog MDCK cells assessed as alteration of cell morphology after 3 days by microscopy,Other,21565516.0,
2352,611771,3,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis,Confirmatory,21565516.0,
2353,611772,3,2,,103619997,37542,Inconclusive,,,,CC50,Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis,Confirmatory,21565516.0,
2354,617985,3,3,,103619997,37542,Unspecified,,,100.8,IC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay,Confirmatory,21879714.0,
2355,622444,2,1,,103619997,37542,Unspecified,,,8190.0,TC50,Cytotoxicity against african green monkey Vero cells infected with Coxsackievirus B3 assessed as growth inhibition after 48 hrs by Reed-Muench analysis,Confirmatory,21880491.0,
2356,622445,3,2,,103619997,37542,Unspecified,,,910.0,IC50,Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis,Confirmatory,21880491.0,
2357,622446,1,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Coxsackievirus B3",Other,21880491.0,
2358,622447,2,1,,103619997,37542,Unspecified,,,8190.0,TC50,Cytotoxicity against african green monkey Vero cells infected with Enterovirus 71 assessed as growth inhibition after 48 hrs by Reed-Muench analysis,Confirmatory,21880491.0,
2359,622448,3,2,,103619997,37542,Unspecified,,,2119.0,IC50,Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis,Confirmatory,21880491.0,
2360,622533,1,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Enterovirus 71",Other,21880491.0,
2361,623870,1,1,,8139972,37542,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2362,623870,1,1,,8139972,37542,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2363,623877,1,1,,8139972,37542,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2364,623901,1,1,,8139972,37542,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2365,624037,1,3,,8139972,37542,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2366,624038,1,3,,8139972,37542,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2367,624040,1,3,,8139972,37542,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2368,624125,1,4,,8139972,37542,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2369,624126,1,3,,8139972,37542,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2370,624127,1,2,,8139972,37542,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2371,624146,1,1,,90341426,37542,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2372,624147,1,1,,90341426,37542,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2373,624148,1,2,,90341426,37542,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2374,624149,1,1,,90341426,37542,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2375,624168,1,1,,8139972,37542,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2376,624169,1,1,,8139972,37542,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2377,624170,1,1,,8139972,37542,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2378,624171,1,1,,8139972,37542,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2379,624172,1,1,,8139972,37542,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2380,624173,1,3,,8139972,37542,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2381,624178,1,1,,8139972,37542,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2382,624202,1,1,,8139972,37542,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2383,624204,1,2,,8139972,37542,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2384,624246,1,1,,8139972,37542,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2385,624256,1,2,,8139972,37542,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2386,624263,1,1,,8139972,37542,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2387,624263,1,1,,8139972,37542,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2388,624267,1,2,,8139972,37542,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2389,624267,1,2,,8139972,37542,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2390,624268,1,3,,8139972,37542,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2391,624288,1,1,,8139972,37542,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2392,624296,1,1,,8139972,37542,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2393,624297,1,1,,8139972,37542,Inconclusive,7705682.0,51053.0,0.1836,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2394,624304,1,2,,8139972,37542,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2395,624330,1,2,,8139972,37542,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2396,624349,1,2,,92308226,37542,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2397,624349,1,2,,92309231,37542,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2398,624349,1,2,,121363662,37542,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2399,624352,1,1,,8139972,37542,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2400,624354,1,1,,8139972,37542,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2401,624377,1,1,,85148371,37542,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2402,624414,1,1,,8139972,37542,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2403,624415,1,2,,8139972,37542,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2404,624416,1,1,,85148371,37542,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2405,624417,1,1,,8139972,37542,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2406,624418,1,1,,8139972,37542,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2407,624455,1,1,,90341426,37542,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2408,624463,1,1,,8139972,37542,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2409,624464,1,1,,8139972,37542,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2410,624465,1,1,,8139972,37542,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2411,624466,1,3,,85148371,37542,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2412,624467,1,1,,85148371,37542,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2413,624483,1,1,,8139972,37542,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2414,625144,5,5,,103619997,37542,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2415,625145,4,7,,103619997,37542,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2416,625146,5,5,,103619997,37542,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2417,625147,4,7,,103619997,37542,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2418,625148,4,7,,103619997,37542,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2419,625149,4,7,,103619997,37542,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2420,625150,5,5,,103619997,37542,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2421,625151,4,7,,103619997,37542,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2422,625152,4,7,,103619997,37542,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2423,625153,4,7,,103619997,37542,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2424,625154,4,7,,103619997,37542,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2425,625155,4,7,,103619997,37542,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2426,625156,1,9,,103619997,37542,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2427,625157,6,2,,103619997,37542,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2428,625158,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2429,625159,5,5,,103619997,37542,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2430,625160,1,9,,103619997,37542,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2431,625161,4,7,,103619997,37542,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2432,625162,4,7,,103619997,37542,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2433,625163,4,7,,103619997,37542,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2434,625164,1,6,,103619997,37542,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2435,625165,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2436,625166,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2437,625167,5,5,,103619997,37542,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2438,625168,4,7,,103619997,37542,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2439,625169,1,6,,103619997,37542,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2440,625170,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2441,625171,4,7,,103619997,37542,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2442,625172,4,7,,103619997,37542,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2443,625173,5,5,,103619997,37542,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2444,625174,5,5,,103619997,37542,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2445,625175,5,5,,103619997,37542,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2446,625176,1,9,,103619997,37542,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2447,625177,5,5,,103619997,37542,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2448,625178,5,5,,103619997,37542,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2449,625179,1,9,,103619997,37542,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2450,625180,5,5,,103619997,37542,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2451,625181,5,5,,103619997,37542,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2452,625182,5,5,,103619997,37542,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2453,625183,5,5,,103619997,37542,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2454,625184,5,5,,103619997,37542,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2455,625185,5,5,,103619997,37542,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2456,625186,5,5,,103619997,37542,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2457,625187,5,5,,103619997,37542,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2458,625188,1,9,,103619997,37542,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2459,625189,1,7,,103619997,37542,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2460,625190,4,5,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2461,625191,4,7,,103619997,37542,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2462,625192,4,7,,103619997,37542,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2463,625193,5,5,,103619997,37542,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2464,625194,4,7,,103619997,37542,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2465,625195,4,7,,103619997,37542,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2466,625196,5,6,,103619997,37542,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2467,625197,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2468,625198,4,7,,103619997,37542,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2469,625199,4,7,,103619997,37542,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2470,625200,4,7,,103619997,37542,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2471,625201,4,7,,103619997,37542,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2472,625202,4,7,,103619997,37542,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2473,625203,4,7,,103619997,37542,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2474,625204,4,7,,103619997,37542,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2475,625205,4,7,,103619997,37542,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2476,625206,4,7,,103619997,37542,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2477,625207,4,7,,103619997,37542,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2478,625208,5,5,,103619997,37542,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2479,625209,4,7,,103619997,37542,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2480,625210,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2481,625211,1,6,,103619997,37542,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2482,625212,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2483,625213,4,7,,103619997,37542,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2484,625214,1,9,,103619997,37542,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2485,625215,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2486,625216,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2487,625217,4,7,,103619997,37542,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2488,625218,4,7,,103619997,37542,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2489,625219,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2490,625220,4,7,,103619997,37542,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2491,625221,4,7,,103619997,37542,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2492,625222,4,7,,103619997,37542,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2493,625223,4,7,,103619997,37542,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2494,625224,3,4,,103619997,37542,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2495,625225,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2496,625226,4,7,,103619997,37542,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2497,625227,4,7,,103619997,37542,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2498,625228,4,7,,103619997,37542,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2499,625229,5,5,,103619997,37542,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2500,625230,1,6,,103619997,37542,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2501,625231,4,7,,103619997,37542,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2502,625232,1,9,,103619997,37542,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2503,625233,4,7,,103619997,37542,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2504,625234,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2505,625235,4,7,,103619997,37542,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2506,625236,5,5,,103619997,37542,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2507,625237,4,7,,103619997,37542,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2508,625238,4,7,,103619997,37542,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2509,625239,4,7,,103619997,37542,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2510,625240,1,9,,103619997,37542,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2511,625241,4,7,,103619997,37542,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2512,625242,4,7,,103619997,37542,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2513,625243,5,5,,103619997,37542,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2514,625244,5,5,,103619997,37542,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2515,625245,5,5,,103619997,37542,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2516,625246,1,9,,103619997,37542,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2517,625247,5,5,,103619997,37542,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2518,625248,5,5,,103619997,37542,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2519,625249,5,5,,103619997,37542,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2520,625250,5,5,,103619997,37542,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2521,625251,5,5,,103619997,37542,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2522,625252,4,7,,103619997,37542,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2523,625253,4,7,,103619997,37542,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2524,625254,4,7,,103619997,37542,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2525,625255,4,7,,103619997,37542,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2526,625256,4,7,,103619997,37542,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2527,625257,4,7,,103619997,37542,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2528,625258,4,7,,103619997,37542,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2529,625259,4,7,,103619997,37542,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2530,625260,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2531,625261,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2532,625262,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2533,625263,4,7,,103619997,37542,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2534,625264,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2535,625265,1,6,,103619997,37542,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2536,625266,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2537,625267,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2538,625268,4,2,,103619997,37542,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2539,625268,4,2,,103619997,37542,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2540,625268,4,2,,103619997,37542,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2541,625268,4,2,,103619997,37542,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2542,625269,4,7,,103619997,37542,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2543,625270,4,7,,103619997,37542,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2544,625271,5,5,,103619997,37542,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2545,625272,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2546,625273,4,6,,103619997,37542,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2547,625274,1,6,,103619997,37542,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2548,625275,3,4,,103619997,37542,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2549,625277,1,3,,103619997,37542,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2550,625279,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2551,625280,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2552,625281,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2553,625282,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2554,625283,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2555,625284,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2556,625285,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2557,625286,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2558,625287,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2559,625288,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2560,625289,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2561,625290,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2562,625291,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2563,625292,1,3,,103619997,37542,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2564,634088,1,4,,103619997,37542,Inconclusive,,,,,Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in luciferase activity at 10 uM after 3 days,Other,22100256.0,
2565,634089,1,5,,103619997,37542,Inconclusive,,,,,Cytotoxicity against human HuH7 cells infected with HCV1b assessed as cell viability at 10 uM after 3 days by MTS assay,Other,22100256.0,
2566,634090,3,3,,103619997,37542,Active,,,14.0,EC50,Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay,Confirmatory,22100256.0,
2567,634091,3,4,,103619997,37542,Active,,,32.0,CC50,Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay,Confirmatory,22100256.0,
2568,634092,1,3,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human HuH7 cells infected with HCV1b to EC50 for HCV genotype 1b",Other,22100256.0,
2569,634746,1,6,,103619997,37542,Inactive,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2570,634747,1,6,,103619997,37542,Inactive,,,,,Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2571,634748,1,6,,103619997,37542,Inactive,,,,,Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2572,634749,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2573,634750,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2574,634751,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2575,634752,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2576,634753,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2577,634754,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2578,634755,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2579,634756,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2580,634757,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2581,634758,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2582,634759,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2583,634760,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2584,634761,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2585,634831,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2586,634832,1,5,,103619997,37542,Inactive,,,,,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2587,634833,1,5,,103619997,37542,Inactive,,,,,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2588,634834,1,5,,103619997,37542,Inactive,,,,,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2589,634835,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2590,634836,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2591,634837,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
2592,634838,1,4,,103619997,37542,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
2593,648645,3,4,,103619997,37542,Active,,,3.9,IC50,Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs,Confirmatory,22341943.0,
2594,648646,3,4,,103619997,37542,Active,,,1.9,IC50,Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs,Confirmatory,22341943.0,
2595,648647,3,4,,103619997,37542,Active,,,14.7,IC50,Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs,Confirmatory,22341943.0,
2596,648648,2,2,,103619997,37542,Unspecified,,,1278.0,TC50,Cytotoxicity against MDCK cells,Confirmatory,22341943.0,
2597,648649,1,5,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H3N2",Other,22341943.0,
2598,648650,1,5,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H1N1",Other,22341943.0,
2599,648651,1,5,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza B virus",Other,22341943.0,
2600,648680,1,4,,103619997,37542,Unspecified,,,,,"Antiviral activity against C4 type Human enterovirus 71 MP10 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip administered 2 hrs post infection qd for 7 days measured up to 14 days",Other,22342145.0,
2601,648684,3,2,,103619997,37542,Unspecified,,,,,Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay,Other,22342145.0,
2602,648685,3,2,,103619997,37542,Inconclusive,,,,,Cytotoxicity against human RD cells,Other,22342145.0,
2603,651550,1,1,,8139972,37542,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2604,651560,1,1,,8139972,37542,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2605,651572,1,2,,85148371,37542,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2606,651582,1,1,,8139972,37542,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2607,651602,1,1,,85148371,37542,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2608,651602,1,1,,85148371,37542,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2609,651602,1,1,,85148371,37542,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2610,651631,4,1,,144203810,37542,Active,269849759.0,7157.0,13.3332,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2611,651631,4,1,,144208165,37542,Active,269849759.0,7157.0,64.44,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2612,651632,4,1,,144203810,37542,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2613,651632,4,1,,144208165,37542,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2614,651633,4,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2615,651633,4,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2616,651634,4,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2617,651634,4,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2618,651635,1,3,,8139972,37542,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2619,651635,1,3,,90341426,37542,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2620,651636,1,1,,8139972,37542,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2621,651640,1,1,,85148371,37542,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2622,651644,1,1,,8139972,37542,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2623,651647,1,1,,8139972,37542,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2624,651654,1,1,,8139972,37542,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2625,651658,1,1,,85148371,37542,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2626,651661,2,1,,85148371,37542,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2627,651687,1,1,,8139972,37542,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2628,651699,1,1,,8139972,37542,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2629,651699,1,1,,8139972,37542,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2630,651702,1,2,,8139972,37542,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2631,651704,2,1,,85148371,37542,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2632,651710,1,1,,85148371,37542,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2633,651711,2,1,,85148371,37542,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2634,651718,1,2,,85148371,37542,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2635,651723,1,1,,8139972,37542,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2636,651724,1,1,,8139972,37542,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2637,651725,1,1,,8139972,37542,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2638,651741,1,1,,17389529,37542,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2639,651743,1,1,,17389529,37542,Active,269849759.0,7157.0,31.6228,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2640,651749,1,1,,17389529,37542,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2641,651751,1,1,,17389529,37542,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2642,651754,1,1,,17389529,37542,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2643,651755,1,1,,17389529,37542,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2644,651757,1,1,,17389529,37542,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2645,651758,1,1,,17389529,37542,Active,186368.0,3576.0,66.8242,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2646,651768,1,2,,8139972,37542,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2647,651777,1,1,,17389529,37542,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2648,651778,1,1,,17389529,37542,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2649,651800,1,1,,85148371,37542,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2650,651802,1,1,,17389529,37542,Active,49066040.0,6097.0,18.8336,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2651,651819,1,1,,8139972,37542,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2652,651820,1,1,,8139972,37542,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2653,651821,2,4,,85148371,37542,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2654,651828,1,2,,92309231,37542,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2655,651828,1,2,,121361852,37542,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2656,651838,1,1,,17389529,37542,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2657,651838,1,1,1.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2658,651838,1,1,2.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2659,651838,1,1,3.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2660,651838,1,1,4.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2661,651838,1,1,5.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2662,651838,1,1,6.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2663,651838,1,1,7.0,17389529,37542,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2664,651838,1,1,8.0,17389529,37542,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2665,651957,1,1,,85148371,37542,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2666,651958,1,1,,85148371,37542,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2667,651965,1,1,,8139972,37542,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2668,651999,1,1,,8139972,37542,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2669,652010,1,1,,85148371,37542,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2670,652017,1,1,,85148371,37542,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2671,652025,1,1,,8139972,37542,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2672,652031,1,1,,26538475,37542,Inactive,119607129.0,4986.0,,,Maybridge screen to identify antagonists of kappa opioid receptor 1 (OPRK1): fluorescence-based cell-based assay,Screening,,
2673,652039,1,1,,85148371,37542,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2674,652048,1,2,,8139972,37542,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2675,652048,1,2,,144203810,37542,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2676,652051,1,1,,8139972,37542,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2677,652051,1,1,,144203810,37542,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2678,652054,1,1,,8139972,37542,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2679,652067,1,4,,85148371,37542,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2680,652104,1,1,,8139972,37542,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2681,652105,1,1,,8139972,37542,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2682,652106,1,1,,8139972,37542,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2683,652106,1,1,,90341426,37542,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2684,652115,1,1,,85148371,37542,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2685,652126,1,3,,85148371,37542,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2686,652154,1,1,,85148371,37542,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2687,652162,2,1,,85148371,37542,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2688,652163,1,1,,85148371,37542,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2689,652197,1,1,,85148371,37542,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2690,652257,1,1,,85148371,37542,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2691,657387,2,2,,103619997,37542,Unspecified,,,114.8,IC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs,Confirmatory,22487178.0,
2692,658606,2,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2693,658607,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology,Other,22459876.0,
2694,658611,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology,Other,22459876.0,
2695,658612,2,2,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2696,658613,2,2,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2697,658614,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2698,658615,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2699,658616,2,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2700,658742,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology,Other,22459876.0,
2701,658743,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2702,658744,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2703,658745,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2704,658746,2,3,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2705,658747,2,4,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2706,658748,2,3,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2707,658749,2,3,,103619997,37542,Active,,,6.7,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2708,658750,2,4,,103619997,37542,Active,,,5.6,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2709,658751,2,3,,103619997,37542,Active,,,4.8,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2710,659146,2,4,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2711,659147,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2712,659148,2,4,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2713,659149,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2714,659150,2,2,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2715,659151,2,2,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HeLa cells,Confirmatory,22464686.0,
2716,659152,2,2,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Coxsackie virus B4 infected in HeLa cells,Confirmatory,22464686.0,
2717,659153,2,2,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Respiratory syncytial virus infected in HeLa cells,Confirmatory,22464686.0,
2718,659154,2,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,22464686.0,
2719,659155,2,4,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,22464686.0,
2720,659156,2,2,,103619997,37542,Unspecified,,,85.0,EC50,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2721,659157,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2722,659282,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2723,659283,2,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2724,659284,2,2,,103619997,37542,Unspecified,,,126.0,EC50,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2725,659285,2,4,,103619997,37542,Active,,,5.1,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2726,659286,2,3,,103619997,37542,Active,,,2.3,EC50,Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2727,659287,2,3,,103619997,37542,Active,,,4.5,EC50,Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,22464686.0,
2728,659288,2,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against HEL cells assessed as morphological changes by microscopic analysis,Other,22464686.0,
2729,659289,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as morphological changes by microscopic analysis,Other,22464686.0,
2730,659290,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as morphological changes by microscopic analysis,Other,22464686.0,
2731,659291,2,2,,103619997,37542,Active,,,,,Cytotoxicity against MDCK cells assessed as morphological changes by microscopic analysis,Other,22464686.0,
2732,665008,2,2,,103619997,37542,Active,,,22.0,IC50,Cytostatic activity against mouse L1210/0 after 48 hrs by cell counting,Confirmatory,22555152.0,
2733,665009,2,2,,103619997,37542,Unspecified,,,63.0,IC50,Cytostatic activity against human CEM/0 after 72 hrs by cell counting,Confirmatory,22555152.0,
2734,665016,2,2,,103619997,37542,Active,,,1.0,IC50,"Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins",Confirmatory,22555152.0,
2735,665017,2,2,,103619997,37542,Active,,,1.0,IC50,"Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins",Confirmatory,22555152.0,
2736,665833,1,3,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against TMV assessed as inhibition rate at 500 ug/mL,Other,22546200.0,
2737,665834,1,3,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as viral inactivation effect at 500 ug/mL,Other,22546200.0,
2738,665835,1,3,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as curative effect at 500 ug/mL,Other,22546200.0,
2739,665836,1,3,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as protection effect at 500 ug/mL,Other,22546200.0,
2740,668362,1,2,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against TMV at 500 ug/ml,Other,22608761.0,
2741,668363,1,2,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as inactivation effect at 500 ug/ml,Other,22608761.0,
2742,668364,1,2,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as curative effect at 500 ug/ml,Other,22608761.0,
2743,668365,1,2,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against TMV assessed as protection effect at 500 ug/ml,Other,22608761.0,
2744,673221,1,3,,103619997,37542,Unspecified,,,,,Antiviral activity at Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication at 10 uM after 3 days by renilla luciferase reporter gene assay,Other,22748708.0,
2745,673223,1,4,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HuH7 cells assessed as cell viability at 10 uM after 3 days by CellTiter Glo assay,Other,22748708.0,
2746,674870,2,1,,103619997,37542,Unspecified,,,4766.8,TC50,Cytotoxicity against MDCK cells incubated for 48 hrs by CPE method,Confirmatory,22824205.0,
2747,674871,2,4,,103619997,37542,Active,,,8.8,IC50,Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,22824205.0,
2748,674872,1,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1))",Other,22824205.0,
2749,674873,2,3,,103619997,37542,Active,,,45.5,IC50,Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,22824205.0,
2750,674874,1,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus (strain B/Jifang/13/97)",Other,22824205.0,
2751,674875,2,4,,103619997,37542,Active,,,35.3,IC50,Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,22824205.0,
2752,674876,1,3,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1))",Other,22824205.0,
2753,686940,1,1,,85148371,37542,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2754,686964,1,1,,85148371,37542,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2755,686970,1,2,,8139972,37542,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2756,686971,1,2,,8139972,37542,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2757,686977,2,1,,49699015,37542,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2758,686978,1,1,,8139972,37542,Active,79154014.0,55775.0,1.0323,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2759,686978,1,1,,144203810,37542,Active,79154014.0,55775.0,1.1582,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2760,686979,1,1,,8139972,37542,Active,79154014.0,55775.0,1.4581,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2761,686979,1,1,,144203810,37542,Active,79154014.0,55775.0,1.1582,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2762,686992,2,1,,85148371,37542,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2763,686996,1,1,,85148371,37542,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2764,687014,1,1,,85148371,37542,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2765,687016,1,1,,85148371,37542,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2766,687035,1,1,,163565017,37542,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2767,687037,1,3,,163565017,37542,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2768,688918,2,2,,103619997,37542,Active,,,4.6,EC50,Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay,Confirmatory,22944333.0,
2769,691388,1,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 20 to 50 ug/mL after 2 days by q-PCR analysis,Other,22985854.0,
2770,691389,1,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 10 ug/mL after 2 days by q-PCR analysis,Other,22985854.0,
2771,691392,2,4,,103619997,37542,Inconclusive,,,,,Cytotoxicity against human HuH7 cells after 2 days by XTT assay,Other,22985854.0,
2772,691394,2,4,,103619997,37542,Unspecified,,,,,Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis,Other,22985854.0,
2773,693524,2,2,,103619997,37542,Active,,,6.8,EC50,Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay,Confirmatory,23149298.0,
2774,693525,2,4,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay,Confirmatory,23149298.0,
2775,693526,2,2,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay,Confirmatory,23149298.0,
2776,693527,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration measured on day 3 post infection by MTS assay,Other,23149298.0,
2777,701507,2,2,,103619997,37542,Active,,,28.4,EC50,Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay,Confirmatory,23043370.0,
2778,701508,2,3,,103619997,37542,Unspecified,,,113.9,CC50,Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay,Confirmatory,23043370.0,
2779,701509,1,2,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Hep2 cells to EC50 for Respiratory syncytial virus Long infected in human Hep2 cells",Other,23043370.0,
2780,701510,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as log reduction in virus titer at 25 uM by virus plaque reduction assay,Other,23043370.0,
2781,701513,1,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against uninfected human Hep2 cells assessed as cell viability at 25 uM measured after 144 hrs by Cell Titer-Glo assay,Other,23043370.0,
2782,701514,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as post infection time duration of protection against virus-induced cytopathogenicity by Cell Titer-Glo assay,Other,23043370.0,
2783,712795,2,3,,103619997,37542,Unspecified,,,20.0,CC50,Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay,Confirmatory,24900429.0,
2784,712796,2,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against dog MDCK cells assessed as cell morphology alterations,Other,24900429.0,
2785,712807,2,4,,103619997,37542,Active,,,8.8,EC50,Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2786,712808,2,3,,103619997,37542,Active,,,8.8,EC50,Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2787,712809,2,4,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2788,712810,2,3,,103619997,37542,Active,,,7.6,EC50,Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2789,712811,2,3,,103619997,37542,Active,,,8.1,EC50,Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay,Confirmatory,24900429.0,
2790,712812,2,3,,103619997,37542,Active,,,8.0,EC50,Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2791,712813,2,4,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay,Confirmatory,24900429.0,
2792,712814,2,4,,103619997,37542,Active,,,7.7,EC50,Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2793,712815,2,3,,103619997,37542,Active,,,8.2,EC50,Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay,Confirmatory,24900429.0,
2794,712816,2,3,,103619997,37542,Active,,,8.7,EC50,Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis,Confirmatory,24900429.0,
2795,717169,2,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay,Confirmatory,23117173.0,
2796,717170,2,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis,Other,23117173.0,
2797,717171,2,2,,103619997,37542,Active,,,0.14,EC50,Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,23117173.0,
2798,717172,2,2,,103619997,37542,Active,,,0.094,EC50,Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis,Confirmatory,23117173.0,
2799,717173,2,4,,103619997,37542,Active,,,8.5,EC50,Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,23117173.0,
2800,717174,2,4,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis,Confirmatory,23117173.0,
2801,717280,2,2,,103619997,37542,Active,,,8.4,EC50,Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay,Confirmatory,23117173.0,
2802,717281,2,2,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis,Confirmatory,23117173.0,
2803,718709,1,2,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CTD50 for MDCK cells to ED50 for influenza virus A/California/07/09 (H1N1) pdm09",Other,23099095.0,
2804,718710,2,2,,103619997,37542,Active,,,24.6,ED50,Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method,Confirmatory,23099095.0,
2805,718711,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells after 48 hrs by MTT assay,Other,23099095.0,
2806,718739,2,2,,103619997,37542,Unspecified,,,,,Toxicity in MDCK cells assessed as induction of cell morphology changes,Other,23099097.0,
2807,718740,2,2,,103619997,37542,Active,,,4.6,EC50,Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2808,718741,2,4,,103619997,37542,Active,,,6.0,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2809,718742,2,2,,103619997,37542,Active,,,6.1,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2810,720504,1,1,,8139972,37542,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2811,720508,1,1,,85148371,37542,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2812,720509,1,1,,85148371,37542,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2813,720511,1,1,,85148371,37542,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2814,720516,2,1,,144203810,37542,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2815,720516,2,1,,144208165,37542,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2816,720532,1,1,,144203810,37542,Inconclusive,420597.0,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2817,720533,1,1,,144203810,37542,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2818,720538,1,2,,90341426,37542,Inactive,220983390.0,410.0,16.9441,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2819,720542,1,2,,8139972,37542,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2820,720543,1,1,,85148371,37542,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2821,720551,1,2,,8139972,37542,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2822,720552,2,1,,144203810,37542,Active,269849759.0,7157.0,13.3332,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2823,720552,2,1,,144208165,37542,Active,269849759.0,7157.0,64.44,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2824,720553,1,2,,8139972,37542,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2825,720559,1,2,,90341426,37542,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2826,720572,1,2,,90341426,37542,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2827,720573,1,2,,90341426,37542,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2828,720579,2,1,,8139972,37542,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2829,720579,2,1,,144203810,37542,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2830,720580,1,1,,8139972,37542,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2831,720580,1,1,,144203810,37542,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2832,720582,1,1,,85148371,37542,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2833,720596,1,1,,85148371,37542,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2834,720634,2,1,,144203810,37542,Inactive,,,2.9849,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2835,720634,2,1,,144208165,37542,Inactive,,,0.6444,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2836,720635,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2837,720635,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2838,720636,1,1,,17389529,37542,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2839,720637,2,1,,144203810,37542,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2840,720637,2,1,,144208165,37542,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2841,720641,1,2,,92308226,37542,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2842,720641,1,2,,92309231,37542,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2843,720647,1,2,,85148371,37542,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2844,720648,1,1,,85148371,37542,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2845,720652,1,1,,17389529,37542,Inconclusive,,,42.1632,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2846,720653,1,1,,17389529,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2847,720659,1,1,,17389529,37542,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2848,720674,2,2,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2849,720674,2,2,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2850,720675,2,2,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2851,720675,2,2,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2852,720678,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2853,720678,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2854,720679,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2855,720679,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2856,720680,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2857,720680,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2858,720681,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2859,720681,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2860,720682,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2861,720682,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2862,720683,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2863,720683,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2864,720684,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2865,720684,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2866,720685,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2867,720685,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2868,720686,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2869,720686,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2870,720687,2,2,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2871,720687,2,2,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2872,720691,4,1,,144203810,37542,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2873,720691,4,1,,144208165,37542,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2874,720692,3,1,,144203810,37542,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2875,720692,3,1,,144208165,37542,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2876,720693,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2877,720693,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2878,720700,1,4,,85148371,37542,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2879,720702,1,1,,85148371,37542,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2880,720704,1,4,,85148371,37542,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2881,720706,1,2,,85148371,37542,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2882,720707,1,2,,8139972,37542,Inactive,317373593.0,10411.0,89.1251,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2883,720708,1,2,,8139972,37542,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2884,720709,1,2,,8139972,37542,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2885,720711,1,2,,8139972,37542,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2886,720717,1,3,,92308226,37542,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2887,720717,1,3,,92309231,37542,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2888,720719,2,1,,144203810,37542,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2889,720719,2,1,,144208165,37542,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2890,720725,2,1,,144203810,37542,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2891,720725,2,1,,144208165,37542,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2892,725579,1,2,,103619997,37542,Unspecified,,,,,"Antiviral activity against Lassa virus infected in guinea pig strain 13 assessed as host survival rate at 80 mg/kg/day, ip administered at 1 hr prior to infection for 14 days relative to control",Other,23265895.0,
2893,726614,1,2,,103619997,37542,Unspecified,,,1160.0,IC50,Antiviral activity against wild type Measles virus mWTFb infected in simian B95a cells assessed as virus-induced cytopathogenicity incubated for 30 mins prior to inoculation measured after 3 days by phase contrast microscopy,Confirmatory,23320521.0,
2894,730331,3,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method,Other,23411074.0,
2895,743012,3,1,,144203810,37542,Active,,,0.6682,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2896,743012,3,1,,144208165,37542,Active,,,5.1187,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2897,743014,3,1,,144203810,37542,Active,,,0.7498,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2898,743014,3,1,,144208165,37542,Active,,,1.6187,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2899,743015,3,1,,144203810,37542,Active,,,1.6785,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2900,743015,3,1,,144208165,37542,Active,,,4.0659,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2901,743033,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2902,743033,3,1,,144208165,37542,Inconclusive,,,25.8743,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2903,743035,2,1,,144203810,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2904,743035,2,1,,144208165,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2905,743036,2,1,,144203810,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2906,743036,2,1,,144208165,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2907,743040,3,1,,144203810,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2908,743040,3,1,,144208165,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2909,743041,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2910,743041,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2911,743042,3,1,,144203810,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2912,743042,3,1,,144208165,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2913,743053,2,1,,144203810,37542,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2914,743053,2,1,,144208165,37542,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2915,743054,2,1,,144203810,37542,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2916,743054,2,1,,144208165,37542,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2917,743063,2,1,,144203810,37542,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2918,743063,2,1,,144208165,37542,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2919,743064,3,1,,144203810,37542,Active,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2920,743064,3,1,,144208165,37542,Inconclusive,,,32.2965,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2921,743065,3,1,,144203810,37542,Active,399498506.0,24831.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2922,743065,3,1,,144208165,37542,Active,399498506.0,24831.0,28.7843,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2923,743066,3,1,,144203810,37542,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2924,743066,3,1,,144208165,37542,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2925,743067,2,1,,144203810,37542,Inconclusive,399498506.0,24831.0,10.1922,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2926,743067,2,1,,144208165,37542,Inconclusive,399498506.0,24831.0,28.7843,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2927,743069,2,1,,144203810,37542,Inconclusive,348019627.0,2099.0,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2928,743069,2,1,,144208165,37542,Active,348019627.0,2099.0,51.626000000000005,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2929,743074,2,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2930,743074,2,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2931,743075,2,1,,144203810,37542,Inactive,348019627.0,2099.0,11.9856,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2932,743075,2,1,,144208165,37542,Inactive,348019627.0,2099.0,2.306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2933,743077,2,1,,144203810,37542,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2934,743077,2,1,,144208165,37542,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2935,743078,2,1,,144203810,37542,Inconclusive,348019627.0,2099.0,18.9959,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2936,743078,2,1,,144208165,37542,Active,348019627.0,2099.0,37.9783,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2937,743079,3,1,,144203810,37542,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2938,743079,3,1,,144208165,37542,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2939,743080,3,1,,144203810,37542,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2940,743080,3,1,,144208165,37542,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2941,743081,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2942,743081,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2943,743083,3,1,,144203810,37542,Inactive,119597822.0,1588.0,4.2163,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2944,743083,3,1,,144208165,37542,Inactive,119597822.0,1588.0,3.2297,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2945,743084,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2946,743084,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2947,743085,3,1,,144203810,37542,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2948,743085,3,1,,144208165,37542,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2949,743086,3,1,,144203810,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2950,743086,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2951,743091,2,1,,144203810,37542,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2952,743091,2,1,,144208165,37542,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2953,743094,3,1,,144203810,37542,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2954,743094,3,1,,144208165,37542,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2955,743122,2,1,,144203810,37542,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2956,743122,2,1,,144208165,37542,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2957,743126,1,1,,85148371,37542,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2958,743139,2,1,,144203810,37542,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2959,743139,2,1,,144208165,37542,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2960,743140,2,1,,144203810,37542,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2961,743140,2,1,,144208165,37542,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2962,743191,3,1,,144208165,37542,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2963,743191,3,1,,170464657,37542,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2964,743194,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2965,743194,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2966,743199,2,1,,144208165,37542,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2967,743199,2,1,,170464657,37542,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2968,743202,4,1,,144208165,37542,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2969,743202,4,1,,170464657,37542,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2970,743203,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2971,743203,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2972,743205,1,1,,90341426,37542,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2973,743205,1,1,,90341426,37542,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2974,743206,1,1,,90341426,37542,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2975,743206,1,1,,90341426,37542,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2976,743207,1,1,,90341426,37542,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2977,743207,1,1,,90341426,37542,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2978,743209,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2979,743209,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2980,743210,4,1,,144208165,37542,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2981,743210,4,1,,170464657,37542,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2982,743211,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2983,743211,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2984,743212,3,1,,144208165,37542,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2985,743212,3,1,,170464657,37542,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2986,743213,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2987,743213,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2988,743215,3,1,,144208165,37542,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2989,743215,3,1,,170464657,37542,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2990,743217,3,1,,144208165,37542,Inconclusive,325495553.0,9971.0,25.8743,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2991,743217,3,1,,170464657,37542,Inconclusive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2992,743218,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2993,743218,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2994,743219,3,1,,144208165,37542,Inconclusive,20149576.0,4780.0,30.4899,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2995,743219,3,1,,170464657,37542,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2996,743220,3,1,,144208165,37542,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2997,743220,3,1,,170464657,37542,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2998,743221,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2999,743221,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3000,743222,3,1,,144208165,37542,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3001,743222,3,1,,170464657,37542,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3002,743223,3,1,,144208165,37542,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3003,743223,3,1,,170464657,37542,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3004,743224,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3005,743224,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3006,743225,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3007,743225,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3008,743226,2,1,,144208165,37542,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3009,743226,2,1,,170464657,37542,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3010,743227,2,1,,144208165,37542,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3011,743227,2,1,,170464657,37542,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3012,743228,3,1,,144208165,37542,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3013,743228,3,1,,170464657,37542,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3014,743238,1,1,,85148371,37542,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3015,743239,2,1,,144208165,37542,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3016,743239,2,1,,170464657,37542,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3017,743240,2,1,,144208165,37542,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3018,743240,2,1,,170464657,37542,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3019,743241,2,1,,144208165,37542,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3020,743241,2,1,,170464657,37542,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3021,743242,2,1,,144208165,37542,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3022,743242,2,1,,170464657,37542,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3023,743244,1,1,,90341426,37542,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3024,743244,1,1,,144203810,37542,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3025,743247,1,2,,85148371,37542,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3026,743255,1,1,,8139972,37542,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3027,743266,1,2,,8139972,37542,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3028,743269,1,1,,85148371,37542,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3029,743269,1,1,,85148371,37542,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3030,743279,1,2,,8139972,37542,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3031,743287,1,1,,85148371,37542,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3032,743288,1,1,,17389529,37542,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3033,743292,1,1,,17389529,37542,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3034,743397,1,1,,85148371,37542,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3035,743398,1,1,,85148371,37542,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3036,751085,1,1,,103619997,37542,Unspecified,,,222.2,IC50,Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23734721.0,
3037,751219,1,2,,103619997,37542,Unspecified,,,87.0,IC50,Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay,Confirmatory,23758051.0,
3038,751301,1,2,,103619997,37542,Active,,,0.41,IC50,Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay,Confirmatory,23806112.0,
3039,751302,1,3,,103619997,37542,Active,,,20.2,IC50,Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay,Confirmatory,23806112.0,
3040,762954,1,1,,103619997,37542,Unspecified,,,113.1,IC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay,Confirmatory,23886345.0,
3041,763858,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza B virus (B/Florida/4/2006)",Other,23811085.0,
3042,763859,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Perth/16/2009(H3N2))",Other,23811085.0,
3043,763860,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/duck/Minnesota/1525/1981(H5N1))",Other,23811085.0,
3044,763861,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/California/07/2009(H1N1))",Other,23811085.0,
3045,763863,1,1,,103619997,37542,Active,,,5.73,EC50,Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay,Confirmatory,23811085.0,
3046,763864,1,3,,103619997,37542,Active,,,18.43,EC50,Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay,Confirmatory,23811085.0,
3047,763865,1,3,,103619997,37542,Active,,,23.75,EC50,Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay,Confirmatory,23811085.0,
3048,763923,1,1,,103619997,37542,Unspecified,,,323.5,CC50,Cytotoxicity against MDCK cells,Confirmatory,23811085.0,
3049,763924,1,3,,103619997,37542,Active,,,18.43,EC50,Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay,Confirmatory,23811085.0,
3050,765048,1,5,,103619997,37542,Inactive,417522.0,5467.0,,,Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity at 10 uM,Other,23891183.0,
3051,765049,1,5,,103619997,37542,Inconclusive,3041727.0,5465.0,,,Antagonist activity at human PPARalpha assessed as effect on TIPP-703-induced activity at 10 uM,Other,23891183.0,
3052,765050,2,3,,103619997,37542,Inconclusive,417522.0,5467.0,,IC50,Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity,Confirmatory,23891183.0,
3053,765051,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey OR6 cells to ED50 for HCV",Other,23891183.0,
3054,765052,1,2,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against african green monkey OR6 cells after 72 hrs by WST1 assay,Confirmatory,23891183.0,
3055,765053,2,1,,103619997,37542,Active,,,5.6,ED50,Antiviral activity against HCV infected in african green monkey OR6 cells assessed as inhibition of viral RNA replication after 72 hrs by luciferase reporter gene assay,Confirmatory,23891183.0,
3056,766685,1,2,,103619997,37542,Active,,,8.3,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3057,766686,1,2,,103619997,37542,Active,,,7.2,EC50,Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3058,766687,1,1,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3059,766688,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3060,766689,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3061,766690,1,3,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3062,766691,1,1,,103619997,37542,Unspecified,,,85.0,EC50,Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3063,766692,1,1,,103619997,37542,Active,,,5.0,EC50,Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3064,766693,1,1,,103619997,37542,Active,,,22.0,EC50,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3065,766694,1,2,,103619997,37542,Active,,,9.6,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3066,766695,1,1,,103619997,37542,Active,,,5.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
3067,766706,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as morphological changes,Other,23911856.0,
3068,766707,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as morphological changes,Other,23911856.0,
3069,766708,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as morphological changes,Other,23911856.0,
3070,767050,1,2,,103619997,37542,Inconclusive,,,,,Antiviral activity against influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method,Other,23920438.0,
3071,767051,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HeLa cells to EC50 for Adenovirus type 7 infected in human HeLa cells",Other,23920438.0,
3072,767052,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method,Other,23920438.0,
3073,767053,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Other,23920438.0,
3074,767054,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Coxsackievirus B5 infected in human HepG2 cells",Other,23920438.0,
3075,767055,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method,Other,23920438.0,
3076,767056,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Other,23920438.0,
3077,767057,1,2,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human rhabdomyosarcoma cells to EC50 for Enterovirus 71 infected in human rhabdomyosarcoma cells",Other,23920438.0,
3078,767058,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Enterovirus 71 infected in human rhabdomyosarcoma cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method,Other,23920438.0,
3079,767059,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay,Other,23920438.0,
3080,768187,1,2,,103619997,37542,Active,,,2.8,EC50,Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay,Confirmatory,23811093.0,
3081,768188,1,2,,103619997,37542,Active,,,1.1,EC50,Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay,Confirmatory,23811093.0,
3082,768189,1,2,,103619997,37542,Active,,,2.5,EC50,Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay,Confirmatory,23811093.0,
3083,768190,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells,Other,23811093.0,
3084,768191,1,1,,103619997,37542,Unspecified,,,126.0,EC50,Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3085,768192,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3086,768193,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3087,768194,1,3,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3088,768195,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,23811093.0,
3089,768196,1,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3090,768197,1,1,,103619997,37542,Active,,,5.0,EC50,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3091,768198,1,1,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3092,768199,1,1,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3093,768212,1,1,,103619997,37542,Unspecified,,,,CC50,Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay,Confirmatory,23811093.0,
3094,774116,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3",Other,24070022.0,
3095,774117,1,1,,103619997,37542,Unspecified,,,900.0,IC50,Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis,Confirmatory,24070022.0,
3096,774118,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells after 48 hrs by Reed-Muench analysis,Other,24070022.0,
3097,774863,1,2,,103619997,37542,Inconclusive,,,,CC50,Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay,Confirmatory,23999140.0,
3098,774864,1,1,,103619997,37542,Inconclusive,,,,IC50,Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis,Confirmatory,23999140.0,
3099,774865,1,1,,103619997,37542,Inconclusive,,,,,"Selectivity index, ratio of CC50 for human Huh7.5 cells to IC50 for HCV expressing pFL-J6/JFH/JC1",Other,23999140.0,
3100,774866,1,1,,103619997,37542,Unspecified,,,8189.67,CC50,Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay,Confirmatory,23999140.0,
3101,774867,1,1,,103619997,37542,Unspecified,,,1576.11,IC50,Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs,Confirmatory,23999140.0,
3102,774868,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Nancy",Other,23999140.0,
3103,774869,1,1,,103619997,37542,Unspecified,,,909.96,IC50,Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs,Confirmatory,23999140.0,
3104,774870,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Schmitt",Other,23999140.0,
3105,776643,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against mouse X5563 cells assessed as growth inhibition,Other,24099993.0,
3106,776644,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against mouse Gardner lymphosarcoma cells assessed as growth inhibition,Other,24099993.0,
3107,776645,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against mouse mammary carcinoma 755 cells assessed as growth inhibition,Other,24099993.0,
3108,776646,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against rat Walker 256 cells assessed as growth inhibition,Other,24099993.0,
3109,977599,1,1,,103619997,37542,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3110,977602,1,2,,103619997,37542,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3111,977611,3,1,,310263415,37542,Active,,,1530.0,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,25082345.0,
3112,1053197,1,1,,85148371,37542,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3113,1055006,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 47.1 +/- 10.5 x 10'6 pfu/ml),Other,24151954.0,
3114,1055007,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human BE(2)-C cells assessed as cell viability at 25 uM after 24 hrs by MTT assay relative to control,Other,24151954.0,
3115,1055008,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 25.7 +/- 5.2 x 10'6 pfu/ml),Other,24151954.0,
3116,1055015,1,1,,103619997,37542,Active,,,16.0,IC50,Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay,Confirmatory,24151954.0,
3117,1055979,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 24 hrs by MTS assay,Other,24237039.0,
3118,1055980,1,1,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 2 log10 reduction of virus yield after 24 hrs by RT-PCR analysis,Other,24237039.0,
3119,1055986,1,1,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 1 log10 reduction of virus yield after 24 hrs by RT-PCR analysis,Other,24237039.0,
3120,1058584,1,1,,103619997,37542,Active,,,14.0,IC50,Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs,Confirmatory,24216089.0,
3121,1066041,1,1,,103619997,37542,Active,,,6.0,EC50,Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3122,1066042,1,1,,103619997,37542,Active,,,12.0,EC50,Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3123,1066043,1,1,,103619997,37542,Active,,,17.0,EC50,Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3124,1066044,1,1,,103619997,37542,Active,,,11.0,EC50,Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3125,1066045,1,1,,103619997,37542,Active,,,6.0,EC50,Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3126,1066046,1,1,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3127,1066047,1,1,,103619997,37542,Active,,,15.0,EC50,Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay,Confirmatory,24313730.0,
3128,1066048,1,1,,103619997,37542,Active,,,2.0,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay,Confirmatory,24313730.0,
3129,1066049,1,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,24313730.0,
3130,1066050,1,3,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay,Confirmatory,24313730.0,
3131,1066051,1,1,,103619997,37542,Active,,,8.0,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay,Confirmatory,24313730.0,
3132,1066678,1,1,,103619997,37542,Unspecified,,,84.0,IC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique,Confirmatory,24495078.0,
3133,1066681,1,1,,103619997,37542,Unspecified,,,131.0,IC50,Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay,Confirmatory,24499327.0,
3134,1069922,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HuH7 cells assessed as beta-actin levels relative to control,Other,24461293.0,
3135,1069923,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of beta-actin level in human HuH7 cells to viral RNA level in HCV infected in human Huh7 cells",Other,24461293.0,
3136,1069924,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV infected in human Huh7 cells assessed as reduction in RNA level by luciferase reporter gene assay relative to control,Other,24461293.0,
3137,1071699,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H5N1",Other,24486419.0,
3138,1071700,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H1N1",Other,24486419.0,
3139,1071701,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H3N2",Other,24486419.0,
3140,1071702,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza B virus",Other,24486419.0,
3141,1071706,1,1,,103619997,37542,Active,,,4.2,EC50,Antiviral activity against Influenza A virus H5N1 by cytopathy assay,Confirmatory,24486419.0,
3142,1071707,1,1,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Influenza A virus H1N1 by cytopathy assay,Confirmatory,24486419.0,
3143,1071708,1,1,,103619997,37542,Active,,,2.4,EC50,Antiviral activity against Influenza B virus by cytopathy assay,Confirmatory,24486419.0,
3144,1071709,1,1,,103619997,37542,Active,,,2.0,EC50,Antiviral activity against Influenza A virus H3N2 by cytopathy assay,Confirmatory,24486419.0,
3145,1073349,3,1,,103619997,37542,Unspecified,,,,EC50,Antiviral activity against Chikungunya virus,Confirmatory,24079775.0,
3146,1075686,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 41 uM after 8 to 10 days by quantitative PCR analysis,Other,24485784.0,
3147,1075687,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for HCV subtype 1a",Other,24485784.0,
3148,1075688,1,1,,103619997,37542,Inconclusive,,,,CC50,Cytotoxicity against human HuH7 cells after 2 days by XTT assay,Confirmatory,24485784.0,
3149,1075689,1,2,,103619997,37542,Unspecified,,,81.9,EC50,Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis,Confirmatory,24485784.0,
3150,1075690,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 81.9 uM after 8 to 10 days by quantitative PCR analysis,Other,24485784.0,
3151,1076996,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay,Other,24583605.0,
3152,1076998,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus jifang/13/97",Other,24583605.0,
3153,1076999,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs,Other,24583605.0,
3154,1077000,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus A/hanfang/359/95(H3N2)",Other,24583605.0,
3155,1077001,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs,Other,24583605.0,
3156,1077002,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjinjinnan/15/2009/H1N1)",Other,24583605.0,
3157,1077003,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs,Other,24583605.0,
3158,1077004,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/FM/1/1947(H1N1))",Other,24583605.0,
3159,1077005,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs,Other,24583605.0,
3160,1077006,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells after 48 hrs,Other,24583605.0,
3161,1079931,1,1,,103619997,37542,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3162,1079932,1,1,,103619997,37542,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3163,1079933,1,1,,103619997,37542,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3164,1079934,1,1,,103619997,37542,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3165,1079935,1,1,,103619997,37542,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3166,1079936,1,1,,103619997,37542,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3167,1079937,1,1,,103619997,37542,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3168,1079938,1,1,,103619997,37542,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3169,1079939,1,1,,103619997,37542,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3170,1079940,1,1,,103619997,37542,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3171,1079941,1,1,,103619997,37542,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3172,1079942,1,1,,103619997,37542,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3173,1079943,1,1,,103619997,37542,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3174,1079944,1,1,,103619997,37542,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3175,1079945,1,1,,103619997,37542,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3176,1079946,1,1,,103619997,37542,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3177,1079947,1,1,,103619997,37542,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3178,1079948,1,1,,103619997,37542,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3179,1079949,1,1,,103619997,37542,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3180,1081155,1,1,,103619997,37542,Unspecified,,,,,Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml,Other,20000685.0,
3181,1081156,1,1,,103619997,37542,Unspecified,,,,,Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml,Other,20000685.0,
3182,1081157,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge,Other,20000685.0,
3183,1081158,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge,Other,20000685.0,
3184,1081159,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge,Other,20000685.0,
3185,1081160,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge,Other,20000685.0,
3186,1081161,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge,Other,20000685.0,
3187,1081162,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge,Other,20000685.0,
3188,1081163,1,1,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml,Other,20000685.0,
3189,1081164,1,1,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml,Other,20000685.0,
3190,1081199,1,1,,103619997,37542,Inactive,,,,,Induction of systemic acquired resistance in Nicotiana tabacum (tobacco) mosaic virus infected Nicotiana tabacum (tobacco) plant at 100 ug/mL at 25 degC for 72 hr,Other,20014761.0,
3191,1081200,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 100 ug/mL at 25 degC for 72 hr,Other,20014761.0,
3192,1081201,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 50 ug/mL at 25 degC for 72 hr,Other,20014761.0,
3193,1081202,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 500 ug/mL at 25 degC for 72 hr,Other,20014761.0,
3194,1081542,1,1,,103619997,37542,Unspecified,,,,,Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml,Other,20557096.0,
3195,1081543,1,1,,103619997,37542,Unspecified,,,,,Phytotoxicity against Nicotiana tabacum (tobacco) plant,Other,20557096.0,
3196,1081544,1,1,,103619997,37542,Unspecified,,,,,Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml,Other,20557096.0,
3197,1081545,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge,Other,20557096.0,
3198,1081546,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge,Other,20557096.0,
3199,1081547,1,1,,103619997,37542,Inconclusive,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge,Other,20557096.0,
3200,1081548,1,1,,103619997,37542,Inconclusive,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge,Other,20557096.0,
3201,1081549,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge,Other,20557096.0,
3202,1081550,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge,Other,20557096.0,
3203,1081551,1,1,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml,Other,20557096.0,
3204,1081553,1,1,,103619997,37542,Unspecified,,,,,In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml,Other,20557096.0,
3205,1082872,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days,Other,22662864.0,
3206,1082873,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days,Other,22662864.0,
3207,1082874,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days,Other,22662864.0,
3208,1082875,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days,Other,22662864.0,
3209,1082876,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days,Other,22662864.0,
3210,1082877,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days,Other,22662864.0,
3211,1082878,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method,Other,22662864.0,
3212,1082879,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method,Other,22662864.0,
3213,1082991,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection protective effect at 500 ug/mL measured 3 to 4 days post inoculation,Other,22880628.0,
3214,1082992,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection curative effect at 500 ug/mL measured 3 to 4 days post inoculation,Other,22880628.0,
3215,1082993,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus inactivation effect at 500 ug/mL measured 3 to 4 days post inoculation,Other,22880628.0,
3216,1082995,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition of viral growth at 500 ug/mL,Other,22880628.0,
3217,1084126,3,1,,103619997,37542,Active,,,15.0,EC50,Antiviral activity against Respiratory syncytial virus infected cell system assessed as inhibition of viral replication,Confirmatory,,
3218,1092193,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days,Other,23035814.0,
3219,1092194,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days,Other,23035814.0,
3220,1092195,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days,Other,23035814.0,
3221,1092196,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days,Other,23035814.0,
3222,1092197,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days,Other,23035814.0,
3223,1092198,1,1,,103619997,37542,Unspecified,,,,,In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days,Other,23035814.0,
3224,1092199,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method,Other,23035814.0,
3225,1092200,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method,Other,23035814.0,
3226,1095311,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 3 days by microscopic analysis,Other,,
3227,1095312,3,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3228,1095313,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3229,1095314,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3230,1095315,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3231,1095316,3,1,,103619997,37542,Active,,,45.0,EC50,Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3232,1095317,3,1,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3233,1095318,3,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3234,1095319,3,1,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3235,1095320,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells after 3 days by microscopic analysis,Other,,
3236,1095321,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3237,1095322,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3238,1095323,3,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3239,1095324,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3240,1095325,3,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3241,1095326,3,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells after 3 days by microscopic analysis,Other,,
3242,1106648,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus infected HeLa cells,Other,,
3243,1106649,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Human coxsackievirus B4 infected HeLa cells,Other,,
3244,1106650,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected HeLa,Other,,
3245,1106651,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Human coxsackievirus B4 infected Vero cells,Other,,
3246,1106652,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Punta Toro virus infected Vero cells,Other,,
3247,1106653,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Sindbis virus infected Vero cells,Other,,
3248,1106654,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells,Other,,
3249,1106655,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Human parainfluenza virus 3 infected Vero cells,Other,,
3250,1106656,1,2,,103619997,37542,Unspecified,,,,,"Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells",Other,,
3251,1106657,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected HEL cells,Other,,
3252,1106658,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected HEL cells,Other,,
3253,1106659,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells,Other,,
3254,1106660,1,2,,103619997,37542,Unspecified,,,,,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells,Other,,
3255,1106661,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells,Other,,
3256,1106662,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells,Other,,
3257,1106663,1,2,,103619997,37542,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells,Other,,
3258,1113452,1,2,,103619997,37542,Active,,,8.4,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3259,1113453,1,2,,103619997,37542,Active,,,6.8,EC50,Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3260,1113454,1,2,,103619997,37542,Active,,,11.5,EC50,Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3261,1113455,1,3,,103619997,37542,Unspecified,,,,CC50,Cytotoxicity against MDCK cells assessed as change in cellular morphology,Confirmatory,,
3262,1113456,1,2,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3263,1113457,1,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3264,1113458,1,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3265,1113459,1,2,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3266,1113460,1,2,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3267,1113461,1,3,,103619997,37542,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as change in cellular morphology,Other,,
3268,1113462,1,2,,103619997,37542,Active,,,4.6,EC50,Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3269,1113463,1,2,,103619997,37542,Active,,,12.1,EC50,Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3270,1113464,1,2,,103619997,37542,Active,,,28.5,EC50,Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3271,1113465,1,3,,103619997,37542,Unspecified,,,,CC50,Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology,Confirmatory,,
3272,1117298,1,2,,170464657,37542,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3273,1117301,1,2,,170464657,37542,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3274,1117302,1,2,,170464657,37542,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3275,1117303,1,2,,170464657,37542,Inactive,,,0.51,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3276,1117304,1,2,,170464657,37542,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3277,1117305,1,2,,170464657,37542,Inactive,,,2.2387,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3278,1117310,1,1,,170464657,37542,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3279,1117311,1,1,,170464657,37542,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3280,1117312,1,1,,170464657,37542,Inactive,,,2.2387200000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3281,1117314,1,1,,170464657,37542,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3282,1117315,1,1,,170464657,37542,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3283,1117318,1,1,,170464657,37542,Inactive,,,0.5011869999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3284,1117326,1,1,,170464657,37542,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3285,1117329,1,1,,170464657,37542,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3286,1117336,1,1,,170464657,37542,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3287,1117340,1,1,,170464657,37542,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3288,1117341,1,1,,170464657,37542,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3289,1117342,1,1,,170464657,37542,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3290,1117343,1,1,,170464657,37542,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3291,1117346,1,1,,170464657,37542,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3292,1118631,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3293,1118632,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3294,1118633,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3295,1118634,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3296,1118635,1,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3297,1118640,1,1,,103619997,37542,Active,,,29.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3298,1118641,1,1,,103619997,37542,Unspecified,,,146.0,EC50,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3299,1118642,1,1,,103619997,37542,Active,,,10.0,EC50,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3300,1118643,1,1,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,24312722.0,
3301,1118644,1,1,,103619997,37542,Unspecified,,,50.0,EC50,Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,24312722.0,
3302,1118645,1,1,,103619997,37542,Unspecified,,,85.0,EC50,Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3303,1118646,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3304,1118647,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3305,1118648,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3306,1118649,1,1,,103619997,37542,Unspecified,,,126.0,EC50,Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3307,1118650,1,1,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3308,1118651,1,1,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3309,1118652,1,1,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,24312722.0,
3310,1118653,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as concentration required to cause microscopically visible alternation of cell morphology,Other,24312722.0,
3311,1118654,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as concentration required to cause microscopically visible alternation of cell morphology,Other,24312722.0,
3312,1118655,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as concentration required to cause microscopically visible alternation of cell morphology,Other,24312722.0,
3313,1118656,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as concentration required to cause microscopically visible alternation of cell morphology,Other,24312722.0,
3314,1121253,1,1,,103619997,37542,Inactive,,,,,Inhibition of Escherichia coli topoisomerase assessed as bacterial proliferation at 200 uM after 24 hrs by visual inspection assay,Other,,
3315,1121257,1,3,,103619997,37542,Unspecified,12644118.0,7150.0,65.88,IC50,Inhibition of human topoisomerase 1 activity assessed as DNA triplex formation and presence of supercoiled DNA by microplate assay,Confirmatory,,
3316,1123336,1,1,,103619997,37542,Active,,,,,Activity at rat liver nucleoside kinase assessed as phosphorylation using [gamma-32P]-ATP after 10 to 20 mins,Other,222909.0,
3317,1126468,1,1,,103619997,37542,Unspecified,,,253.1,IC50,Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Confirmatory,24679044.0,
3318,1126469,1,1,,103619997,37542,Unspecified,,,1000.0,CC50,Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay,Confirmatory,24679044.0,
3319,1126470,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Enterovirus 71 BrCr",Other,24679044.0,
3320,1127179,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 5 uM after 3 days by luciferase reporter gene assay,Other,24727241.0,
3321,1127180,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 20 uM after 3 days by luciferase reporter gene assay,Other,24727241.0,
3322,1127181,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HuH7 cells assessed as cell viability at 20 uM after 3 days by XTT assay,Other,24727241.0,
3323,1127182,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HuH7 cells assessed as cell viability at 100 uM after 3 days by XTT assay,Other,24727241.0,
3324,1127183,1,1,,103619997,37542,Active,,,12.61,IC50,Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay,Confirmatory,24727241.0,
3325,1127184,1,1,,103619997,37542,Unspecified,,,56.31,CC50,Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay,Confirmatory,24727241.0,
3326,1127185,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HuH7 cells to IC50 for DENV2 16681",Other,24727241.0,
3327,1131474,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection,Other,561847.0,
3328,1131475,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 3 days after virus infection,Other,561847.0,
3329,1131476,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection,Other,561847.0,
3330,1131477,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Poliovirus type 1 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection,Other,561847.0,
3331,1131478,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection,Other,561847.0,
3332,1131479,1,1,,103619997,37542,Unspecified,,,,,Inhibition of DNA synthesis in primary rabbit kidney cells assessed as inhibition of [3H]thymidine incorporation into DNA,Other,561847.0,
3333,1132044,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Bacillus subtilis,Other,619151.0,
3334,1132045,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus Oxford,Other,619151.0,
3335,1132046,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus Russel,Other,619151.0,
3336,1132047,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus 1517,Other,619151.0,
3337,1132048,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Streptococcus faecalis I,Other,619151.0,
3338,1132049,1,1,,103619997,37542,Inconclusive,,,,,Antibacterial activity against Streptococcus pyogenes CN10,Other,619151.0,
3339,1132056,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells by agar diffusion assay,Other,619151.0,
3340,1132057,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against BHK cells,Other,619151.0,
3341,1132058,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B1 infected in human HeLa cells by agar diffusion assay,Other,619151.0,
3342,1132059,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against human HeLa cells by neutral red assay,Other,619151.0,
3343,1132065,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells at 1 mg/ml by agar diffusion assay,Other,619151.0,
3344,1132066,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Coxsackievirus B1 infected in human HeLa cells at 1 mg/ml by agar diffusion assay,Other,619151.0,
3345,1133177,1,2,,103619997,37542,Active,,,,,Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3346,1133178,1,1,,103619997,37542,Active,,,,,Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3347,1133179,1,1,,103619997,37542,Active,,,,,Antiviral activity against HSV2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3348,1133180,1,1,,103619997,37542,Active,,,,,Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3349,1133181,1,1,,103619997,37542,Active,,,,,Antiviral activity against Parainfluenza virus 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3350,1133182,1,2,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control,Other,722730.0,
3351,1133193,1,1,,103619997,37542,Unspecified,,,,,Inhibition of adenine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis,Other,722730.0,
3352,1133194,1,1,,103619997,37542,Unspecified,,,,,Inhibition of guanine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis,Other,722730.0,
3353,1135408,1,1,,103619997,37542,Unspecified,,,,,"Toxicity in mouse assessed as survival at 99 mg/kg, po",Other,189032.0,
3354,1135412,1,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 99 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days)",Other,189032.0,
3355,1135413,1,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 49.5 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days)",Other,189032.0,
3356,1135720,1,1,,103619997,37542,Unspecified,,,,,Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 1 uM after 6 days by [3H]thymidine incorporation method relative to control,Other,209191.0,
3357,1135739,1,1,,103619997,37542,Active,,,,,Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs,Other,211234.0,
3358,1135740,1,1,,103619997,37542,Active,,,,,Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs,Other,211234.0,
3359,1135741,1,1,,103619997,37542,Active,,,,,Antiviral activity against Parainfluenza virus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs,Other,211234.0,
3360,1135742,1,2,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs,Other,211234.0,
3361,1135743,1,2,,103619997,37542,Active,,,,,Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs,Other,211234.0,
3362,1135867,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells at 1 mg/ml by agar diffusion method,Other,218010.0,
3363,1135868,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells assessed as plaque reduction after 3 days by agar diffusion method,Other,218010.0,
3364,1135871,1,1,,103619997,37542,Unspecified,,,,,Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control,Other,218010.0,
3365,1135872,1,1,,103619997,37542,Unspecified,,,,,Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control,Other,218010.0,
3366,1135873,1,1,,103619997,37542,Unspecified,,,,,Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control,Other,218010.0,
3367,1135877,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in rectal temperature at 7 to 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 relative to untreated control,Other,218010.0,
3368,1135878,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control,Other,218010.0,
3369,1135879,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control,Other,218010.0,
3370,1135880,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control,Other,218010.0,
3371,1135881,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control,Other,218010.0,
3372,1135882,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control,Other,218010.0,
3373,1135883,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control,Other,218010.0,
3374,1135884,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control,Other,218010.0,
3375,1135885,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control,Other,218010.0,
3376,1135886,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control,Other,218010.0,
3377,1135894,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells infected with Influenza A virus Port Chalmers/1/73 (H3N2) after 3 days by carbol fuchsin staining-based assay,Other,218010.0,
3378,1140807,1,1,,103619997,37542,Active,,,1.3,EC50,Antiviral activity against BVDV AV-69 infected in MDBK cells assessed as cytopathic effect after 3 to 4 days by plaque reduction assay,Confirmatory,24745970.0,
3379,1140809,1,1,,103619997,37542,Unspecified,,,20.0,CC50,Cytotoxicity against MDBK cells after 48 hrs by MTT assay,Confirmatory,24745970.0,
3380,1144797,1,1,,103619997,37542,Active,,,,,"Antiviral activity against Influenza A virus (A2/Asian/J305) infected in Swiss albino mouse assessed as increase in host survival at 20 mg/kg, ip administered 4 hrs before infection, 1 hr after infection followed by twice daily for next 6 days for total of 14 treatments measured on 21st day post-infection",Other,1249809.0,
3381,1146287,1,1,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus 1A infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control,Other,214563.0,
3382,1146288,1,1,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus 2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control,Other,214563.0,
3383,1146289,1,1,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus 8 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control,Other,214563.0,
3384,1146290,1,1,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control,Other,214563.0,
3385,1146291,1,1,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus 30 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control,Other,214563.0,
3386,1150890,1,1,,103619997,37542,Active,,,,,Antiviral activity against Herpes simplex virus type 1 infected in human KB cells,Other,950655.0,
3387,1150891,1,2,,103619997,37542,Active,,,,,Antiviral activity against Rhinovirus type 13 infected in human KB cells,Other,950655.0,
3388,1150892,1,1,,103619997,37542,Active,,,,,Antiviral activity against Parainfluenza virus type 3 infected in human KB cells,Other,950655.0,
3389,1151007,1,1,,103619997,37542,Active,,,,,"Antiviral activity against Influenza A virus A2/Asian/J305 infected in Swiss albino mouse assessed as increase in host survival at 50 mg/kg, ip administered as 7 doses immediately before virus inoculation and at 1, 5, 24, 30, 48 and 72 hrs after virus infection measured on 21st day post-infection",Other,966248.0,
3390,1152077,1,1,,103619997,37542,Inconclusive,,,,IC50,Inhibition of Influenza A virus GST-tagged PB1 (1 to 25) expressed in Escherichia coli binding to Influenza A virus 6His-tagged PA (239 to 716) expressed in Escherichia coli BL21(DE3) by ELISA,Confirmatory,24785979.0,
3391,1152078,1,1,,103619997,37542,Active,,,,IC50,Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay,Confirmatory,24785979.0,
3392,1152079,1,1,,103619997,37542,Active,,,15.6,EC50,Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay,Confirmatory,24785979.0,
3393,1152080,1,2,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay,Confirmatory,24785979.0,
3394,1152081,1,1,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against MDCK cells after 48 hrs by MTT assay,Confirmatory,24785979.0,
3395,1154644,1,1,,103619997,37542,Active,,,20.4,IC50,Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay,Confirmatory,24882250.0,
3396,1154645,1,1,,103619997,37542,Unspecified,,,3000.0,TC50,Cytotoxicity against mock-infected human Hep2 cells by XTT assay,Confirmatory,24882250.0,
3397,1154646,1,1,,103619997,37542,Unspecified,,,,,Therapeutic ratio of TC50 for mock-infected human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells,Other,24882250.0,
3398,1159509,1,1,,144208165,37542,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3399,1159509,1,1,,170464657,37542,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3400,1159515,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3401,1159515,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3402,1159516,1,1,,144208165,37542,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3403,1159516,1,1,,170464657,37542,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3404,1159517,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3405,1159517,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3406,1159518,1,1,,144208165,37542,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3407,1159518,1,1,,170464657,37542,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3408,1159519,1,1,,144208165,37542,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3409,1159519,1,1,,170464657,37542,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3410,1159520,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3411,1159520,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3412,1159521,1,1,,144208165,37542,Active,15928672.0,19885.0,4.562,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3413,1159521,1,1,,170464657,37542,Active,15928672.0,19885.0,3.7578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3414,1159523,1,1,,144208165,37542,Active,15928672.0,19885.0,6.20139,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3415,1159523,1,1,,170464657,37542,Active,15928672.0,19885.0,5.0111099999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3416,1159524,1,1,,8139972,37542,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3417,1159524,1,1,,144203810,37542,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3418,1159525,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3419,1159525,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3420,1159526,1,1,,144208165,37542,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3421,1159526,1,1,,170464657,37542,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3422,1159527,1,1,,144208165,37542,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3423,1159527,1,1,,170464657,37542,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3424,1159528,1,1,,144208165,37542,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3425,1159528,1,1,,170464657,37542,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3426,1159529,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3427,1159529,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3428,1159531,1,1,,144208165,37542,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3429,1159531,1,1,,170464657,37542,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3430,1159550,3,1,,252402787,37542,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3431,1159551,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3432,1159551,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3433,1159552,1,1,,144208165,37542,Inactive,325495463.0,5914.0,81.1252,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3434,1159552,1,1,,170464657,37542,Inconclusive,325495463.0,5914.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3435,1159553,2,1,,144208165,37542,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3436,1159553,2,1,,170464657,37542,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3437,1159555,1,1,,144208165,37542,Inconclusive,325495463.0,5914.0,51.1865,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3438,1159555,1,1,,170464657,37542,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3439,1159580,2,1,,268734991,37542,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3440,1159606,1,1,,8139972,37542,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3441,1159607,2,1,,312596201,37542,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3442,1159614,1,2,,170464657,37542,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3443,1159620,1,1,,103619997,37542,Active,,,,,Summary of drug indications.,Other,,
3444,1167618,1,1,,103619997,37542,Active,,,5.6,EC50,Antiviral activity against Hepatitis C virus infected in African green monkey OR6 cells after 72 hrs by luciferase reporter gene assay,Confirmatory,25282652.0,
3445,1167619,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against human ORL8 cells after 72 hrs by WST-1 assay,Confirmatory,25282652.0,
3446,1167620,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human ORL8 cells to EC50 for Hepatitis C virus infected in African green monkey OR6 cells",Other,25282652.0,
3447,1168656,1,1,,103619997,37542,Active,,,49.0,EC50,Antiviral activity against Dengue virus,Confirmatory,25305334.0,
3448,1169734,1,1,,103619997,37542,Active,,,12.6,EC50,Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay,Confirmatory,25330401.0,
3449,1169735,1,1,,103619997,37542,Unspecified,,,56.0,CC50,Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay,Confirmatory,25330401.0,
3450,1169736,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 against human HuH7 cells to EC50 against dengue virus 2",Other,25330401.0,
3451,1171740,1,1,,103619997,37542,Active,,,20.0,IC50,Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay,Confirmatory,25420212.0,
3452,1171741,1,1,,103619997,37542,Unspecified,,,3000.0,TC50,Cytotoxicity against human Hep2 cells after 48 hrs,Confirmatory,25420212.0,
3453,1171742,1,1,,103619997,37542,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus",Other,25420212.0,
3454,1179390,1,1,,103619997,37542,Active,,,17.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,24906510.0,
3455,1181192,1,1,,103619997,37542,Unspecified,,,101.0,IC50,Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay,Confirmatory,24967847.0,
3456,1181478,1,1,,103619997,37542,Active,,,21.0,EC50,Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay,Confirmatory,24974341.0,
3457,1181479,1,1,,103619997,37542,Active,,,6.8,EC50,Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy,Confirmatory,24974341.0,
3458,1181480,1,1,,103619997,37542,Active,,,12.0,EC50,Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy,Confirmatory,24974341.0,
3459,1181481,1,1,,103619997,37542,Active,,,11.0,EC50,Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay,Confirmatory,24974341.0,
3460,1181482,1,1,,103619997,37542,Active,,,6.8,EC50,Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy,Confirmatory,24974341.0,
3461,1181483,1,1,,103619997,37542,Active,,,7.3,EC50,Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay,Confirmatory,24974341.0,
3462,1181484,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay,Confirmatory,24974341.0,
3463,1181485,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy,Other,24974341.0,
3464,1181493,1,1,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy,Confirmatory,24974341.0,
3465,1181494,1,1,,103619997,37542,Active,,,8.2,EC50,Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay,Confirmatory,24974341.0,
3466,1186327,1,1,,103619997,37542,Active,,,31.0,CC50,Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay,Confirmatory,25082514.0,
3467,1186329,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
3468,1186330,1,1,,103619997,37542,Active,,,8.0,EC50,Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
3469,1186331,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
3470,1186332,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
3471,1186333,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay,Confirmatory,25082514.0,
3472,1186334,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay,Confirmatory,25082514.0,
3473,1186335,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
3474,1186336,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay,Confirmatory,25082514.0,
3475,1186337,1,1,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay,Confirmatory,25082514.0,
3476,1186338,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay,Confirmatory,25082514.0,
3477,1186339,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
3478,1186340,1,1,,103619997,37542,Unspecified,,,100.0,EC50,Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay,Confirmatory,25082514.0,
3479,1186342,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Respiratory syncytial virus",Other,25082514.0,
3480,1186430,1,1,,103619997,37542,Active,,,8.7,EC50,Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) by renilla luciferase reporter gene based replication assay,Confirmatory,25086684.0,
3481,1186434,1,1,,103619997,37542,Active,,,,,Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) in presence of 1 IU/mL IFN-alpha by renilla luciferase reporter gene based replication assay,Other,25086684.0,
3482,1194165,1,1,,103619997,37542,Active,,,47.9,EC50,Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay,Confirmatory,25791449.0,
3483,1194166,1,1,,103619997,37542,Unspecified,,,410.0,CC50,Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay,Confirmatory,25791449.0,
3484,1194167,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, CC50 for african green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea C by virus yield-reduction assay",Other,25791449.0,
3485,1200484,1,1,,103619997,37542,Unspecified,,,200.0,CC50,Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay,Confirmatory,25681711.0,
3486,1200495,1,1,,103619997,37542,Active,,,1.05,IC50,Antiviral activity against OSV-resistant influenza A virus A/LiaoNing-ZhenXing/1109/2010 (H1N1) strain,Confirmatory,25681711.0,
3487,1200496,1,1,,103619997,37542,Unspecified,,,150.38,IC50,Antiviral activity against amantadine and ribavirin-resistant influenza A virus A/HuNan-huHui/1222/2010 (H3N2) strain,Confirmatory,25681711.0,
3488,1201115,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis,Other,25752526.0,
3489,1201116,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells after 72 hrs by MTS assay,Confirmatory,25752526.0,
3490,1201117,1,1,,103619997,37542,Active,,,9.0,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis,Confirmatory,25752526.0,
3491,1201118,1,1,,103619997,37542,Active,,,8.9,EC50,Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay,Confirmatory,25752526.0,
3492,1201119,1,1,,103619997,37542,Active,,,12.0,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis,Confirmatory,25752526.0,
3493,1201120,1,1,,103619997,37542,Active,,,12.0,EC50,Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay,Confirmatory,25752526.0,
3494,1201121,1,1,,103619997,37542,Active,,,7.0,EC50,Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis,Confirmatory,25752526.0,
3495,1201122,1,1,,103619997,37542,Active,,,3.4,EC50,Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay,Confirmatory,25752526.0,
3496,1204068,1,1,,103619997,37542,Unspecified,,,57.0,CC50,Cytotoxicity against bovine MDBK cells assessed as cell viability after 72 hrs by MTT method,Confirmatory,25913116.0,
3497,1204069,1,1,,103619997,37542,Active,,,19.0,EC50,Antiviral activity against BVDV infected in bovine MDBK cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method,Confirmatory,25913116.0,
3498,1204070,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for BVDV infected in bovine MDBK cells",Other,25913116.0,
3499,1204074,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method,Confirmatory,25913116.0,
3500,1204075,1,1,,103619997,37542,Active,,,35.0,EC50,Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay,Confirmatory,25913116.0,
3501,1204076,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero 76 cells to EC50 for RSV infected in African green monkey Vero 76 cells",Other,25913116.0,
3502,1204998,1,1,,103619997,37542,Unspecified,,,8197.0,TC50,Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by CPE assay,Confirmatory,25699158.0,
3503,1204999,1,1,,103619997,37542,Unspecified,,,694.6,IC50,Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect,Confirmatory,25699158.0,
3504,1205000,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3 infected in african green monkey Vero cells",Other,25699158.0,
3505,1205001,1,1,,103619997,37542,Unspecified,,,1951.0,IC50,Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect,Confirmatory,25699158.0,
3506,1205002,1,1,,103619997,37542,Unspecified,,,2101.0,IC50,Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect,Confirmatory,25699158.0,
3507,1205003,1,1,,103619997,37542,Unspecified,,,910.8,IC50,Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect,Confirmatory,25699158.0,
3508,1205004,1,1,,103619997,37542,Unspecified,,,1708.0,IC50,Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect,Confirmatory,25699158.0,
3509,1205005,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B1 infected in african green monkey Vero cells",Other,25699158.0,
3510,1205006,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B2 infected in african green monkey Vero cells",Other,25699158.0,
3511,1205007,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B5 infected in african green monkey Vero cells",Other,25699158.0,
3512,1205008,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6 infected in african green monkey Vero cells",Other,25699158.0,
3513,1207766,1,1,,103619997,37542,Unspecified,,,622.5,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
3514,1224818,1,1,,312345186,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3515,1224819,1,1,,312345186,37542,Inactive,325495545.0,2101.0,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3516,1224820,1,1,,312345186,37542,Active,325495545.0,2101.0,0.8413,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3517,1224821,1,1,,312345186,37542,Inactive,325495545.0,2101.0,1.6785,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3518,1224822,1,1,,312345186,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3519,1224823,1,1,,312345186,37542,Inconclusive,325495545.0,2101.0,2.1132,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3520,1224834,3,1,,144208165,37542,Inconclusive,,,3.6237,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3521,1224834,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3522,1224835,1,1,,144208165,37542,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3523,1224835,1,1,,170464657,37542,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3524,1224836,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3525,1224836,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3526,1224837,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3527,1224837,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3528,1224838,1,1,,144208165,37542,Active,66775687.0,9970.0,7.2303,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3529,1224838,1,1,,170464657,37542,Inconclusive,66775687.0,9970.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3530,1224839,1,1,,144208165,37542,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3531,1224839,1,1,,170464657,37542,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3532,1224840,3,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3533,1224840,3,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3534,1224841,3,1,,144208165,37542,Inactive,325495545.0,2101.0,3.2297,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3535,1224841,3,1,,170464657,37542,Inactive,325495545.0,2101.0,2.371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3536,1224842,3,1,,144208165,37542,Active,325495545.0,2101.0,2.8784,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3537,1224842,3,1,,170464657,37542,Active,325495545.0,2101.0,2.371,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3538,1224843,1,1,,144208165,37542,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3539,1224843,1,1,,170464657,37542,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3540,1224844,1,1,,144208165,37542,Active,,,18.3176,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3541,1224844,1,1,,170464657,37542,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3542,1224845,1,1,,144208165,37542,Active,344243002.0,100757539.0,53.2273,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3543,1224845,1,1,,170464657,37542,Inconclusive,344243002.0,100757539.0,24.6554,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3544,1224846,1,1,,144208165,37542,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3545,1224846,1,1,,170464657,37542,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3546,1224847,1,1,,144208165,37542,Inconclusive,,,94.65299999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3547,1224847,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3548,1224848,3,1,,144208165,37542,Inactive,325495545.0,2101.0,2.2864,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3549,1224848,3,1,,170464657,37542,Inactive,325495545.0,2101.0,2.1132,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3550,1224849,3,1,,144208165,37542,Active,325495545.0,2101.0,2.0378,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3551,1224849,3,1,,170464657,37542,Active,325495545.0,2101.0,1.8834,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3552,1224857,2,1,,170464657,37542,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3553,1224857,2,1,,312345186,37542,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3554,1224859,2,1,,90341426,37542,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3555,1224859,2,1,,170464657,37542,Inactive,,,35.4813,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3556,1224863,1,1,,176484457,37542,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3557,1224863,1,1,,176485028,37542,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3558,1224863,1,1,,316920424,37542,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3559,1224865,1,2,,8139972,37542,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3560,1224867,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3561,1224867,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3562,1224868,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3563,1224868,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3564,1224869,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3565,1224869,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3566,1224870,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3567,1224870,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3568,1224871,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3569,1224871,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3570,1224872,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3571,1224872,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3572,1224873,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3573,1224873,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3574,1224874,1,1,,144208165,37542,Inconclusive,,,57.9253,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3575,1224874,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3576,1224875,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3577,1224875,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3578,1224876,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3579,1224876,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3580,1224877,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3581,1224877,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3582,1224878,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3583,1224878,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3584,1224879,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3585,1224879,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3586,1224880,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3587,1224880,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3588,1224881,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3589,1224881,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3590,1224882,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3591,1224882,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3592,1224883,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3593,1224883,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3594,1224884,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3595,1224884,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3596,1224885,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3597,1224885,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3598,1224886,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3599,1224886,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3600,1224887,1,1,,144208165,37542,Inconclusive,,,46.0117,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3601,1224887,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3602,1224888,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3603,1224888,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3604,1224889,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3605,1224889,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3606,1224890,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3607,1224890,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3608,1224892,1,1,,144208165,37542,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3609,1224892,1,1,,170464657,37542,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3610,1224893,1,1,,144208165,37542,Active,66775687.0,9970.0,8.11252,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3611,1224893,1,1,,170464657,37542,Active,66775687.0,9970.0,7.4978,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3612,1224894,1,1,,144208165,37542,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3613,1224894,1,1,,170464657,37542,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3614,1224895,1,1,,144208165,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3615,1224895,1,1,,170464657,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3616,1224896,1,1,,144208165,37542,Active,344243002.0,100757539.0,27.7205,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3617,1224896,1,1,,170464657,37542,Inconclusive,344243002.0,100757539.0,31.0393,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3618,1224905,2,1,,92309231,37542,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3619,1224905,2,1,,92309231,37542,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3620,1224905,2,1,,121361852,37542,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3621,1224905,2,1,,121361852,37542,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3622,1226133,1,1,,103619997,37542,Inconclusive,,,,IC50,Inhibition of Influenza A virus (A/PR/8/34) (H1N1) RNA-dependent-RNA polymerase 6His-tagged-PA/GST-tagged-BP 1 interaction by ELISA,Confirmatory,25856229.0,
3623,1226134,1,1,,103619997,37542,Active,,,8.0,EC50,Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay,Confirmatory,25856229.0,
3624,1226135,1,1,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay,Confirmatory,25856229.0,
3625,1226136,1,1,,103619997,37542,Unspecified,,,250.0,CC50,Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay,Confirmatory,25856229.0,
3626,1226137,1,1,,103619997,37542,Active,,,18.0,EC50,Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay,Confirmatory,25856229.0,
3627,1229714,1,1,,103619997,37542,Unspecified,,,409.0,CC50,Cytotoxicity against african green monkey Vero B cells,Confirmatory,26039671.0,
3628,1229723,1,1,,103619997,37542,Active,,,42.0,EC50,Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis,Confirmatory,26039671.0,
3629,1229725,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea V",Other,26039671.0,
3630,1229768,1,1,,103619997,37542,Unspecified,,,115.0,IC50,Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay,Confirmatory,26046820.0,
3631,1230106,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3632,1230107,1,1,,103619997,37542,Unspecified,,,112.0,EC50,Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3633,1230119,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as alternation of cell morphology by microscopic analysis,Other,26001344.0,
3634,1234159,1,1,,103619997,37542,Unspecified,,,185.9,IC50,Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay,Confirmatory,26114936.0,
3635,1234202,1,1,,103619997,37542,Unspecified,,,8189.67,TC50,Cytotoxic activity against African green monkey Vero cells assessed as cytopathogenic effect incubated for 48 hrs,Confirmatory,26132528.0,
3636,1234203,1,1,,103619997,37542,Unspecified,,,1197.58,IC50,Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption,Confirmatory,26132528.0,
3637,1234204,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for coxsackievirus B3 infected in African green monkey Vero cells",Other,26132528.0,
3638,1234205,1,1,,103619997,37542,Unspecified,,,4766.8,TC50,Cytotoxic activity against MDCK cells assessed as cytopathogenic effect incubated for 48 hrs,Confirmatory,26132528.0,
3639,1234206,1,1,,103619997,37542,Active,,,5.86,IC50,Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption,Confirmatory,26132528.0,
3640,1234207,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for African green monkey MDCK cells to IC50 for influenza A virus (A/Hanfang/359/95(H3N2))",Other,26132528.0,
3641,1235015,1,1,,103619997,37542,Unspecified,,,1200.0,IC50,Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,26110443.0,
3642,1235016,1,1,,103619997,37542,Unspecified,,,8196.0,TC50,Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CPE assay,Confirmatory,26110443.0,
3643,1235017,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3-induced cytopathic effect in African green monkey Vero cells",Other,26110443.0,
3644,1237440,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against SARS-CoV assessed as inhibition of viral replication,Other,26048809.0,
3645,1238137,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against HCV genotype 1 in patient assessed as virological response rate,Other,26077493.0,
3646,1241019,1,1,,103619997,37542,Active,,,37.3,IC50,Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay,Confirmatory,26260336.0,
3647,1241020,1,1,,103619997,37542,Active,,,26.7,IC50,Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay,Confirmatory,26260336.0,
3648,1241024,1,1,,103619997,37542,Active,,,9.0,IC50,Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay,Confirmatory,26260336.0,
3649,1241028,1,1,,103619997,37542,Unspecified,,,1000.0,CC50,Cytotoxicity against African green monkey Vero 76 cells,Confirmatory,26260336.0,
3650,1241029,1,1,,103619997,37542,Unspecified,,,1000.0,CC50,Cytotoxicity against African green monkey Vero 76 cells relative to control,Confirmatory,26260336.0,
3651,1241033,1,1,,103619997,37542,Unspecified,,,100.0,CC50,Cytotoxicity against MDCK cells relative to control,Confirmatory,26260336.0,
3652,1242265,1,1,,103619997,37542,Unspecified,,,,,"Antiviral activity against human enterovirus 71 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip qd for 8 days dosed 2 hrs post infection and measured at 14 days post infection",Other,26189894.0,
3653,1246929,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay,Other,26291036.0,
3654,1246930,1,1,,103619997,37542,Unspecified,,,,,Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay,Other,26291036.0,
3655,1246931,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as cell viability by visual assay,Other,26291036.0,
3656,1246932,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay,Other,26291036.0,
3657,1246933,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells by visual method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by visual method",Other,26291036.0,
3658,1246934,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for MDCK cells by neutral red method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by neutral red method",Other,26291036.0,
3659,1249918,1,1,,103619997,37542,Active,,,6.8,EC50,Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis,Confirmatory,26288686.0,
3660,1249919,1,1,,103619997,37542,Active,,,,,Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 2-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis,Other,26288686.0,
3661,1249920,1,1,,103619997,37542,Unspecified,,,200.0,CC50,Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay,Confirmatory,26288686.0,
3662,1249921,1,1,,103619997,37542,Active,,,8.4,EC50,Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay,Confirmatory,26288686.0,
3663,1249922,1,1,,103619997,37542,Unspecified,,,200.0,CC50,Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay,Confirmatory,26288686.0,
3664,1252402,1,1,,103619997,37542,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells assessed as alteration in cell morphology by microscopy,Other,26291038.0,
3665,1252403,1,1,,103619997,37542,Unspecified,,,73.5,EC50,Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity,Confirmatory,26291038.0,
3666,1252404,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity,Confirmatory,26291038.0,
3667,1252405,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity,Confirmatory,26291038.0,
3668,1252406,1,1,,103619997,37542,Unspecified,,,250.0,EC50,Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity,Confirmatory,26291038.0,
3669,1252407,1,1,,103619997,37542,Unspecified,,,150.0,EC50,Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity,Confirmatory,26291038.0,
3670,1253091,1,1,,103619997,37542,Active,,,30.4,EC50,Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs,Confirmatory,26428870.0,
3671,1253093,1,1,,103619997,37542,Unspecified,,,30.0,CC50,Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay,Confirmatory,26428870.0,
3672,1253095,1,1,,103619997,37542,Active,,,33.5,EC50,Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs,Confirmatory,26428870.0,
3673,1253096,1,1,,103619997,37542,Active,,,30.5,CC50,Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 assay,Confirmatory,26428870.0,
3674,1253097,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene incubated for 1 hr to EC50 for HCV JFH1 infected in human HuH7-J20 cells preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs",Other,26428870.0,
3675,1253098,1,1,,103619997,37542,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene preincubated for 1 hr followed by fresh drug administration every 24 hrs for 48 hrs to EC50 for HCV JFH1 infected in human HuH7-J20 cells preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs",Other,26428870.0,
3676,1259241,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3677,1259241,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3678,1259242,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3679,1259242,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3680,1259243,1,1,,144208165,37542,Inactive,124375976.0,367.0,5.7432,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3681,1259243,1,1,,170464657,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3682,1259244,1,1,,144208165,37542,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3683,1259244,1,1,,170464657,37542,Inactive,348019627.0,2099.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3684,1259247,1,1,,144208165,37542,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3685,1259247,1,1,,170464657,37542,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3686,1259248,1,1,,144208165,37542,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3687,1259248,1,1,,170464657,37542,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3688,1259310,1,1,,332950208,37542,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3689,1259310,1,1,,332950597,37542,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3690,1259310,1,1,,332950646,37542,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3691,1259313,1,1,,8139972,37542,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3692,1259318,1,1,,85148371,37542,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3693,1259344,1,1,,144203810,37542,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3694,1259354,1,1,,348438288,37542,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3695,1259356,1,1,,144203810,37542,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3696,1259364,1,1,,144208165,37542,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3697,1259364,1,1,,170464657,37542,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3698,1259365,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3699,1259365,1,1,,170464657,37542,Inconclusive,,,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3700,1259366,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3701,1259366,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3702,1259367,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3703,1259367,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3704,1259368,1,1,,144208165,37542,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3705,1259368,1,1,,170464657,37542,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3706,1259369,1,1,,144208165,37542,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3707,1259369,1,1,,170464657,37542,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3708,1259370,2,2,,124636827,37542,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3709,1259370,2,2,,124636827,37542,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3710,1259370,2,2,,124636827,37542,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3711,1259377,1,1,,144208165,37542,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3712,1259377,1,1,,170464657,37542,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3713,1259378,1,1,,144208165,37542,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3714,1259378,1,1,,170464657,37542,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3715,1259379,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3716,1259379,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3717,1259380,1,1,,144208165,37542,Inconclusive,,,28.7843,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3718,1259380,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3719,1259381,1,1,,144208165,37542,Active,124375976.0,367.0,14.4263,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3720,1259381,1,1,,170464657,37542,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3721,1259382,1,1,,144208165,37542,Inconclusive,,,28.7843,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3722,1259382,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3723,1259383,1,1,,144208165,37542,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3724,1259383,1,1,,170464657,37542,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3725,1259384,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3726,1259384,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3727,1259385,1,1,,144208165,37542,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3728,1259385,1,1,,170464657,37542,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3729,1259386,1,1,,144208165,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3730,1259386,1,1,,170464657,37542,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3731,1259387,1,1,,144208165,37542,Inconclusive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3732,1259387,1,1,,170464657,37542,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3733,1259388,1,1,,144208165,37542,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3734,1259388,1,1,,170464657,37542,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3735,1259389,1,1,,124636827,37542,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3736,1259390,1,1,,144208165,37542,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3737,1259390,1,1,,170464657,37542,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3738,1259391,1,1,,144208165,37542,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3739,1259391,1,1,,170464657,37542,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3740,1259392,1,1,,144208165,37542,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3741,1259392,1,1,,170464657,37542,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3742,1259393,1,1,,144208165,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3743,1259393,1,1,,170464657,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3744,1259394,1,1,,144208165,37542,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3745,1259394,1,1,,170464657,37542,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3746,1259395,1,1,,144208165,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3747,1259395,1,1,,170464657,37542,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3748,1259396,1,1,,144208165,37542,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3749,1259396,1,1,,170464657,37542,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3750,1259400,1,1,,170464657,37542,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3751,1259401,1,1,,144208165,37542,Inconclusive,325495545.0,2101.0,1.33605,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3752,1259401,1,1,,170464657,37542,Inconclusive,325495545.0,2101.0,2.5601599999999998,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3753,1259402,1,1,,144208165,37542,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3754,1259402,1,1,,170464657,37542,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3755,1259403,1,1,,144208165,37542,Inconclusive,325495545.0,2101.0,1.02131,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3756,1259403,1,1,,170464657,37542,Inconclusive,325495545.0,2101.0,2.11317,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3757,1259404,1,1,,144208165,37542,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3758,1259404,1,1,,170464657,37542,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3759,1259415,1,1,,85148371,37542,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3760,1259416,1,2,,375162938,37542,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3761,1259421,1,1,,375162938,37542,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3762,1259423,1,2,,354784877,37542,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3763,1259423,1,2,,354791594,37542,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3764,1259423,1,2,,354998052,37542,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
